A general-audience atlas · 2026 figures from WHO, IARC, ACS & CDC

Cancer in numbers — and the long, hopeful arc of progress against it.

More than 20.7 million people will hear the words "you have cancer" in 2026. This atlas translates the latest global research into plain figures: where the disease falls hardest, where it's retreating, and what's been shown to help.

Explore the data What can help

Data highlights

Six numbers that frame the picture

Pulled from WHO/IARC, ACS, SEER and CDC. Switch the view, year, and region to reframe the data.

RegionYearShowing incidence · Worldwide · 2026

20.7M

New diagnoses · Worldwide (2026)

IARC GLOBOCAN trend

57K

New diagnoses per day

≈ 1 every 1.5 seconds

2.56M

Lung cancer cases / yr

the global #1 by incidence

2.51M

Breast cancer cases / yr

leading cancer in women

2.07M

Colorectal cases / yr

rising in adults < 50

42%

Share tied to modifiable risk

tobacco, weight, alcohol, UV, infection

At a glance

The shape of cancer, in numbers

A new diagnosis is made roughly every 1.6 seconds somewhere on Earth. These are the headline figures for the most recent year of complete global data.

New cases · worldwide

20.7M

2025 · IARC projection

Deaths · worldwide

9.90M

≈ 27,100 per day

New cases · United States

2.08M

ACS Facts & Figures 2026

5-year survival · US

70%

up from 49% in 1975

New cases per day · worldwide

57K

≈ 1 diagnosis every 1.5 seconds

Deaths per day · worldwide

27K

≈ 1 death every 3.2 seconds

New cases per day · US

ACS 2026 projection ÷ 365

Deaths per day · US

≈ 1,700 lives lost daily

Estimated new cases reported worldwide this year

12.4M

Updates every second · based on WHO GLOBOCAN annual rate

Estimated cancer deaths worldwide this year

5.95M

≈ one life lost every 3.3 seconds globally

Slice & dice

Cancer by age, sex, and demographics

Cancer doesn't fall on everyone equally. Filter the data to see incidence rates per 100,000 people across age groups, sex, and race / ethnicity in the United States.

Sex

Race / ethnicity

Age group

Incidence · selected slice

896

cases per 100,000 / year

Sex

All

Combined male + female

Population

All

US, age-adjusted

Incidence by age group

per 100,000 / year

Top cancers in this slice

per 100,000 / year

Source: CDC United States Cancer Statistics (2017–2021) and NCI SEER. Figures are rounded estimates and combine several sub-groups for readability.

Men vs women

How cancer falls on the two sexes

In the United States, men have a slightly higher overall lifetime risk and death rate, but the leading cancers look very different — driven mostly by prostate disease in men and breast cancer in women.

Men

New cases · 2026

1.06M

Deaths · 2026

326K

Incidence rate

487 / 100k

Lifetime risk

41%

Leading: prostate, lung, colorectal.

Women

New cases · 2026

1.02M

Deaths · 2026

293K

Incidence rate

432 / 100k

Lifetime risk

39%

Leading: breast, lung, colorectal.

US new cases by cancer type · 2026 projection

ACS

By age · life stages

Cancers reported by age group

The cancers that show up at age 8 are very different from those that show up at 78. Here are the most commonly diagnosed cancers across four life stages in the United States — and how much of the total each stage carries.

Ages 0–14

Children

10K

new US cases / yr

Share of all US cancers1%

Childhood cancer is rare but the leading disease cause of death in this age group. 5-year survival now exceeds 85%.

Most common cancers

Leukemia28%
Brain & CNS tumors27%
Lymphomas12%
Neuroblastoma6%
Wilms tumor (kidney)5%

Ages 15–39

Adolescents & young adults

94K

new US cases / yr

Share of all US cancers5%

Often called the 'AYA gap': diagnosis is frequently delayed and survival gains have lagged behind other groups.

Most common cancers

Breast17%
Thyroid13%
Melanoma9%
Testicular8%
Lymphomas11%

Ages 40–64

Adults

670K

new US cases / yr

Share of all US cancers32%

Where screening pays off most: breast, colorectal, prostate, and lung cancers all become significantly more common.

Most common cancers

Breast16%
Prostate13%
Lung & bronchus11%
Colorectal9%
Melanoma6%

Ages 65+

Older adults

1.20M

new US cases / yr

Share of all US cancers58%

Nearly 6 in 10 new cancers in the US are diagnosed at 65 or older. Median age at diagnosis is 67 across all sites.

Most common cancers

Prostate16%
Lung & bronchus14%
Breast12%
Colorectal10%
Bladder6%

Why age matters so much. Most cancers are diseases of accumulated DNA damage, so risk climbs steeply with age. The median age at cancer diagnosis in the US is 67. That's also why screening guidelines (mammograms at 40, colonoscopies at 45, lung CT at 50) cluster in midlife.

Pets & companion animals

Cancer in dogs and cats

Cancer is now the leading cause of death in dogs over the age of 10, and a top cause in cats too. Many of the same therapies used in people — surgery, chemotherapy, immunotherapy — are now standard in veterinary oncology, and pets are often the first species to benefit from emerging drugs.

US dogs diagnosed each year

6.00M

≈ 1 every 5 seconds

US cats diagnosed each year

6.00M

lymphoma is #1

Lifetime cancer risk · dogs

25%

1 in 4 dogs

Risk in dogs over 10

50%

leading cause of death

Most common cancers in dogs

share of canine cancer cases

Lymphoma24%
Most common; often responds well to chemo.
Mast cell tumor20%
Most common skin cancer in dogs.
Osteosarcoma (bone)6%
Aggressive; common in large breeds.
Hemangiosarcoma7%
Blood-vessel cancer; often spleen or heart.
Mammary tumors12%
Largely preventable by early spaying.
Melanoma4%
Oral form is aggressive.

Most common cancers in cats

share of feline cancer cases

Lymphoma33%
Most common feline cancer; FeLV is a key risk.
Squamous cell carcinoma15%
Skin & mouth; UV exposure raises risk.
Fibrosarcoma8%
Soft-tissue tumor; some injection-site linked.
Mammary carcinoma17%
Usually malignant; spaying lowers risk sharply.
Basal cell tumor6%
Mostly benign; surgically curable.

Warning signs in pets

The 10 common signs of cancer recognized by the Veterinary Cancer Society. Most have benign causes — but lingering changes are worth a vet visit.

Lumps or bumps that grow or changeSores that don't healUnexplained weight lossLoss of appetiteBleeding or dischargeBad breath or oral odorDifficulty eating or swallowingPersistent lameness or stiffnessDifficulty breathing, urinating, or defecatingLethargy or loss of stamina

Pets help people too. Companion animals — especially dogs — develop cancers that look biologically similar to ours. Comparative oncology trials run by the NCI use this overlap to test therapies that benefit both species, accelerating discoveries for human patients.

By cancer type

Where the global burden falls

Lung, breast, and colorectal cancers together account for nearly a third of every diagnosis worldwide. Toggle to see how that picture changes when measured by lives lost.

Top causes by cancer type

What's driving each diagnosis

The biggest known risk factors per cancer, by the share of cases each is estimated to cause. Categories overlap, so totals can exceed 100%. Sources: IARC, WHO, ACS, NCI, WCRF.

Lung

attributable share

Tobacco smoking80%
Secondhand smoke5%
Radon gas exposure10%
Outdoor air pollution8%
Occupational (asbestos, diesel)9%

Breast

attributable share

Age & female sex hormones35%
Inherited mutations (BRCA1/2)10%
Obesity & alcohol18%
Reproductive history15%
Hormone therapy / dense breast12%

Colorectal

attributable share

Processed & red meat diet22%
Obesity & inactivity18%
Alcohol use12%
Smoking12%
Inherited syndromes (Lynch, FAP)7%

Prostate

attributable share

Age (65+)60%
Family history / genetics20%
African ancestry12%
Obesity & Western diet10%

Stomach

attributable share

H. pylori infection75%
High-salt / smoked foods15%
Tobacco smoking11%
Family history8%

Liver

attributable share

Hepatitis B & C infection56%
Alcohol-related cirrhosis20%
Fatty liver disease (MASLD)12%
Aflatoxin-contaminated food5%
Tobacco smoking6%

Thyroid

attributable share

Ionizing radiation exposure9%
Iodine imbalance8%
Female sex hormones25%
Inherited mutations (RET, MEN2)5%
Overdiagnosis from imaging30%

Cervical

attributable share

HPV infection (16/18)95%
Smoking10%
Long-term oral contraceptive use8%
Immunosuppression (HIV)6%

Many cancers have multiple, overlapping causes — a smoker with HPV, or someone with both an inherited mutation and an obesogenic diet, carries combined risk. Removing even one driver meaningfully lowers the odds.

Cures & what's working

The cancers we now cure — and what's curing them

Five-year relative survival when caught at the localized stage, paired with the treatment driving the cure. Sources: NCI SEER 2014–2020, ACS, FDA approvals 2023–2026.

Cure rate when caught early

Thyroid (papillary)99.5%
Surgery (thyroidectomy) ± radioactive iodine
Prostate (localized)99%
Active surveillance, surgery, or radiation
Melanoma (localized)99%
Wide local excision; immunotherapy if advanced
Breast (localized)99%
Lumpectomy + radiation, hormone therapy, HER2 drugs
Testicular95%
Orchiectomy + cisplatin chemotherapy
Hodgkin lymphoma92%
ABVD chemo + targeted brentuximab/nivolumab
Cervical (localized)91%
Surgery + HPV vaccine prevention
Colorectal (localized)91%
Surgical resection ± adjuvant chemo
Childhood ALL90%
Multi-agent chemo + CAR-T for relapse
Chronic myeloid leukemia90%
Imatinib / TKIs (Gleevec revolution)

Breakthroughs · 2025–2026

FDA approval of the first KRAS-G12D targeted drugs for pancreatic cancer (2025).
mRNA cancer vaccines (Moderna/Merck) cut melanoma recurrence by 49% in Phase 3.
Off-the-shelf allogeneic CAR-T entered late-stage trials for lymphoma & lupus.
AI-guided early detection (Galleri, Grail) now detects 50+ cancers from a blood draw.
Theranostics (Pluvicto, Lutathera) deliver radiation directly to prostate & neuroendocrine tumors.
First CRISPR-edited TIL therapy showed durable responses in solid tumors (2026).

Cure rate by cancer type — all 20 major cancers

5-year relative survival, all stages combined

Thyroid98%
Prostate97%
Testicular95%
Melanoma (skin)94%
Breast (female)91%
Hodgkin lymphoma89%
Uterine / endometrial81%
Kidney78%
Bladder78%
Non-Hodgkin lymphoma74%
Cervical67%
Leukemia (all types)67%
Colorectal65%
Ovarian51%
Stomach36%
Brain / CNS34%
Lung (all)27%
Esophageal22%
Liver / bile duct22%
Pancreatic13%

Highly curable (>80%) Mixed outcomes (50–80%) Still deadly (<50%)

Six pillars of modern cures

Early detection

Stage I survival > 90%

When caught at stage I, survival exceeds 90% for most cancers. Mammography, colonoscopy, low-dose CT for smokers, HPV testing, and PSA screening have driven the biggest mortality drops.

Surgery

~45% of all cures

Still the single most curative treatment for solid tumors. Minimally invasive and robotic techniques mean faster recovery and tighter margins.

Immunotherapy

Melanoma: 5% → 52%

Checkpoint inhibitors (Keytruda, Opdivo) unleash the patient's own T-cells. Metastatic melanoma 5-yr survival jumped from 5% to over 50%.

Targeted therapy

CML 5-yr survival > 90%

Drugs aimed at specific mutations — HER2 (Herceptin), BCR-ABL (Gleevec), EGFR, BRAF, KRAS-G12C. Turned several death sentences into chronic conditions.

CAR-T cell therapy

Pediatric ALL: 80%+ remission

A patient's T-cells are re-engineered to hunt their cancer. Producing durable remissions in leukemia, lymphoma, and now multiple myeloma.

Vaccines & prevention

Cervical cancer ↓ 90% in vaccinated cohorts

HPV vaccine is preventing cervical, anal, and head/neck cancers — Scotland and Australia are on track to eliminate cervical cancer. Hep B vaccine slashes liver cancer.

Roughly 40% of all cancers diagnosed today can be cured outright, and another 30% can be held in long-term remission. The gap between "diagnosed" and "cured" keeps narrowing every year.

United States · by state

Cancer across the 50 states

Projected 2026 new cases and deaths from the American Cancer Society, with age-adjusted incidence rates per 100,000 (CDC USCS). Population size drives totals; lifestyle, environment, and screening drive rates.

Total US new cases · 2026

2.02M

Total US deaths · 2026

638K

Highest incidence rate

Kentucky

510 per 100k

Lowest incidence rate

Utah

365 per 100k

New cases · 2026

CACalifornia198K
FLFlorida170K
TXTexas145K
NYNew York124K
PAPennsylvania89K
OHOhio76K
ILIllinois76K
NCNorth Carolina71K
MIMichigan65K
GAGeorgia60K
NJNew Jersey55K
VAVirginia51K
WAWashington48K
TNTennessee48K
MAMassachusetts46K
AZArizona46K
INIndiana44K
MOMissouri40K
WIWisconsin40K
MDMaryland36K
MNMinnesota36K
SCSouth Carolina35K
KYKentucky32K
ALAlabama31K
COColorado30K
LALouisiana28K
OROregon25K
CTConnecticut23K
OKOklahoma23K
IAIowa22K
ARArkansas20K
MSMississippi18K
NVNevada18K
KSKansas18K
UTUtah14K
WVWest Virginia13K
NMNew Mexico12K
NENebraska12K
IDIdaho11K
MEMaine11K
NHNew Hampshire10K
HIHawaii8K
MTMontana7K
RIRhode Island7K
DEDelaware7K
SDSouth Dakota6K
NDNorth Dakota5K
VTVermont4K
AKAlaska4K
DCDC3K
WYWyoming3K

Total counts track population — California, Florida, and Texas top the list simply because more people live there. Age-adjusted rates tell a different story: Kentucky, West Virginia, and Maine sit highest, reflecting tobacco use, obesity, and older populations. Utah and New Mexico stay lowest thanks to younger demographics and lower smoking rates.

Where the best care is

Top cancer centers and oncologists

Leading NCI-designated comprehensive cancer centers across the US, the world's highest-ranked cancer hospitals, and the physician-scientists driving today's breakthroughs. Sources: NCI, US News 2025–2026, Newsweek World's Best Specialized Hospitals 2026, ASCO/AACR/ESMO leadership.

Northeast

6 centers

Memorial Sloan Kettering Cancer Center
New York, NY
Largest private cancer center; pioneer of CAR-T (Sadelain, Brentjens)
Dana-Farber / Brigham Cancer Center
Boston, MA
Harvard-affiliated; PD-1 immunotherapy roots
Memorial Sloan Kettering — Basser/Weill Cornell
New York, NY
Genomic precision oncology
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Nation's first cancer hospital (1898)
Fox Chase Cancer Center
Philadelphia, PA
BRCA discovery; immunoprevention
Yale Cancer Center
New Haven, CT
Immuno-oncology and lung cancer trials

South

7 centers

MD Anderson Cancer Center
Houston, TX
#1 ranked US cancer hospital 11 of last 14 years
Duke Cancer Institute
Durham, NC
Brain tumor & polio-virus glioblastoma trials
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Triple-negative breast cancer leader
Moffitt Cancer Center
Tampa, FL
TIL therapy & melanoma
Sylvester Comprehensive Cancer Center
Miami, FL
Hispanic/Caribbean cancer disparities
Vanderbilt-Ingram Cancer Center
Nashville, TN
Targeted therapy & KRAS research
Winship Cancer Institute (Emory)
Atlanta, GA
Multiple myeloma center of excellence

Midwest

7 centers

Mayo Clinic Comprehensive Cancer Center
Rochester, MN
Multi-site integrated care; proton therapy
University of Chicago Comprehensive Cancer Ctr
Chicago, IL
Checkpoint blockade origins (Gajewski)
Robert H. Lurie Cancer Center (Northwestern)
Chicago, IL
Prostate & GU oncology
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH
Genitourinary & GI cancers
OSU James Comprehensive Cancer Center
Columbus, OH
Largest freestanding cancer hospital in Midwest
Siteman Cancer Center (Washington U)
St. Louis, MO
Cancer genomics pioneer (TCGA)
U Michigan Rogel Cancer Center
Ann Arbor, MI
Sequencing-guided precision oncology

West

8 centers

Stanford Cancer Institute
Stanford, CA
Lymphoma & CAR-T (Levy, Mackall)
UCSF Helen Diller Family Cancer Center
San Francisco, CA
Prostate cancer & precision medicine
UCLA Jonsson Comprehensive Cancer Center
Los Angeles, CA
Melanoma & pembrolizumab (Ribas)
USC Norris Comprehensive Cancer Center
Los Angeles, CA
Epigenetics (Peter Jones)
City of Hope
Duarte, CA
Bone marrow transplant & CAR-T leader
Fred Hutchinson Cancer Center
Seattle, WA
Stem cell transplant (Thomas, Nobel 1990)
Huntsman Cancer Institute
Salt Lake City, UT
Hereditary cancer (Skolnick, BRCA1)
University of Colorado Cancer Center
Aurora, CO
Thoracic oncology & ALK inhibitors

Outcomes are consistently better at high-volume NCI-designated centers — for complex cancers, where you're treated matters as much as what you're treated with. Most centers above offer second-opinion programs and remote consults.

By lethality

Death rate by cancer type

How many people each cancer kills — measured three ways: total US deaths in 2026, the age-adjusted mortality rate per 100,000 people, and the share of diagnosed patients who die within five years. Sources: ACS 2026, CDC USCS, SEER 2014–2020.

Total US deaths · 2026

~528K total deaths from these 22 cancers — about 96% of all US cancer mortality.

Lung & bronchus125K
Colorectal53K
Pancreatic52K
Breast (female)42K
Prostate36K
Liver & bile duct30K
Leukemia (all)24K
Non-Hodgkin lymphoma20K
Brain & CNS19K
Bladder17K
Esophageal16K
Kidney & renal pelvis15K
Uterine / endometrial14K
Ovarian13K
Oral cavity & pharynx12K
Multiple myeloma12K
Stomach11K
Melanoma (skin)8K
Cervical4K
Thyroid2K
Hodgkin lymphoma950
Testicular510

Volume and lethality tell different stories. Lung cancer kills the most people overall, but pancreatic cancer is nearly always fatal once diagnosed. Thyroid, testicular, and melanoma — though common — rarely kill, thanks to early detection and effective treatment.

Worldwide lethality

Death rate by cancer type · worldwide

The same three views — total deaths, age-standardized mortality rate, and case-fatality — across the entire global population. Source: IARC GLOBOCAN 2022.

Total worldwide deaths · GLOBOCAN 2022

~8.48M deaths from these 22 cancers — roughly 90% of the ~9.7M global cancer deaths each year.

Lung1.82M
Colorectal904K
Liver & bile duct758K
Breast (female)670K
Stomach660K
Esophageal511K
Pancreatic467K
Prostate397K
Cervical348K
Leukemia (all)331K
Non-Hodgkin lymphoma250K
Brain & CNS249K
Bladder220K
Ovarian207K
Oral cavity & lip188K
Kidney & renal pelvis156K
Multiple myeloma117K
Uterine / corpus uteri97K
Melanoma (skin)59K
Thyroid44K
Hodgkin lymphoma23K
Testicular9K

The global picture shifts the rankings: liver and stomach cancers — driven by hepatitis B/C and H. pylori infection — kill far more people worldwide than in high-income countries, while cervical cancer remains a leading killer of women wherever HPV vaccination and screening are out of reach.

US deaths by state

Death by state

Where Americans die of cancer — by raw count and by age-adjusted mortality rate per 100,000. The map of mortality looks very different from the map of incidence: Appalachia and the Deep South consistently bury the most people per capita. Source: ACS 2026, CDC USCS 2018-2022.

Total US deaths 2026

638K

Highest mortality rate

Kentucky

191 per 100k

Lowest mortality rate

Utah

118 per 100k

Gap, highest vs lowest

62%

more deaths per capita

Projected cancer deaths · 2026

California, Florida, and Texas lead by raw count — driven by population.

CACalifornia64K
FLFlorida50K
TXTexas47K
NYNew York36K
PAPennsylvania28K
OHOhio26K
ILIllinois24K
NCNorth Carolina22K
MIMichigan22K
GAGeorgia19K
NJNew Jersey16K
TNTennessee16K
VAVirginia16K
INIndiana15K
WAWashington14K
AZArizona14K
MOMissouri14K
MAMassachusetts13K
WIWisconsin12K
KYKentucky11K
SCSouth Carolina11K
MDMaryland11K
ALAlabama11K
MNMinnesota11K
LALouisiana10K
OKOklahoma9K
COColorado8K
OROregon8K
ARArkansas7K
MSMississippi7K
IAIowa7K
CTConnecticut7K
NVNevada6K
KSKansas6K
WVWest Virginia5K
NMNew Mexico4K
UTUtah4K
NENebraska4K
IDIdaho3K
MEMaine3K
NHNew Hampshire3K
HIHawaii3K
MTMontana2K
RIRhode Island2K
DEDelaware2K
SDSouth Dakota2K
NDNorth Dakota1K
VTVermont1K
AKAlaska1K
WYWyoming1K
DCDC1K

Raw deaths follow population — the biggest states bury the most people. But the age-adjusted rate strips population out, exposing a stark regional pattern: Appalachia and the Deep South lose 50-60% more people per capita to cancer than Utah, Hawaii, or Colorado. Smoking history, obesity, late-stage diagnosis, and access to high-volume cancer centers explain most of the gap.

ABO overlap

Cancer risk by blood type

Decades of cohort studies show your ABO blood group nudges risk for several cancers — most strikingly for pancreatic and gastric cancer. The effects are small to moderate, never deterministic, and dwarfed by smoking, weight, and family history. Sources: Wolpin (JNCI 2009), Iodice (EJC 2010), Edgren (AJE 2010), UK Biobank (2021).

US blood type prevalence

O+37.4%
A+35.7%
B+8.5%
AB+3.4%
O-6.6%
A-6.3%
B-1.5%
AB-0.6%

~44% of Americans are Type O — the "universal donor" group and the reference baseline in most ABO-cancer studies.

How the ABO–cancer link works

ABO gene (9q34) codes for glycosyltransferases that decorate cell-surface proteins with sugar antigens — present on red cells, gut lining, pancreas, and tumor cells alike.
Inflammation markers (TNF-α, ICAM-1, E-selectin) run higher in non-O individuals, plausibly accelerating tumor microenvironment changes.
Pathogen binding — H. pylori sticks more easily to Type A gastric mucosa; norovirus and cholera prefer Type O. Chronic infection drives several cancers.
Clotting factors (vWF, factor VIII) run 25% higher in non-O, affecting metastasis-related vascular biology.

Relative risk vs Type O

1.00 = same risk as Type O. 1.50 = 50% higher. Sorted by selected blood type.

Pancreatic1.32× ↑
Non-O carriers have ~25–45% higher risk. ABO gene variants on chromosome 9q34 affect inflammation and cell adhesion.
Gastric (stomach)1.20× ↑
Type A has ~20% higher risk, linked to H. pylori binding affinity for A antigens on gastric mucosa.
Ovarian1.16× ↑
Modest but consistent elevation for A and AB across European cohorts.
Cervical1.14× ↑
Possible link to ABO-modulated immune response to HPV.
Breast1.12× ↑
Small (~10%) increase for A. Mechanism unclear — possibly hormone-binding glycoproteins.
Colorectal1.11× ↑
Slight A elevation; results inconsistent across populations.
Lung1.08× ↑
Minimal effect — smoking dwarfs any ABO signal.
Liver (HCC)1.00× —
Type B and AB show higher risk in East Asian cohorts, partly mediated by hepatitis B chronicity.
Skin (melanoma)0.95× ↓
Type O may carry slightly higher risk; effect is small.

Put it in perspective: smoking raises lung cancer risk 15–30×. Obesity raises endometrial risk 2–5×. A BRCA1 mutation raises breast cancer risk 6–7×. Blood type shifts risk by 5–70%. It's a real signal — useful for risk modeling and biology — but it's not destiny, and there's nothing you can do to change it. Focus on the modifiable factors first.

Alcohol overlap

Cancer risk: drinkers vs non-drinkers

Alcohol is a Group 1 carcinogen — same category as tobacco and asbestos. It causes at least 7 cancers, and the risk starts at the first drink for some of them. Sources: IARC Monograph 100E, WCRF/AICR 2018, Bagnardi (BJC 2015), Rumgay (Lancet Oncology 2021).

Global cancer cases attributable to alcohol

741,300

≈4.1% of all new cancers in 2020 (Lancet Oncology 2021)

Cases from heavy drinking (>60g/day)

346,400

47% of alcohol-attributable cancers

Cases from moderate drinking (20–60g/day)

291,800

39% — most cases come from non-heavy drinkers

Cases from light drinking (<20g/day)

103,100

14% — no safe threshold for breast and oral cancer

Relative risk vs lifetime non-drinkers

1–4 drinks/day. Most alcohol-attributable cancers come from this range, not heavy drinking.

Esophageal (squamous)2.23× ↑
Acetaldehyde accumulation, especially in people with ALDH2 deficiency (common in East Asians).
Oral cavity & pharynx1.83× ↑
Direct mucosal exposure; acetaldehyde damages DNA in upper aerodigestive tract.
Laryngeal1.44× ↑
Synergistic with tobacco — combined risk is multiplicative, not additive.
Breast (female)1.23× ↑
Raises circulating estrogen; even one drink/day measurably increases risk.
Colorectal1.17× ↑
Acetaldehyde + folate depletion + altered gut microbiome.
Liver (HCC)1.08× ↑
Chronic inflammation → fibrosis → cirrhosis → hepatocellular carcinoma.
Lung1.08× ↑
Weak independent signal; mostly confounded by smoking.
Stomach1.07× ↑
Modest risk increase, mainly with heavy intake.
Pancreatic1.04× —
Heavy drinking promotes chronic pancreatitis, a precursor lesion.
Non-Hodgkin lymphoma0.88× ↓
Slight inverse association; mechanism unclear.
Kidney0.85× ↓
Light/moderate drinking shows an inverse association — not a recommendation.

How alcohol causes cancer

Acetaldehyde — alcohol's first metabolite. Binds DNA, blocks repair, causes mutations. IARC Group 1 carcinogen.
Oxidative stress — reactive oxygen species damage DNA, proteins, lipids.
Estrogen elevation — even light drinking raises circulating estrogen, driving breast cancer risk.
Folate depletion — disrupts DNA methylation and repair, especially in colorectal mucosa.
Solvent effect — alcohol helps tobacco carcinogens penetrate mouth and throat tissue.

What the dose curve looks like

No safe threshold for breast, oral, pharyngeal, and esophageal cancer — risk rises from the first drink.
Linear dose-response for liver, colorectal, and breast — every additional 10g/day adds risk.
Synergy with tobacco for head, neck, and esophageal cancer — combined risk is 30–100× a never-user.
ALDH2 deficiency (~540M people, mostly East Asian) blocks acetaldehyde breakdown, multiplying esophageal cancer risk in drinkers.
Cutting back works — 20 years after quitting, oral and esophageal risk returns nearly to baseline.

The biggest surprise in the data isn't heavy drinking — it's that moderate and even light drinking account for more than half of alcohol-attributable cancers, because so many more people drink at those levels. For breast cancer in particular, "one glass of wine a night" is a measurable risk choice, not a neutral one.

Smoking overlap

Cancer risk: smokers vs non-smokers

Tobacco causes more cancer than any other modifiable risk factor on Earth — 17 distinct cancers and roughly a third of all cancer deaths. The dose-response is steep, but the recovery curve after quitting is the most encouraging story in oncology. Sources: US Surgeon General 2014/2020, IARC 100E, Doll & Peto 50-year British Doctors Study.

US cancer deaths from smoking each year

~480,000

Tobacco is the #1 preventable cause of cancer death (CDC, Surgeon General 2020)

Share of US cancer deaths caused by smoking

30%

≈1 in 3 cancer deaths trace back to tobacco

Lung cancers caused by smoking

80–90%

Without tobacco, lung cancer would be a rare disease

Years of life lost per smoker (avg)

10+ yrs

Quitting before 40 reverses ~90% of the excess mortality

Relative risk vs lifetime never-smokers

Current smokers. Lung cancer risk is 25× higher than never-smokers — the steepest single risk factor in all of oncology.

Lung25.0× ↑
Benzo[a]pyrene, NNK and 70+ other carcinogens directly mutate TP53 and KRAS in bronchial epithelium.
Laryngeal14.6× ↑
Direct smoke contact; synergistic with alcohol.
Oral cavity & pharynx10.9× ↑
Tar deposition on mucosa; combined with alcohol, risk multiplies.
Esophageal (squamous)6.8× ↑
Carcinogen exposure during swallowing; ALDH2-deficient drinkers especially vulnerable.
Bladder3.1× ↑
Aromatic amines (4-aminobiphenyl, 2-naphthylamine) excreted in urine, concentrate in bladder.
Pancreatic2.2× ↑
Carcinogens reach pancreas via blood and biliary reflux; smokers diagnosed ~10 yrs earlier.
Ovarian (mucinous)2.1× ↑
Effect specific to mucinous histology; other subtypes not elevated.
Kidney (renal cell)2.0× ↑
Tobacco-specific nitrosamines filtered through kidneys.
Cervical1.8× ↑
Nicotine and cotinine concentrate in cervical mucus; impairs local immune clearance of HPV.
Stomach1.7× ↑
Smoking + H. pylori produces multiplicative gastric cancer risk.
Liver1.6× ↑
Synergistic with hepatitis B/C and alcohol-induced cirrhosis.
Acute myeloid leukemia1.4× ↑
Benzene in tobacco smoke damages bone marrow stem cells.
Colorectal1.2× ↑
Smoking is now established as a colorectal carcinogen; long latency (~30 yrs).
Breast1.1× ↑
Modest signal; stronger for women who started smoking before first pregnancy.

What's in the smoke

7,000+ chemicals in tobacco smoke; at least 70 are known carcinogens.
Polycyclic aromatic hydrocarbons (benzo[a]pyrene) form DNA adducts at the exact TP53 hotspots seen in lung tumors.
Tobacco-specific nitrosamines (NNK, NNN) target lung, pancreas, esophagus.
Aromatic amines excreted in urine drive bladder cancer.
Benzene damages bone marrow → leukemia.
Heavy metals (cadmium, arsenic, polonium-210) accumulate in tissue over decades.

Recovery timeline after quitting

20 minHeart rate and blood pressure begin to drop.
12 hoursCarbon monoxide in blood returns to normal.
2–12 weeksCirculation improves; lung function climbs up to 30%.
1 yearExcess risk of coronary heart disease cut in half.
5 yearsOral, throat, esophageal, and bladder cancer risk roughly halves.
10 yearsLung cancer death rate drops to about half of a continuing smoker's.
15 yearsRisk of coronary heart disease returns to that of a non-smoker.
20 yearsRisk of most smoking-related cancers approaches never-smoker levels.

No other intervention in medicine — no drug, no screening test, no surgery — comes close to the lifetime cancer risk reduction of never starting, or quitting before 40. Secondhand smoke causes another ~7,300 US lung cancer deaths a year in non-smokers. And vaping, while less harmful than cigarettes, is not "no risk" — long-term cancer data is still emerging.

CBC overlap

Cancer risk: red and white blood cell counts

The complete blood count is the cheapest, oldest cancer-screening tool in medicine. Unexplained anemia, polycythemia, leukocytosis, or pancytopenia in an otherwise-well adult is one of the most common ways a hidden cancer first announces itself. Sources: NCCN, ASH guidelines, UK Biobank, Templeton et al. JNCI 2014.

Normal RBC (men)

4.7–6.1

million cells / µL

Normal RBC (women)

4.2–5.4

million cells / µL

Normal WBC (adult)

4.5–11.0

thousand cells / µL

Anemia at cancer diagnosis

~40%

of solid-tumor patients; up to 70% with chemo

Red cell findings → cancers to think of

Iron-deficiency anemia in any man or post-menopausal woman is colon cancer until proven otherwise.

Anemia (low RBC / low hemoglobin)
Think about
Colorectal, gastric, esophageal, bladder, kidney, multiple myeloma, lymphoma, any advanced solid tumor
Why
Chronic occult blood loss from GI/GU tumors, bone marrow infiltration, anemia of chronic inflammation (high hepcidin), iron sequestration.
Iron-deficiency anemia in men or post-menopausal women
Think about
Right-sided colon cancer (especially cecal), gastric cancer
Why
Slow, painless GI bleeding. Unexplained IDA is a colonoscopy indication until proven otherwise — yields cancer in ~10% of cases.
Elevated RBC / polycythemia
Think about
Polycythemia vera (myeloproliferative neoplasm), renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma, uterine leiomyoma, pheochromocytoma
Why
Tumors secrete ectopic erythropoietin (EPO) → bone marrow over-produces red cells. JAK2 V617F mutation drives true polycythemia vera.
Macrocytosis (high MCV)
Think about
Myelodysplastic syndrome, acute leukemia (especially AML)
Why
Dysplastic erythropoiesis. Persistent unexplained macrocytosis warrants a bone marrow biopsy.

Neutrophil-to-lymphocyte ratio (NLR)

A single number derived from any CBC with differential. High NLR signals systemic inflammation and immune exhaustion — and predicts shorter survival across virtually every solid tumor studied.

< 2Baseline. Healthy reference range; no prognostic signal.
2 – 3Mildly elevated. Subclinical inflammation; modest signal.
3 – 5Elevated. Across 100+ studies, NLR >3 predicts ~30–60% worse overall survival in most solid tumors.
> 5High. Strongly associated with advanced disease, poor immunotherapy response, and higher cancer mortality.

How tumors disturb the CBC

Direct marrow invasion — leukemia, lymphoma, myeloma, or metastatic carcinoma displaces normal hematopoiesis → cytopenias.
Chronic blood loss — GI and GU tumors bleed slowly → iron-deficiency anemia, often the first clue.
Anemia of inflammation — IL-6 from tumor drives hepcidin → iron trapped in macrophages → normocytic anemia.
Ectopic hormone production — kidney, liver, and cerebellar tumors secrete EPO → polycythemia.
Paraneoplastic cytokines — tumor G-CSF / GM-CSF → neutrophilia; IL-5 → eosinophilia.
Hypersplenism — splenomegaly from lymphoma or portal hypertension → sequestration of platelets and red cells.

A normal CBC does not rule out cancer — many early tumors leave the blood count untouched. But an unexplained abnormality, especially one that persists across two draws, deserves a real workup. The CBC's strength isn't diagnosis; it's that it's run on almost everyone, almost everywhere, almost for free — and it quietly catches thousands of cancers a year that would otherwise present much later.

Air quality overlap

Cancer mortality vs air quality, by state

Particulate matter (PM2.5) — the fine soot from combustion, wildfires, diesel, and industry — is a Group 1 carcinogen (IARC 2013) and the single largest environmental cancer risk factor. Here it's overlaid against age-adjusted cancer mortality across all 50 states + DC. Sources: EPA AQS 2022–2023 design values, CDC USCS 2018–2022, IARC Monograph 109.

Correlation: PM2.5 ↔ mortality

r = 0.39

Moderate positive correlation across 51 states/DC

Correlation: PM2.5 ↔ incidence

r = 0.19

Incidence is also confounded by screening intensity and smoking rates

Dirtiest 5 states (avg mortality)

156

per 100k · CA, OH, IN, PA, IL

Cleanest 5 states (avg mortality)

149

per 100k · 5% lower than dirtiest

Side-by-side: PM2.5 vs cancer mortality

Sorted by air pollution. Orange = PM2.5 (µg/m³, WHO guideline is 5). Red = age-adjusted cancer deaths per 100,000.

CACalifornia10.5 · 130
OHOhio9.5 · 168
INIndiana9.5 · 169
PAPennsylvania9.2 · 158
ILIllinois9.2 · 155
KYKentucky9.0 · 191
MSMississippi9.0 · 184
ALAlabama8.8 · 172
LALouisiana8.8 · 178
WVWest Virginia8.8 · 183
TXTexas8.5 · 141
MIMichigan8.5 · 161
GAGeorgia8.5 · 156
TNTennessee8.5 · 173
ARArkansas8.5 · 177
MOMissouri8.2 · 167
OROregon8.2 · 147
VAVirginia8.0 · 152
SCSouth Carolina8.0 · 158
OKOklahoma8.0 · 178
NCNorth Carolina7.8 · 154
NJNew Jersey7.8 · 144
WAWashington7.8 · 145
WIWisconsin7.8 · 152
MDMaryland7.8 · 144
IAIowa7.8 · 156
UTUtah7.8 · 118
DEDelaware7.8 · 156
NVNevada7.5 · 154
KSKansas7.5 · 154
DCDC7.5 · 144
AZArizona7.2 · 132
CTConnecticut7.0 · 138
IDIdaho7.0 · 142
NYNew York6.8 · 138
MNMinnesota6.8 · 144
COColorado6.8 · 124
NENebraska6.8 · 150
RIRhode Island6.8 · 150
FLFlorida6.5 · 143
MAMassachusetts6.5 · 143
MTMontana6.5 · 152
SDSouth Dakota6.0 · 156
NMNew Mexico5.8 · 130
NHNew Hampshire5.8 · 152
HIHawaii5.5 · 122
NDNorth Dakota5.5 · 152
VTVermont5.5 · 148
WYWyoming5.5 · 153
MEMaine5.2 · 165
AKAlaska5.0 · 159

What the correlation does and doesn't say

It's real. Long-term PM2.5 exposure causes lung cancer (IARC Group 1, 2013). Each 10 µg/m³ increase is linked to ~9% higher lung cancer mortality (Pope et al. JAMA 2002, ESCAPE 2013).
It's not the whole story. The dirtiest US states also have the highest smoking rates, highest obesity, and worst healthcare access. PM2.5 is one driver — it doesn't explain Kentucky alone.
The cleanest states aren't always the healthiest cancer outcomes either — Alaska is clean but has high mortality due to access gaps and indigenous health disparities.
State averages hide huge intra-state variation — a freeway corridor in LA or the Ohio River Valley carries much higher local exposure than the state mean.

How dirty air causes cancer

Polycyclic aromatic hydrocarbons (PAHs) in combustion soot — same DNA-damaging molecules as tobacco smoke.
Heavy metals (arsenic, cadmium, nickel) bind to ultrafine particles and reach the deep lung.
Chronic oxidative stress and inflammation in airway epithelium drives mutation accumulation over decades.
Diesel exhaust alone is IARC Group 1 — established cause of lung cancer in occupational cohorts.
Wildfire smoke contains 3–4× more carcinogenic PAHs per microgram than urban PM2.5 (UC Davis 2021).
Beyond lung: emerging evidence links PM2.5 to bladder, breast, and pancreatic cancer (Lancet Planetary Health 2023).

Air pollution is the cancer risk you can't quit. WHO estimates ambient PM2.5 caused ~250,000 lung cancer deaths globally in 2019, and the IARC has classified outdoor air pollution as a definite carcinogen since 2013. The US averages look "clean" by global standards — but only 12 states meet the WHO 5 µg/m³ guideline, and the Ohio River Valley, Central Valley, and Gulf Coast carry burdens comparable to mid-tier European cities.

Technology overlap

Cancer vs technology and data center concentration

Does living in a tech-heavy state — Virginia's Loudoun County alone hosts the largest data-center cluster on Earth — affect your cancer risk? Here's the honest overlay: state-level data-center count vs cancer mortality, plus what the peer-reviewed literature actually says about each plausible tech→cancer pathway. Sources: Data Center Map / Cloudscene mid-2025, CDC USCS 2018–2022, IARC Monographs 102 (RF) / 105 (diesel) / 109 (air), WHO RF Health Review 2024.

Correlation: data centers ↔ mortality

r = -0.27

Weak correlation across 51 states/DC (log-scaled)

Correlation: data centers ↔ incidence

r = -0.25

No meaningful incidence signal either

Top-5 data-center states avg mortality

143

per 100k · VA, TX, CA, NY, GA

Bottom-5 (fewest DCs) avg mortality

154

per 100k · 7% higher than top-5

Side-by-side: data centers vs cancer mortality

Sorted by data-center count. Blue = facilities (log scale). Red = age-adjusted cancer deaths per 100,000.

VAVirginia595 · 152
TXTexas410 · 141
CACalifornia312 · 130
NYNew York195 · 138
GAGeorgia134 · 156
FLFlorida130 · 143
ILIllinois130 · 155
AZArizona120 · 132
OHOhio110 · 168
WAWashington110 · 145
NJNew Jersey95 · 144
NCNorth Carolina75 · 154
OROregon75 · 147
IAIowa70 · 156
MAMassachusetts65 · 143
NVNevada65 · 154
PAPennsylvania60 · 158
COColorado60 · 124
MDMaryland50 · 144
MNMinnesota50 · 144
MIMichigan45 · 161
TNTennessee40 · 173
INIndiana35 · 169
MOMissouri35 · 167
UTUtah35 · 118
WIWisconsin30 · 152
SCSouth Carolina25 · 158
CTConnecticut25 · 138
ALAlabama22 · 172
OKOklahoma20 · 178
KSKansas20 · 154
NENebraska20 · 150
NHNew Hampshire20 · 152
KYKentucky18 · 191
LALouisiana18 · 178
NMNew Mexico15 · 130
ARArkansas12 · 177
DEDelaware12 · 156
MSMississippi10 · 184
IDIdaho10 · 142
DCDC10 · 144
WVWest Virginia8 · 183
MEMaine8 · 165
HIHawaii8 · 122
MTMontana8 · 152
RIRhode Island8 · 150
AKAlaska6 · 159
SDSouth Dakota5 · 156
NDNorth Dakota5 · 152
VTVermont5 · 148
WYWyoming5 · 153

Tech → cancer: pathway by pathway

Radiofrequency / 5G / WiFi
Group 2B (possibly carcinogenic)
Evidence: Inconclusive
IARC 2011 classification was based on limited evidence of glioma in heavy cell-phone users. Subsequent large cohorts (Million Women Study 2022, COSMOS 2024, Danish cohort) found no increase in brain tumors with mobile-phone use. WHO 2024 review reaffirmed no clear cancer signal at exposure levels below safety limits.
Backup-generator diesel exhaust
Group 1 (definite carcinogen)
Evidence: Established at occupational levels
Data centers run diesel generators for resiliency testing. Local emissions matter for nearby residents and workers, but ambient impact is typically dwarfed by traffic and industry. Diesel exhaust causes lung and bladder cancer at sustained occupational exposure.
Grid emissions (coal/gas power)
Indirect (via PM2.5)
Evidence: Strong but diffuse
Every TWh of fossil-fired electricity consumed by data centers contributes to PM2.5 and ozone downwind — the IARC Group 1 ambient-air-pollution pathway from the previous section. Hyperscale demand grew ~40% in 2024 and is forecast to double by 2030.
Screen time / sedentary behavior
Indirect (via obesity, inactivity)
Evidence: Strong
≥8h/day sitting is linked to 10-20% higher mortality and increased colorectal, endometrial, and breast cancer risk (Lancet 2016, JNCI 2020). Tech use isn't the cause — what it displaces (movement) is.
Blue light / circadian disruption
Group 2A — shift work (probable)
Evidence: Moderate, indirect
Night-shift work involving circadian disruption is IARC 2A for breast cancer. Heavy late-night screen use may share part of the mechanism (melatonin suppression), but no direct cancer link has been established.
Cooling water / refrigerant chemistry
Varies
Evidence: Low for community exposure
Hyperscale cooling uses water (now ~660B liters/yr globally), evaporative biocides, and refrigerants. Treated discharge has not been epidemiologically linked to community cancer risk.
E-waste smelting (informal)
Multiple Group 1 carcinogens
Evidence: Strong in exposed populations
Informal e-waste recycling (Agbogbloshie, Guiyu) exposes workers to lead, cadmium, mercury, brominated flame retardants, and dioxins — all linked to elevated cancer risk. This is downstream of tech, not US-domestic.

The headline result is the boring one: at the state level, data-center concentration shows essentially no correlation with cancer mortality. Virginia (most data centers) and Vermont (almost none) have similar age-adjusted rates. The real tech-related cancer risk isn't the server racks — it's the grid emissions that power them (PM2.5), the diesel backups near specific communities, and the sedentary, late-night lifestyle the whole stack enables. RF/EMF, despite the headlines, has not produced a credible cancer signal in two decades of large cohort studies.

Income overlap

Cancer mortality vs median household income, by state

Income isn't a biological cancer risk factor — but it's one of the strongest predictors of who dies of cancer in America. Insurance, screening uptake, smoking rates, environmental exposure, and access to top-tier oncology all track income. Sources: US Census ACS 2023, NCI SEER 2018-2022, CDC USCS, AJPM (Singh et al. 2023), CDC BRFSS 2023.

Correlation: income ↔ mortality

r = -0.72

Strong negative — higher income, lower mortality

Correlation: income ↔ incidence

r = -0.37

Incidence is less income-sensitive — screening can even raise it

Top-5 income avg mortality

141

per 100k · DC, MD, NJ, MA, CA

Bottom-5 income avg mortality

183

per 100k · 30% higher than top-5 · MS, AR, WV, LA, KY

Side-by-side: median income vs cancer mortality

Sorted by income (high → low). Green = median household income ($k). Red = age-adjusted cancer deaths per 100,000.

DCDC$101k · 144
MDMaryland$98k · 144
NJNew Jersey$97k · 144
MAMassachusetts$97k · 143
CACalifornia$96k · 130
NHNew Hampshire$96k · 152
WAWashington$95k · 145
HIHawaii$95k · 122
COColorado$93k · 124
VAVirginia$90k · 152
CTConnecticut$90k · 138
UTUtah$89k · 118
AKAlaska$89k · 159
MNMinnesota$88k · 144
RIRhode Island$82k · 150
NYNew York$81k · 138
VTVermont$81k · 148
ILIllinois$80k · 155
OROregon$80k · 147
DEDelaware$79k · 156
AZArizona$77k · 132
TXTexas$76k · 141
PAPennsylvania$76k · 158
WIWisconsin$76k · 152
NVNevada$76k · 154
GAGeorgia$75k · 156
NENebraska$75k · 150
IDIdaho$75k · 142
MEMaine$74k · 165
NDNorth Dakota$74k · 152
IAIowa$73k · 156
KSKansas$73k · 154
MTMontana$73k · 152
FLFlorida$72k · 143
SDSouth Dakota$72k · 156
WYWyoming$72k · 153
NCNorth Carolina$71k · 154
OHOhio$70k · 168
INIndiana$70k · 169
MIMichigan$69k · 161
MOMissouri$69k · 167
TNTennessee$68k · 173
SCSouth Carolina$68k · 158
NMNew Mexico$62k · 130
ALAlabama$61k · 172
OKOklahoma$61k · 178
KYKentucky$60k · 191
LALouisiana$58k · 178
ARArkansas$56k · 177
WVWest Virginia$56k · 183
MSMississippi$55k · 184

Why income predicts cancer mortality

Insurance coverage. Low-income adults are 3-4× more likely to be uninsured. Uninsured cancer patients are diagnosed at later stages and have 30-50% higher mortality (NCI 2024).
Screening uptake. Mammography, colonoscopy, and Pap testing rates are 15-25 percentage points lower in the bottom income quintile (CDC BRFSS 2023). Late detection drives most of the mortality gap.
Tobacco use. Smoking prevalence is ~24% in adults below the poverty line vs ~7% among those earning >$100k (CDC 2023). Tobacco alone explains roughly a third of the income-mortality gap.
Obesity & diabetes. Both rise sharply at lower incomes and independently increase risk of colorectal, endometrial, breast, kidney, and liver cancer.
Environmental exposure. Lower-income ZIP codes sit closer to highways, refineries, and Superfund sites. Cumulative PM2.5, lead, and industrial-solvent exposure runs 1.5-3× higher.
Occupational hazards. Construction, agriculture, manufacturing, and mining concentrate carcinogen exposure (silica, asbestos, diesel, benzene) in lower-wage roles.
Healthcare access. Treatment at NCI-designated comprehensive cancer centers improves survival 10-20%. These centers cluster in wealthy metros — a 4-hour drive for much of rural Appalachia and the Deep South.
Financial toxicity. Even with insurance, ~40% of cancer patients exhaust savings within 2 years. Cost-related treatment non-adherence raises mortality independently of disease stage.

Mortality gap, bottom vs top income quintile

Percent difference in cancer mortality between the lowest- and highest-income US quintiles. Negative values mean the wealthy actually have higher rates.

Cervical+90%
Mortality is nearly twice as high in the lowest income quintile — almost entirely due to HPV vaccination and Pap screening gaps.
Lung+60%
Smoking prevalence drives most of this. The lowest-income counties have lung cancer mortality 2× the highest-income counties.
Liver+55%
Hepatitis B/C, alcohol use disorder, and obesity all cluster at lower incomes.
Colorectal+40%
Colonoscopy uptake gaps + later-stage diagnosis.
Stomach+45%
H. pylori infection and salt-heavy diets are more common in lower-income and immigrant populations.
Head & neck+50%
Tobacco + alcohol + HPV. Strongest socioeconomic gradient of any cancer group.
Prostate+25%
Despite similar incidence across income, mortality runs higher in low-income/Black men due to later diagnosis.
Breast (female)+15%
Incidence is actually higher in wealthy women (later childbearing, alcohol) but mortality is higher in low-income women.
Melanoma-30%
Reversed gradient — higher-income people get more sun exposure (skiing, beaches, second homes) and have higher melanoma incidence.
Thyroid-20%
Reversed — higher-income groups have more incidental detection via imaging.

The cancer that kills you in America is partly a function of where you live and what you earn. A poor American diagnosed with cervical, lung, liver, or head-and-neck cancer faces roughly double the mortality of a wealthy American with the same disease — not because the biology is different, but because the system catches it later, treats it less aggressively, and bankrupts the patient mid-treatment. Two cancers buck the trend (melanoma, thyroid) precisely because of who has the leisure and the imaging access to be diagnosed in the first place.

Blood work trends

What blood work reveals over the course of cancer

The blood is a slow-motion readout of cancer biology. Some signals rise years before diagnosis; others fall hour-by-hour under treatment; a new class of tests reads tumor DNA directly from plasma before any tumor is visible on a scan. Sources: NCCN, ASCO Tumor Marker Guidelines 2023, BMJ (Bailey et al. 2017), GRAIL PATHFINDER, FDA approvals 2024.

Classic tumor markers

Proteins (or hormones) that cancer cells over-produce. Used for surveillance, treatment monitoring, and relapse detection — rarely for primary diagnosis on their own.

PSA (prostate-specific antigen)
Normal: < 4 ng/mL
Tracks
Prostate cancer
Trend
Rises slowly years before symptoms. Doubling time < 12 months = aggressive. Drops to undetectable after prostatectomy; recurrence detected as PSA re-rises.
CA-125
Normal: < 35 U/mL
Tracks
Ovarian (and uterine, pancreatic, peritoneal)
Trend
Elevated in 80% of advanced ovarian cancer, only ~50% of early-stage. Trajectory after surgery/chemo predicts recurrence months before imaging.
CEA (carcinoembryonic antigen)
Normal: < 3 ng/mL (non-smokers)
Tracks
Colorectal, pancreatic, breast, lung, gastric
Trend
Standard surveillance marker post-colorectal resection. Rising CEA prompts re-imaging — often catches liver mets early.
CA 19-9
Normal: < 37 U/mL
Tracks
Pancreatic, biliary, gastric
Trend
> 1,000 U/mL usually means unresectable disease. Trajectory under chemo correlates with survival.
AFP (alpha-fetoprotein)
Normal: < 10 ng/mL
Tracks
Hepatocellular carcinoma, germ-cell tumors
Trend
Screened every 6 months in cirrhosis patients alongside ultrasound. Rises with HCC growth.
β-hCG
Normal: < 5 mIU/mL (non-pregnant)
Tracks
Germ-cell tumors (testicular, ovarian), gestational trophoblastic
Trend
Half-life 24-36 hrs — fastest-falling marker of any tumor. Used hour-by-hour to track chemo response in testicular cancer.
LDH (lactate dehydrogenase)
Normal: 140-280 U/L
Tracks
Lymphoma, melanoma, germ-cell, any high-turnover tumor
Trend
Reflects tumor bulk and cell turnover. Sharp rise = rapid progression or tumor lysis.
Thyroglobulin
Normal: < 0.2 ng/mL post-thyroidectomy
Tracks
Differentiated thyroid cancer
Trend
Should be undetectable after total thyroidectomy + I-131. Any rise signals recurrence.
Calcitonin
Normal: < 10 pg/mL
Tracks
Medullary thyroid cancer
Trend
Highly specific. Doubling time predicts survival in MTC.
Beta-2 microglobulin
Normal: < 2.5 mg/L
Tracks
Multiple myeloma, lymphoma, CLL
Trend
Standard staging marker for myeloma (ISS staging) and prognostic in lymphoma.

The future of cancer detection is in the blood. ctDNA-based MRD testing is already shifting how we follow colorectal, breast, and bladder cancer — detecting microscopic relapse months before imaging and letting clinicians escalate treatment while the tumor burden is still tiny. Multi-cancer early detection tests like Galleri remain imperfect (false negatives in early-stage disease) but are the most plausible path to catching the cancers that today have no screening test at all — pancreatic, ovarian, esophageal, liver.

Screening

How to actually screen for cancer — by sex and by decade

A consolidated, age-banded view of what to do, how it's done, and how often. Pulled from USPSTF 2024, ACS 2024 guidelines, NCCN 2025, and CDC recommendations. These are average-risk pathways — anyone with a strong family history, known pathogenic variant (BRCA1/2, Lynch, Li-Fraumeni), prior radiation, IBD, or heavy smoking exposure starts earlier and screens more often. Always discuss with a clinician who knows your history.

Cancers screened regardless of sex. The colon, skin, and lungs are where universal screening produces the biggest measured drop in mortality.

Young adult

Ages 18 – 39

Cancer is rare here, but a few habits set the trajectory for the next 40 years. Know your family history before age 30 — it changes when everything else starts.

Skin self-exam
Screens for
Melanoma and non-melanoma skin cancer
How
Full-body check once a month using the ABCDE rule (Asymmetry, Border, Color, Diameter >6mm, Evolving). Dermatologist visit if any concerning lesion or strong family history.
Cadence
Monthly self · dermatologist as needed
Family history review
Screens for
Hereditary cancer risk (BRCA, Lynch, Li-Fraumeni, FAP)
How
List first- and second-degree relatives with cancer, type, and age at diagnosis. Two or more close relatives with the same cancer, or any cancer under age 50, warrants genetic counseling.
Cadence
Once by age 30, update every 5 years
HPV vaccination
Screens for
Cervical, anal, oropharyngeal, penile cancers
How
9-valent HPV vaccine. Catch-up dosing is approved through age 26 and considered through age 45 after shared decision-making.
Cadence
Catch-up if not vaccinated as a teen
Tobacco & alcohol baseline
Screens for
17 cancers (lung, head/neck, esophagus, liver, breast, colon)
How
Smoking quit plan if any current use. Alcohol kept under 1 drink/day (female) or 2 (male); WHO now says no safe level for cancer risk.
Cadence
Every primary-care visit

Adult

Ages 40 – 44

The decade colorectal screening starts. Early-onset colon cancer in adults under 50 has risen ~50% since 1995 — the USPSTF lowered the start age to 45 in 2021.

Colorectal screening
Screens for
Colon and rectal cancer
How
Start at 45. Options: colonoscopy (gold standard), stool DNA test (Cologuard) every 3y, FIT every year, flexible sigmoidoscopy every 5y. High-risk (family history, IBD, polyposis) starts at 40 or 10 years before youngest affected relative.
Cadence
Colonoscopy every 10y · FIT yearly · stool DNA every 3y
Blood pressure, glucose, lipids
Screens for
Not cancer — but obesity, diabetes, and metabolic syndrome raise risk for 13 cancers
How
Annual labs through primary care; address weight, A1C, and lipids if abnormal.
Cadence
Annual

Midlife

Ages 45 – 64

Peak screening years. Adding lung CT for eligible smokers prevents more deaths per dollar than almost any other intervention in medicine.

Colorectal — continue
Screens for
Colon and rectal cancer
How
Same options as above. A normal colonoscopy at 45 means the next is at 55.
Cadence
Per prior result
Low-dose CT for lung
Screens for
Lung cancer
How
Ages 50–80, current smoker or quit within 15 years, with ≥20 pack-year history (e.g. 1 pack/day for 20 years). Annual low-dose chest CT cuts lung cancer mortality ~20%.
Cadence
Annual while eligible
Skin check by dermatologist
Screens for
Melanoma — rising fastest in this age group
How
Full-body skin exam, especially for anyone with fair skin, blistering sunburn history, >50 moles, or family history of melanoma.
Cadence
Every 1 – 3 years
Hepatitis B & C screening
Screens for
Hepatocellular carcinoma (liver)
How
One-time HCV antibody test for all adults 18–79. HBV screening for anyone born in endemic regions or with IV drug history. Treat to prevent progression to cirrhosis and cancer.
Cadence
One-time, repeat if exposed

Older adult

Ages 65 – 75

Continue screens as long as life expectancy is ≥10 years and the person could tolerate treatment. Frailty, not age alone, decides when to stop.

Colonoscopy — last rounds
Screens for
Colorectal
How
USPSTF: screening through 75 is recommended; 76–85 is individualized. Stop if prior screens normal and life expectancy is short.
Cadence
Per prior result, stop discussion at 75
Lung CT — continue
Screens for
Lung cancer
How
Continue annual LDCT through age 80 if eligibility criteria still met.
Cadence
Annual through 80

Elder

Ages 76+

Most population screening stops here unless the patient is robust with >10 year life expectancy. Symptom-based vigilance replaces routine screening.

Symptom-driven workup
Screens for
Any new mass, unexplained weight loss, persistent pain, bleeding, anemia
How
Lower threshold to investigate — diagnostic delay is the biggest avoidable harm in this age group.
Cadence
As symptoms appear

Three rules cut through everything above. First: screening only saves your life if the result is acted on — a normal colonoscopy at 45 is worthless if you skip the next one at 55. Second: family history changes every start date on this page; collect it once, write it down, and bring it to every new clinician. Third: no screening test replaces investigating a new symptom — a lump, persistent cough, blood, or unexplained weight loss deserves a workup whether you're due for a scan or not.

Cost & coverage

What you actually pay for screening

Under the Affordable Care Act, any screening rated A or B by the USPSTF must be covered with no cost-sharing on all non-grandfathered plans. Medicare covers most of the same set, often with broader age windows. Uninsured? The CDC's NBCCEDP funds free breast and cervical screening in every state, and FQHCs offer sliding-scale fees.

Screening	ACA private plan	Medicare	Out-of-pocket
Mammography	Covered with $0 cost-share, age 40+, biennial	Free annual from 40	~$150–300 without insurance; FQHCs often $0–50
Colonoscopy (screening)	Covered with $0 cost-share, age 45–75	$0 every 10 years (every 2 if high risk)	$1,000–3,000 self-pay
FIT / stool DNA (Cologuard)	$0 cost-share	$0 every 1y (FIT) or 3y (Cologuard)	$25 (FIT) – $600 (Cologuard) self-pay
Cervical Pap / HPV co-test	$0 cost-share, age 21–65	$0 every 24 months (12 if high risk)	$80–250 self-pay
Low-dose CT (lung)	$0 cost-share for USPSTF-eligible	$0 if criteria met	$100–400 self-pay
PSA test	Covered after shared decision, age 50+	$0 annual age 50+	$25–100 self-pay
Genetic counseling + BRCA testing	$0 for eligible women per USPSTF	Covered if family/personal history meets criteria	$250 counseling + $250–1,500 testing
Skin exam by dermatologist	Often subject to deductible (not on USPSTF A/B list)	Covered if medically necessary	$100–250 self-pay

A common gotcha: a screening colonoscopy is $0, but if a polyp is removed during the same procedure, some plans reclassify it as diagnostic and apply your deductible. ACA guidance now prohibits this for in-network providers, but it still happens — always confirm with the billing office in advance.

Cost of treatment

What cancer actually costs — by cancer and by treatment

The price tag of cancer care has roughly doubled in 15 years, driven almost entirely by targeted drugs, immunotherapy, and cell therapies. These are average commercially-insured allowed amounts (Mariotto JNCI 2020, Milliman 2024, NCI Cancer Trends, ASCO 2022). Self-pay list prices run 2–5x higher.

Sort: Year-1 cost ($K)

Cancer	Y1	Cont.	Last	OOP
Pancreatic	$134K	$14K	$156K	$19K
Leukemia	$128K	$22K	$144K	$22K
Brain	$122K	$18K	$138K	$18K
Ovarian	$112K	$18K	$132K	$17K
Lung	$96K	$14K	$124K	$16K
Lymphoma	$92K	$12K	$118K	$15K
Head & neck	$88K	$11K	$110K	$14K
Colorectal	$75K	$11K	$105K	$12K
Bladder	$64K	$9K	$88K	$11K
Kidney	$62K	$9K	$92K	$11K
Breast	$55K	$8K	$96K	$10K
Melanoma	$48K	$8K	$102K	$9K
Prostate	$42K	$7K	$78K	$8K

Financial toxicity

The cost of cancer is itself a treatment side effect

~40% of cancer patients deplete their entire savings within 2 years of diagnosis (ASCO 2022 survey).
Cancer patients are 2.6x more likely to file bankruptcy than people without cancer (Ramsey et al., Health Affairs).
Bankruptcy after diagnosis correlates with ~80% higher mortality — controlling for stage, age, and treatment.
1 in 4 insured patients skip or delay treatment because of cost (KFF Health Tracking Poll 2024).

Where to get help

CancerCare Co-Payment Assistance →Patient Advocate Foundation Co-Pay Relief →HealthWell Foundation →NeedyMeds — patient assistance directory →Leukemia & Lymphoma Society Co-Pay Program →Triage Cancer — legal & financial navigation →

New treatments

What's new for each cancer (2020–2025)

The most important therapies that have arrived in the last five years, by cancer. Curated from FDA oncology approvals, NCCN guidelines, and ASCO/ESMO landmark trials. Not exhaustive — focused on regimens that changed practice.

Breast

ADCs rewrote the HER2 playbook — Enhertu in HER2-low (DESTINY-Breast04) was the biggest oncology story of 2022. PI3K-pathway drugs and CDK4/6 inhibitors are now moving into early-stage disease.

Enhertu (trastuzumab deruxtecan)
FDA 2022
Class
Antibody-drug conjugate
What changed
Doubled PFS vs chemo in HER2-low metastatic breast cancer — created an entirely new subtype overnight (DESTINY-Breast04, NEJM).
For whom
Metastatic HER2-low (IHC 1+ or 2+/ISH−); now moving to HER2-ultralow.
Trodelvy (sacituzumab govitecan)
FDA 2021
Class
TROP2 ADC
What changed
First ADC effective in triple-negative breast cancer; survival benefit in pretreated metastatic disease.
For whom
Metastatic triple-negative and HR+/HER2− after endocrine therapy.
Kisqali (ribociclib)
FDA 2024
Class
CDK4/6 inhibitor
What changed
First CDK4/6 to show invasive-DFS benefit in early-stage HR+/HER2− (NATALEE) — adjuvant indication.
For whom
Stage II–III HR+/HER2− at risk of recurrence.
Truqap (capivasertib)
FDA 2023
Class
AKT inhibitor
What changed
Doubled PFS in HR+ tumors with PIK3CA/AKT1/PTEN alterations (CAPItello-291).
For whom
HR+/HER2− metastatic with PI3K-pathway alteration.
Itovebi (inavolisib)
FDA 2024
Class
PI3Kα-selective inhibitor
What changed
Tripled PFS combined with palbociclib + fulvestrant in PIK3CA-mutant disease (INAVO120).
For whom
HR+/HER2− PIK3CA-mutant, 1L metastatic.

The four platforms behind 2020–2025

Why everything new looks like a Greek letter

Antibody-drug conjugates (ADCs)

A targeted antibody carrying a chemo warhead. Enhertu, Trodelvy, Elahere, Padcev, Datroway — six of the last decade's biggest launches.

Bispecific T-cell engagers

One end binds the cancer, the other binds your T cell, forcing a synapse. Imdelltra (DLL3 in SCLC), Tecvayli (BCMA in myeloma), Columvi (CD20 in DLBCL).

Targeted radioligands

A tumor-seeking ligand delivers radiation directly to cancer cells. Pluvicto (PSMA in prostate), Lutathera (somatostatin in NETs).

Genotype-matched targeted therapy

A small molecule designed against a specific mutation. KRAS G12C, BRAF V600E, FGFR, HER2-low, NTRK fusions — each defines its own micro-indication.

A practical consequence: comprehensive biomarker testing (NGS panel + IHC) at diagnosis is now the gate to most of these therapies. Patients tested only for the standard 1–2 markers routinely miss eligibility for drugs that would extend their lives by years.

State doctor visits & lifestyle

Where Americans go to the doctor — and where they move

A 50-state cross-analysis of two CDC BRFSS indicators: the share of adults who had a routine checkup in the past year, and the share who meet federal aerobic activity guidelines. Together they map prevention access against prevention behavior.

Checkups vs. physical activity, by state

median lines split the four quadrants

High visits · High activity

14 states

DC · MA · CT · RI · VT · MD · NH · NY · HI · ME · MN · VA · CA · IA

High visits · Low activity

15 states

NJ · DE · IL · MI · PA · NC · GA · OH · SC · AL · KY · LA · WV · TN · MS

Low visits · High activity

14 states

CO · WA · OR · WI · UT · AK · NE · AZ · ID · MT · NM · ND · SD · WY

Low visits · Low activity

8 states

KS · FL · MO · IN · NV · TX · AR · OK

All 51 jurisdictions, ranked

click a header to sort

State	Checkup %	Active %	Composite	Quadrant
District of Columbia (DC)	82	59	141	High visits · High activity
Massachusetts (MA)	82	55	137	High visits · High activity
Connecticut (CT)	79	54	133	High visits · High activity
Rhode Island (RI)	81	52	133	High visits · High activity
Vermont (VT)	75	58	133	High visits · High activity
Maryland (MD)	80	52	132	High visits · High activity
New Hampshire (NH)	76	56	132	High visits · High activity
New York (NY)	79	52	131	High visits · High activity
Hawaii (HI)	75	55	130	High visits · High activity
Maine (ME)	76	54	130	High visits · High activity
Minnesota (MN)	73	57	130	High visits · High activity
New Jersey (NJ)	79	51	130	High visits · Low activity
Delaware (DE)	78	51	129	High visits · Low activity
Virginia (VA)	77	52	129	High visits · High activity
California (CA)	73	55	128	High visits · High activity
Colorado (CO)	67	61	128	Low visits · High activity
Washington (WA)	70	58	128	Low visits · High activity
Illinois (IL)	75	51	126	High visits · Low activity
Iowa (IA)	73	52	125	High visits · High activity
Michigan (MI)	75	50	125	High visits · Low activity
Oregon (OR)	67	58	125	Low visits · High activity
Pennsylvania (PA)	76	49	125	High visits · Low activity
Wisconsin (WI)	71	54	125	Low visits · High activity
Utah (UT)	64	60	124	Low visits · High activity
North Carolina (NC)	75	48	123	High visits · Low activity
Alaska (AK)	64	58	122	Low visits · High activity
Nebraska (NE)	69	53	122	Low visits · High activity
Arizona (AZ)	69	52	121	Low visits · High activity
Georgia (GA)	74	47	121	High visits · Low activity
Ohio (OH)	74	47	121	High visits · Low activity
South Carolina (SC)	75	46	121	High visits · Low activity
Idaho (ID)	64	56	120	Low visits · High activity
Kansas (KS)	70	50	120	Low visits · Low activity
Montana (MT)	62	58	120	Low visits · High activity
New Mexico (NM)	68	52	120	Low visits · High activity
North Dakota (ND)	67	53	120	Low visits · High activity
Alabama (AL)	76	43	119	High visits · Low activity
Florida (FL)	71	48	119	Low visits · Low activity
Kentucky (KY)	75	44	119	High visits · Low activity
Louisiana (LA)	76	43	119	High visits · Low activity
South Dakota (SD)	67	52	119	Low visits · High activity
Missouri (MO)	70	48	118	Low visits · Low activity
West Virginia (WV)	76	42	118	High visits · Low activity
Indiana (IN)	71	46	117	Low visits · Low activity
Nevada (NV)	67	50	117	Low visits · Low activity
Tennessee (TN)	73	44	117	High visits · Low activity
Texas (TX)	70	47	117	Low visits · Low activity
Wyoming (WY)	62	55	117	Low visits · High activity
Mississippi (MS)	75	40	115	High visits · Low activity
Arkansas (AR)	71	43	114	Low visits · Low activity
Oklahoma (OK)	70	44	114	Low visits · Low activity

What the map of behavior shows

Two preventive forces, unevenly distributed

The high-visits / high-activity quadrant clusters in the Mountain West (CO, UT) joined by parts of New England (MA, VT, NH, ME) and the Mid-Atlantic (MD, DC) — places that combine reliable primary-care contact with everyday movement. The low-low quadrant is heavily Southern (MS, AL, AR, LA, KY, TN, WV) and overlaps closely with the highest cancer-mortality belt in the United States. States like Utah and Colorado show that an active population can keep cancer risk down even when routine-checkup rates lag; states like Massachusetts and Maryland show the opposite — high clinical contact compensating for moderate activity.

Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2022 prevalence tables, age-adjusted, self-reported. Values rounded. Self-report introduces social-desirability bias for physical activity and recall bias for checkups; treat as directional, not exact.

State alcohol & drug use

What Americans drink and use, state by state

Self-reported prevalence from SAMHSA's National Survey on Drug Use and Health (NSDUH 2021–2022), broken out by substance and frequency. Most figures are past-30-day use; opioid misuse is past-year.

Alcohol — any use

Any drink in the past month. · past 30 days · 51 jurisdictions

national median 53.0%

What the patterns show

Alcohol clusters in the Upper Midwest, opioid misuse in Appalachia

Wisconsin, North Dakota, Montana and the Mountain North lead binge and heavy drinking; Utah is the clear outlier on the low end for almost every substance. Past-month marijuana use is highest in legal-recreational states (VT, DC, OR, MA, CO, ME, RI, WA). Opioid misuse and tobacco track each other closely and peak in West Virginia, Kentucky, and the broader Appalachian corridor — the same belt that carries the highest cancer mortality.

Why this matters for cancer

Three of these substances are Group 1 carcinogens

Alcohol (7 cancers including breast, colorectal, liver, head & neck) and tobacco (≥17 cancers, ~30% of all US cancer deaths) are IARC Group 1 carcinogens. Opioid misuse is not directly carcinogenic but correlates with delayed screening and later-stage diagnosis. Marijuana smoke contains many of the same combustion carcinogens as tobacco; epidemiology is still maturing.

Source: SAMHSA National Survey on Drug Use and Health (NSDUH), 2021–2022 state estimates, ages 12+. Self-reported; values rounded. Past-month prevalence except opioid misuse (past year).

State cancer & water quality

Cancer outcomes vs. drinking-water violations, by state

A 51-jurisdiction cross-analysis of CDC cancer incidence and mortality against EPA Safe Drinking Water Act health-based violations. Water quality is one of many environmental drivers; this view shows where the two co-vary.

Cancer metric:Water metric:

Cancer deaths per 100,000 vs water violations

Pearson r = 0.33

Water violation tiers:< 5%5–7%7–10%≥ 10%

Top 5 — cancer mortality

Kentucky195/100k · water 7.9%
West Virginia192/100k · water 11.6%
Mississippi184/100k · water 11.3%
Oklahoma184/100k · water 10.1%
Arkansas181/100k · water 10.4%

Top 5 — water violations

Alaska14.2% · mort 152/100k
New Mexico12.4% · mort 138/100k
Montana11.7% · mort 154/100k
West Virginia11.6% · mort 192/100k
Mississippi11.3% · mort 184/100k

Lowest 5 — cancer mortality

Utah123/100k · water 6.7%
Hawaii128/100k · water 3.4%
Colorado136/100k · water 7.2%
Arizona138/100k · water 9.7%
California138/100k · water 5.6%

All 51 jurisdictions

click a header to sort

State	Incidence /100k	Mortality /100k	Systems in violation %	Pop. on bad water %
Kentucky (KY)	510	195	7.9	11
West Virginia (WV)	489	192	11.6	16
Mississippi (MS)	451	184	11.3	15
Oklahoma (OK)	461	184	10.1	12
Arkansas (AR)	467	181	10.4	14
Alabama (AL)	458	178	8.1	11
Louisiana (LA)	475	178	9.5	13
Tennessee (TN)	467	178	8.2	11
Missouri (MO)	463	173	7.6	9
Indiana (IN)	462	171	7.7	10
Ohio (OH)	465	169	6.9	9
South Carolina (SC)	450	163	7.3	9
Iowa (IA)	489	162	8.0	10
Kansas (KS)	445	161	7.5	9
North Carolina (NC)	449	161	6.5	8
Delaware (DE)	469	159	6.8	9
Georgia (GA)	461	159	7.1	9
Illinois (IL)	466	159	6.4	8
Michigan (MI)	460	159	6.8	9
District of Columbia (DC)	446	158	1.2	2
Maine (ME)	491	158	9.1	11
Pennsylvania (PA)	477	158	6.1	8
Nevada (NV)	401	156	5.8	7
South Dakota (SD)	469	156	9.4	11
Nebraska (NE)	444	155	9.2	11
Wisconsin (WI)	468	155	7.0	9
Montana (MT)	437	154	11.7	14
North Dakota (ND)	462	154	8.9	10
Alaska (AK)	437	152	14.2	17
Virginia (VA)	437	152	6.4	8
Rhode Island (RI)	484	151	5.0	6
Maryland (MD)	442	149	4.2	6
New Hampshire (NH)	477	149	7.8	9
Vermont (VT)	463	149	8.2	10
Idaho (ID)	433	148	9.6	12
Texas (TX)	414	148	8.6	11
Oregon (OR)	429	146	8.4	10
Wyoming (WY)	422	146	10.8	13
Florida (FL)	437	145	5.5	7
Minnesota (MN)	469	145	6.2	7
New Jersey (NJ)	471	145	5.1	6
Massachusetts (MA)	461	144	4.7	5
Connecticut (CT)	470	143	4.9	6
Washington (WA)	437	143	7.1	9
Arizona (AZ)	389	138	9.7	13
California (CA)	419	138	5.6	9
New Mexico (NM)	384	138	12.4	16
New York (NY)	470	138	4.4	5
Colorado (CO)	410	136	7.2	8
Hawaii (HI)	395	128	3.4	5
Utah (UT)	372	123	6.7	8

What the correlation does and doesn't say

A real, modest signal — not a smoking gun

Across all 51 jurisdictions the correlation between water-system violations and cancer mortality is positive but moderate (Pearson r typically 0.3–0.5). States with the worst drinking-water compliance — West Virginia, Mississippi, New Mexico, Montana, Oklahoma, Louisiana — sit disproportionately in the high-mortality belt. But Kentucky has high mortality with mid-tier water, and California has below-average water issues with average mortality, so water is one driver among many (tobacco, obesity, screening, poverty, air quality).

Which contaminants matter for cancer

Arsenic, nitrate, radium, DBPs, PFAS

The IARC-classified or strongly suspected carcinogens most often driving SDWA violations: arsenic (bladder, lung, skin), nitrate (colorectal, thyroid), radium and radon (bone, leukemia), disinfection byproducts like trihalomethanes (bladder, colorectal), and the newer PFAS family (kidney, testicular). Rural and tribal systems carry disproportionate exposure.

Sources: CDC United States Cancer Statistics (USCS) 2017–2021, age-adjusted per 100,000. EPA SDWIS / ECHO Safe Drinking Water Act community water system summaries (latest reporting year); population-served figures approximated from EPA ECHO and NRDC "Watered Down Justice." Values rounded; ecological correlations do not establish causation.

Map · North vs South

Cancer on the map: where the burden lands

Age-adjusted cancer incidence and mortality per 100,000 by state. The South — defined by the US Census — carries consistently higher mortality, driven by smoking history, obesity, screening access, insurance coverage, and rural distance to care.

Metric:Color by:Overlay NCI cancer centers

Cancer deaths per 100k, age-adjusted

range 123–195

123

195

Corner badge = number of NCI-Designated Cancer Centers in that state (the federal designation for high-volume, research-grade cancer care). Red 0 = no NCI center in-state.

South vs North

South averages 168 deaths/100k

vs 150 in the North — a +12.3% gap. Census South: 17 states (17) including DC; everything else is North (34).

Highest deaths

Kentucky195
West Virginia192
Mississippi184
Oklahoma184
Arkansas181

Lowest deaths

Utah123
Hawaii128
Colorado136
New York138
New Mexico138

Cancer-care deserts

16 states with 0 NCI centers

Residents drive 4–10+ hours for trial access and complex multidisciplinary care. Mortality runs above the US mean in most of these states.

West Virginia192/100k
Mississippi184/100k
Oklahoma184/100k
Arkansas181/100k
Louisiana178/100k
Delaware159/100k
Maine158/100k
Nevada156/100k

High-volume hubs

States with the most NCI-Designated Cancer Centers

California7 centers · 138/100k
New York6 centers · 138/100k
Pennsylvania4 centers · 158/100k
Texas4 centers · 148/100k
Michigan3 centers · 159/100k
North Carolina3 centers · 161/100k

Map uses a tile-grid layout (each state = one equal-sized cell) so small Northeastern states are as visible as Texas. Region split follows the US Census Bureau definition. Rates are age-adjusted per 100,000, CDC USCS 2017–2021. NCI Cancer Center counts from the National Cancer Institute directory (2024, 65 centers in 36 states + DC). Hover any tile for the exact value.

World map · Cancer by country

The global cancer burden — incidence, mortality, and the rich-world paradox

Wealthy countries diagnose far more cancer per 100k (long lives + screening) but lose a smaller share of patients. Low-income countries diagnose less but die more — late presentation, no radiotherapy, no targeted drugs. WHO GLOBOCAN 2022.

New cases · 50 countries

17Kk

≈ 87% of global cases

Deaths · 50 countries

8Kk

per year, GLOBOCAN 2022

Highest mortality rate

162/100k

Mongolia

Highest incidence rate

419/100k

Australia

Metric:

World cancer-death map, sized by annual deaths

Each tile is a country. Tile size = annual cancer deaths. Color = continent. Hover for the mortality rate (age-standardized, per 100k).

AfricaAmericasAsiaEuropeOceania

Top 10 by death rate

Mortality rate (age-standardized, per 100k)

By continent

Continent	Avg incidence	Avg mortality	Mort/Inc	Annual deaths
Asia	170/100k	88/100k	0.52	5Kk
Europe	296/100k	102/100k	0.35	2Kk
Americas	237/100k	90/100k	0.38	1Kk
Africa	143/100k	90/100k	0.63	358k
Oceania	274/100k	95/100k	0.34	71k

The mortality-to-incidence ratio is the cleanest single proxy for cancer-care quality. Wealthy regions hover around 0.30 — most diagnosed patients survive. Low-income regions sit at 0.65+ — most diagnosed patients die. The gap is treatment, not biology.

The rich-world paradox

More diagnoses, fewer deaths

Australia (419/100k), Ireland (372), Canada (374), and the US (367) post the world's highest age-standardized incidence rates — yet their mortality rates (79, 98, 85, 86) sit at or below the global mean. Aging populations, intense screening, and access to surgery, radiotherapy, and modern systemic therapy convert diagnoses into long-term survivors.

Mongolia, Serbia, Hungary, Cuba, and Zimbabwe show the inverse: lower or middling incidence but the world's highest mortality rates. Liver cancer (HBV/HCV, alcohol), late-stage diagnosis, scarce radiotherapy machines (Sub-Saharan Africa: ≈1 LINAC per 5 million people vs ≈1 per 100k in the US), and limited drug access dominate.

Sources: WHO IARC GLOBOCAN 2022 — Cancer Today (age-standardized incidence and mortality, all cancers, both sexes); Ferlay et al., Int. J. Cancer 2024; WHO Global Atlas of Medical Devices 2022 (radiotherapy capacity). Rates are world-age-standardized per 100,000. Selection covers 50 countries representing ≈87% of global cancer deaths.

Innovation map · 17 landmark treatments

Breakthrough cancer treatments — where they were invented, and where you can actually get them

Modern oncology runs on roughly two dozen platform technologies: checkpoint inhibitors, CAR-T cell therapy, antibody-drug conjugates, radioligands, targeted kinase inhibitors, mRNA neoantigen vaccines, FLASH radiation, and tumor-infiltrating lymphocytes. These were born in specific labs in specific countries — and 25 years later, access to them still varies more by passport than by biology. Sources: FDA / EMA / PMDA / NMPA approval databases; Nature Medicine 2024 landmark approvals review; WHO Atlas of Medical Devices 2022; ASCO Annual Meeting 2024 plenary sessions.

Therapies tracked

approved or late-stage

Originating countries

USA, JP, DE, UK, NL, CH, IN, CU

Most therapies invented

🇺🇸 United States

Median US list price

$175k+

per course or year

Filter:

Where each breakthrough was born

8 originating countries

🇺🇸 United States7 therapies

Pembrolizumab (Keytruda) · Axicabtagene ciloleucel (Yescarta) · Sotorasib (Lumakras) · Tisagenlecleucel (Kymriah) · Da Vinci robotic surgery · Galleri multi-cancer early detection (MCED) blood test · Tumor-infiltrating lymphocyte (TIL) therapy

🇩🇪 Germany2 therapies

Lutetium-177 PSMA-617 (Pluvicto) · BNT122 / mRNA neoantigen vaccines

🇨🇭 Switzerland2 therapies

FLASH proton therapy · Imatinib (Gleevec)

🇯🇵 Japan2 therapies

Carbon ion radiotherapy · Trastuzumab deruxtecan (Enhertu)

🇮🇳 India1 therapy

NexCAR19

🇳🇱 Netherlands1 therapy

Lutetium-177 DOTATATE (Lutathera)

🇬🇧 United Kingdom1 therapy

Osimertinib (Tagrisso)

🇨🇺 Cuba1 therapy

Cuban CIMAvax-EGF

Where you can actually get them

Loading map…

Access concentrates in ~12 countries with FDA-equivalent regulators, hospital infrastructure for cell/radioligand therapy, and insurance/public coverage. Most of Sub-Saharan Africa, Central Asia, and rural Southeast Asia have access to none.

The therapies, one by one

17 of 17 shown

Pembrolizumab (Keytruda) — PD-1 checkpoint inhibitor

Immunotherapy

Born 2014 · 🇺🇸 United States · Merck / Dana-Farber

Used in: 40+ approved indications: melanoma, NSCLC, head & neck, MSI-high tumors, triple-negative breast

How it works: Blocks PD-1 receptor on T cells, releasing the immune brake tumors use to hide.

Access

🇺🇸 United States · ✓🇪🇺 European Union · ✓🇯🇵 Japan · ✓🇨🇳 China · ✓🇮🇳 India · limited🇧🇷 Brazil · limited🌍 Sub-Saharan Africa · Not available

Best-selling drug in human history ($25 B in 2023). $175,000/year US list price — a single dose costs more than the average household income in 100+ countries.

Axicabtagene ciloleucel (Yescarta) — CAR-T cell therapy

CAR-T

Born 2017 · 🇺🇸 United States · Kite / NIH / Gilead

Used in: Aggressive B-cell lymphoma, follicular lymphoma after 2nd-line failure

How it works: Patient's T cells are extracted, genetically reprogrammed with a chimeric antigen receptor targeting CD19, and reinfused — a 'living drug.'

Access

🇺🇸 United States · ✓🇪🇺 European Union · ✓🇬🇧 United Kingdom · ✓🇯🇵 Japan · ✓🇨🇦 Canada · ✓🇦🇺 Australia · ✓🇮🇳 India · limited🇨🇳 China · limited

List price ~$424,000 in the US; total episode cost often exceeds $1 M with hospitalization for cytokine release syndrome. Manufacturing takes 2–4 weeks per patient.

NexCAR19 — India's homegrown CAR-T

CAR-T

Born 2023 · 🇮🇳 India · ImmunoACT / IIT Bombay / Tata Memorial

Used in: B-cell lymphoma and acute lymphoblastic leukemia

How it works: Same CD19-targeting CAR architecture as Yescarta, but manufactured locally with humanized binders to lower neurotoxicity.

Access

🇮🇳 India · ✓🇲🇽 Mexico · Clinical trial only🇧🇷 Brazil · Clinical trial only

Priced at ~$40,000 — roughly one-tenth of US CAR-T. The first CAR-T developed and manufactured in the Global South. CDSCO approval October 2023.

Lutetium-177 PSMA-617 (Pluvicto) — radioligand therapy

Radioligand

Born 2015 · 🇩🇪 Germany · University Hospital Heidelberg / Endocyte / Novartis

Used in: Metastatic castration-resistant prostate cancer (PSMA-positive)

How it works: A small molecule binds PSMA on prostate cancer cells and delivers a beta-emitting Lutetium-177 atom that destroys the cell from inside.

Access

🇩🇪 Germany · ✓🇺🇸 United States · ✓🇪🇺 European Union · ✓🇦🇺 Australia · ✓🇬🇧 United Kingdom · ✓🇯🇵 Japan · ✓🇮🇳 India · limited

Pioneered in German academic medicine 5+ years before FDA approval. Patients traveled to Heidelberg, Bad Berka, and Munich for compassionate-use access. ~$42,000 per cycle.

Lutetium-177 DOTATATE (Lutathera) — neuroendocrine tumors

Radioligand

Born 2000 · 🇳🇱 Netherlands · Erasmus MC Rotterdam

Used in: Gastroenteropancreatic neuroendocrine tumors (somatostatin-receptor positive)

How it works: Same beta-emitter as Pluvicto, but targeted by a peptide that binds somatostatin receptors over-expressed on NETs.

Access

🇳🇱 Netherlands · ✓🇪🇺 European Union · ✓🇺🇸 United States · ✓🇨🇭 Switzerland · ✓🇦🇺 Australia · ✓

Rotterdam was performing this therapy off-label for 17 years before FDA approval in 2018. Showed 79% reduction in disease progression in the NETTER-1 trial.

FLASH proton therapy

Radiation

Born 2014 · 🇨🇭 Switzerland · CHUV Lausanne / Vincent Favaudon group, Institut Curie 🇫🇷

Used in: Glioblastoma, skin, head & neck (trials), pediatric brain (trials)

How it works: Delivers radiation in <1 second at 40+ Gy/second — 1,000× faster than standard. Tumors are killed; normal tissue is spared by an unexplained 'FLASH effect.'

Access

🇨🇭 Switzerland · Clinical trial only🇫🇷 France · Clinical trial only🇺🇸 United States · Clinical trial only🇳🇱 Netherlands · Clinical trial only🇯🇵 Japan · Clinical trial only

First human treatment performed in Lausanne in 2018. The FAST-01 trial (Cincinnati, 2022) confirmed safety. Could halve toxicity and shrink 30-session courses to one visit.

Carbon ion radiotherapy

Radiation

Born 1994 · 🇯🇵 Japan · QST / NIRS Chiba

Used in: Sarcoma, pancreatic, locally recurrent rectal, head & neck (especially salivary gland)

How it works: Heavy carbon nuclei deposit nearly all energy at a precise tumor depth (Bragg peak) and cause more complex DNA double-strand breaks than X-rays — overcoming radio-resistant tumors.

Access

🇯🇵 Japan · ✓🇩🇪 Germany · ✓🇮🇹 Italy · ✓🇨🇳 China · ✓🇦🇹 Austria · ✓🇰🇷 South Korea · ✓🇺🇸 United States · Not available

Only ~14 centers worldwide. Japan treats >2,000 patients/year. A facility costs $150–300 M — explaining why no center exists in the US despite 30 years of evidence.

Trastuzumab deruxtecan (Enhertu) — HER2 antibody-drug conjugate

Targeted

Born 2019 · 🇯🇵 Japan · Daiichi Sankyo / AstraZeneca

Used in: HER2+ and HER2-low breast, gastric, lung, colorectal

How it works: Trastuzumab antibody acts as a homing missile, carrying 8 molecules of a topoisomerase-I inhibitor directly into HER2-expressing cells.

Access

🇯🇵 Japan · ✓🇺🇸 United States · ✓🇪🇺 European Union · ✓🇬🇧 United Kingdom · ✓🇨🇦 Canada · ✓🇦🇺 Australia · ✓🇨🇳 China · ✓🇧🇷 Brazil · limited

DESTINY-Breast04 (NEJM 2022) extended life by 6.4 months in 'HER2-low' patients previously considered ineligible for HER2 therapy — redefining a whole subtype overnight.

Osimertinib (Tagrisso) — EGFR T790M inhibitor

Targeted

Born 2015 · 🇬🇧 United Kingdom · AstraZeneca Cambridge

Used in: EGFR-mutant non-small cell lung cancer (especially Asian patients, where EGFR mutations are 5× more common)

How it works: Third-generation tyrosine kinase inhibitor that crosses the blood-brain barrier and overcomes resistance from the T790M gatekeeper mutation.

Access

🇬🇧 United Kingdom · ✓🇪🇺 European Union · ✓🇺🇸 United States · ✓🇨🇳 China · ✓🇯🇵 Japan · ✓🇰🇷 South Korea · ✓🇹🇼 Taiwan · ✓🇮🇳 India · ✓ (generic)

ADAURA trial showed 5-year disease-free survival of 88% in early-stage EGFR+ lung cancer — unprecedented. Indian generic versions sell at ~5% of the brand-name price.

Imatinib (Gleevec) — the first targeted therapy

Targeted

Born 2001 · 🇨🇭 Switzerland · Novartis / Brian Druker, OHSU 🇺🇸

Used in: Chronic myeloid leukemia (CML), GIST, Ph+ ALL

How it works: Inhibits the BCR-ABL fusion kinase that drives CML — turning a uniformly fatal cancer into a chronic, manageable disease.

Access

🇨🇭 Switzerland · ✓🇺🇸 United States · ✓🇪🇺 European Union · ✓🇮🇳 India · ✓ (generic)🇧🇷 Brazil · ✓ (generic)🇿🇦 South Africa · ✓ (generic)🌐 Most of Asia & Africa · ✓ (generic)

India's 2013 Supreme Court ruling against Novartis allowed cheap generics, raising 10-year CML survival in low-income countries from <20% to ~80%. Considered a landmark for global drug access.

Sotorasib (Lumakras) — first KRAS G12C inhibitor

Targeted

Born 2021 · 🇺🇸 United States · Amgen Thousand Oaks

Used in: KRAS G12C-mutant lung and colorectal cancer

How it works: Covalently binds the previously 'undruggable' KRAS G12C mutation — a target chemists pursued for 40 years.

Access

🇺🇸 United States · ✓🇪🇺 European Union · ✓🇯🇵 Japan · ✓🇨🇦 Canada · ✓🇦🇺 Australia · ✓🇨🇳 China · Clinical trial only

Proved 'undruggable' targets can be cracked. Adagrasib (Mirati, 2022) and dozens of other KRAS-mutant inhibitors are now in trials.

Tisagenlecleucel (Kymriah) — pediatric CAR-T for ALL

CAR-T

Born 2017 · 🇺🇸 United States · University of Pennsylvania / Novartis

Used in: B-cell acute lymphoblastic leukemia (children & young adults), DLBCL

How it works: First-ever FDA-approved gene therapy; same CD19-CAR concept as Yescarta but tested first in children with relapsed ALL.

Access

🇺🇸 United States · ✓🇪🇺 European Union · ✓🇯🇵 Japan · ✓🇦🇺 Australia · ✓🇨🇭 Switzerland · ✓🇧🇷 Brazil · limited

Emily Whitehead, treated at age 6 in 2012, remains in remission 13 years later — the patient whose recovery launched the CAR-T era.

BNT122 / mRNA neoantigen vaccines

Immunotherapy

Born 2017 · 🇩🇪 Germany · BioNTech Mainz / Genentech 🇺🇸

Used in: Melanoma, pancreatic, colorectal (all trial-stage)

How it works: Tumor is sequenced, patient-specific mutations are identified, an mRNA vaccine encoding those neoantigens is manufactured in 4–6 weeks and trains T cells against the individual tumor.

Access

🇩🇪 Germany · Clinical trial only🇺🇸 United States · Clinical trial only🇬🇧 United Kingdom · Clinical trial only🇦🇺 Australia · Clinical trial only

Phase II pancreatic trial (Nature 2023): 8/16 patients mounted T-cell responses, none of those 8 had recurrence at 18 months — extraordinary in pancreatic cancer. Phase III melanoma trials reading out 2025–2027.

Da Vinci robotic surgery

Surgery

Born 2000 · 🇺🇸 United States · Intuitive Surgical Sunnyvale

Used in: Prostate, gynecologic, colorectal, head & neck, thoracic

How it works: Surgeon controls 4 wristed instruments via a console; allows millimeter-scale dissection through 8mm ports, reducing blood loss, hospital stay, and continence complications.

Access

🇺🇸 United States · ✓🇪🇺 European Union · ✓🇯🇵 Japan · ✓🇰🇷 South Korea · ✓🇨🇳 China · ✓🇧🇷 Brazil · limited🇮🇳 India · ✓ (urban only)

Over 13,000 systems worldwide perform 2.2 M procedures/year. The South Korean and Indian competing systems (Revo-i, SSi Mantra) cost half as much and are expanding access.

Galleri multi-cancer early detection (MCED) blood test

Diagnostic

Born 2021 · 🇺🇸 United States · Grail Inc. / Illumina

Used in: Detects shared methylation signatures across 50+ cancer types from a single blood draw

How it works: Sequences cell-free DNA in plasma, looks for cancer-specific methylation patterns, and predicts tissue of origin with ~88% accuracy.

Access

🇺🇸 United States · limited🇬🇧 United Kingdom · Clinical trial only🇦🇺 Australia · Clinical trial only

NHS-Galleri trial enrolling 140,000 UK volunteers; interim results expected 2026. US list price $949 — not yet covered by Medicare. Could redefine population screening if mortality benefit confirmed.

Cuban CIMAvax-EGF — therapeutic lung cancer vaccine

Immunotherapy

Born 2008 · 🇨🇺 Cuba · Center of Molecular Immunology, Havana

Used in: Advanced non-small cell lung cancer (maintenance after chemo)

How it works: Vaccine raises antibodies against epidermal growth factor (EGF), starving EGFR-driven lung cancer of its growth signal.

Access

🇨🇺 Cuba · ✓🇵🇪 Peru · ✓🇵🇾 Paraguay · ✓🇦🇷 Argentina · ✓🇧🇦 Bosnia · ✓🇺🇸 United States · Clinical trial only

Roswell Park Cancer Institute (Buffalo, NY) opened US trials in 2016 under a special FDA exemption. A reminder that breakthrough oncology innovation is not the exclusive product of wealthy countries.

Tumor-infiltrating lymphocyte (TIL) therapy — Lifileucel (Amtagvi)

Cell therapy

Born 2024 · 🇺🇸 United States · NIH Surgery Branch (Steven Rosenberg) / Iovance

Used in: Metastatic melanoma after checkpoint failure

How it works: T cells are extracted directly from the patient's tumor, expanded to billions of cells in the lab, and reinfused — the first FDA-approved solid-tumor cellular therapy.

Access

🇺🇸 United States · ✓🇪🇺 European Union · Clinical trial only🇦🇺 Australia · Clinical trial only

Approved February 2024 — the culmination of 40 years of work by Rosenberg's lab at the NIH. List price ~$515,000. First successful cell therapy for any solid tumor.

The medical tourism map

Heidelberg & Bad Berka (Germany), Rotterdam (NL), Lausanne (CH) for radioligand and FLASH; Chiba (Japan) and Heidelberg for carbon-ion; Boston, Houston, Memphis (US) for CAR-T; Mumbai (Tata Memorial) for NexCAR19 at one-tenth US prices. Patient travel for unavailable therapy is now a multi-billion-dollar segment.

The Global South is innovating

India's NexCAR19 (2023), Cuba's CIMAvax-EGF (2008), South Korea's Revo-i robot, China's domestic CAR-T programs (Relma-cel, Carteyva), and Indian generic Gleevec/osimertinib have collectively reshaped global access. The next decade of low-cost biosimilars (pembrolizumab biosimilar trials underway in 2025) could be transformative.

What's coming 2025–2028

mRNA neoantigen vaccines (Phase III melanoma readouts); allogeneic 'off-the-shelf' CAR-T (no patient cell extraction); CRISPR-edited solid-tumor cell therapies; alpha-emitting radioligands (Actinium-225); pan-RAS inhibitors; FLASH proton therapy moving toward first regulatory approval. Each will follow the same arc: US/EU/Japan first, Global South 5–10 years later, or via biosimilar/generic.

Sources: US FDA Oncology Approvals 2014–2024; EMA Centralised Procedure decisions; Japan PMDA approval database; China NMPA register; India CDSCO approval list; Nature Medicine 30:1209-1226 (2024) — "Cancer breakthrough approvals of the year"; Nature Reviews Drug Discovery 23:631-650 (2024); ASCO Annual Meeting plenary abstracts 2018–2024; WHO Global Atlas of Medical Devices 2022; Particle Therapy Co-Operative Group (PTCOG) facility registry; LANCET Oncol Global Health series 2023; The ASCO Post drug-price database 2024.

Country deep dive

Why China carries so much of the world's cancer burden

China has ~17% of the world's people but ~24% of new cancer cases and ~26% of cancer deaths. The reasons stack: a billion-plus aging population, a metabolic transition that arrived in one generation, the worst urban air in any G20 economy, contaminated water in industrial corridors, and the largest reservoir of cancer-driving chronic infections on earth.

China's share of the global total

Each bar shows China's % of the world for that quantity. The cancer bars run 1.4–2.5× the population bar — a real, not just demographic, overrepresentation.

Top cancers in China — 3,503K / yr shown

2022 GLOBOCAN. Lung, liver, stomach, and esophageal — the four cancers most tied to smoking, infection, and pollution — together account for over half of all cancer deaths.

Lung · 1061K cases · 733K deaths

Smoking + PM2.5 air pollution

Colorectal · 517K cases · 240K deaths

Urbanization, Western diet, obesity

Thyroid · 466K cases · 9K deaths

Over-detection from ultrasound screening

Liver · 368K cases · 317K deaths

Chronic HBV (~70M carriers), aflatoxin

Stomach · 359K cases · 261K deaths

H. pylori ~44%, salt-preserved foods

Breast (F) · 357K cases · 75K deaths

Later childbearing, obesity, screening

Esophageal · 224K cases · 187K deaths

Hot drinks, nitrosamines, Taihang belt

Cervical · 151K cases · 56K deaths

HPV; uneven screening coverage

Population scale

1.41 billion people, rapid aging

China holds ~17% of humanity but accounts for ~24% of cancer cases and ~26% of cancer deaths. The 60+ population grew from 178M (2010) to 297M (2023) and will pass 500M by 2050 — pushing absolute case counts up even as some age-adjusted rates fall.

297M (21%)

Adults 60+

4.82M

New cases / yr

2.57M

Deaths / yr

Obesity & metabolic shift

From famine to fast food in 40 years

Adult overweight prevalence climbed from ~20% (1992) to ~50% (2020); obesity from ~3% to ~16%. Childhood obesity rose ~6× since 1985. The shift is driving colorectal, breast, endometrial, kidney, and pancreatic cancer increases — especially in urban coastal provinces.

~50%

Adult overweight

~16%

Adult obesity

~140M

Diabetes adults

Air pollution

PM2.5 still 6–8× WHO guideline

National mean PM2.5 fell from ~62 µg/m³ (2013) to ~30 µg/m³ (2023) — real progress — but remains far above WHO's 5 µg/m³. Outdoor air pollution is classified IARC Group 1 (carcinogenic). Modeling attributes ~250K–400K lung cancer deaths per year in China to ambient PM2.5 alone.

~30 µg/m³

PM2.5 (2023)

5 µg/m³

WHO guideline

1.06M cases

Lung Ca / yr

Water & soil

"Cancer villages" along industrial rivers

Investigations along the Huai, Yangtze, and Pearl River basins documented clusters of digestive-tract cancers tied to industrial discharge, heavy metals, and nitrate-laden groundwater. Arsenic in well water across Inner Mongolia, Shanxi, and Xinjiang exposes 15–20M people above WHO limits — raising bladder, lung, and skin cancer risk.

~15–20M

Arsenic exposed

~450 documented

Cancer villages

Huai, Yangtze, Pearl

Affected basins

Chronic infections

HBV, H. pylori, HPV — the big three

Roughly 1 in 3 cancers in China are linked to chronic infection — the highest share of any major economy. ~70M chronic HBV carriers drive most of the world's liver cancer; H. pylori infects ~44% of adults and fuels stomach cancer; HPV vaccine coverage in adolescent girls is still under 5%.

~70M

Chronic HBV

~44%

H. pylori adults

<5% girls

HPV vax coverage

Tobacco & diet

300M+ smokers, salt + hot drinks

China consumes ~40% of the world's cigarettes; ~48% of adult men smoke. Daily salt intake (~10 g) remains roughly double WHO's 5 g target, and very-hot tea/soup is an IARC Group 2A esophageal carcinogen. Pickled and salt-preserved foods amplify gastric and esophageal risk in northern and central provinces.

~48%

Adult male smokers

~2.4 trillion

Cigarettes / yr

~10 g/day

Salt intake

Where it's heading

Falling fast

Stomach, esophageal, and cervical cancers — driven down by H. pylori treatment, refrigeration replacing salt curing, and slowly rising HPV vaccination.

Rising fast

Colorectal, breast, prostate, thyroid, and pancreatic — the "Western" cancers of obesity, sedentary work, processed food, and intensive imaging.

Still dominant

Lung and liver. Smoking has plateaued, not fallen; PM2.5 is improving but still hazardous; universal HBV birth-dose vaccination since 2002 will only fully pay off after 2040.

Sources: IARC GLOBOCAN 2022 (Sung et al., CA Cancer J Clin 2024); Cao et al., "Cancer burden of major cancers in China" (Chin Med J 2021); Zhao et al., "Epidemiology of cancer in China" (Lancet Oncol 2024); Chinese CDC Chronic Disease Surveillance 2018; WHO Global Air Quality Guidelines 2021; Greenpeace East Asia PM2.5 City Rankings 2023; Lu et al., "Prevalence of overweight and obesity in Chinese adults" (Lancet Diabetes Endocrinol 2021); Liu et al., "Hepatitis B in China" (Lancet Gastroenterol Hepatol 2022); Zhang et al., "Cancer villages along the Huai River" (Environ Pollut 2020); Smith et al., "Arsenic in drinking water in China" (Bull WHO 2013).

Cancer deep dive

Pancreatic cancer — the hardest common cancer

About 67,000 Americans are diagnosed and 52,000 die each year. The 5-year survival is ~13% — the worst of any common cancer — and pancreatic cancer is projected to pass colorectal as the #2 cancer killer in the US before 2030. The reason isn't one thing; it's a stack of biology, geography, and timing that all favor the tumor.

~67,000

New US cases / yr

~52,000

US deaths / yr

13%

5-yr survival

52%

Found at Stage IV

Why survival is so low: stage at diagnosis

The pancreas is buried behind the stomach with no nerve fibers that signal early pain. Most patients have no symptoms until the tumor has already spread.

Causes — risk factors ranked

Sort by relative risk (how much each factor multiplies your odds) or population attributable fraction (how much of all pancreatic cancer it explains).

Note: new-onset diabetes after 50 has a high relative risk but explains few cases because the underlying tumor is the cause, not a separate driver. It matters clinically as a screening trigger.

Somatic mutations — what's broken in the tumor

Four genes drive almost every pancreatic ductal adenocarcinoma. KRAS is the engine; the others are the failed brakes.

KRAS93% of tumors

Driver — locks cells in growth signaling. Targetable (G12C, G12D, pan-RAS) since 2021.

TP5372% of tumors

Tumor suppressor loss — removes apoptosis brake.

CDKN2A50% of tumors

Cell-cycle brake (p16) lost — uncontrolled division.

SMAD455% of tumors

TGF-β signaling — its loss predicts metastatic spread.

ARID1A8% of tumors

Chromatin remodeling — emerging therapeutic angle.

BRCA27% of tumors

DNA repair — sensitizes to platinum + PARP inhibitors (olaparib).

Germline syndromes — inherited risk

~10% of pancreatic cancer is hereditary. Identifying these patients enables surveillance (annual MRI/EUS) and targeted therapy.

Gene	Syndrome	Lifetime risk	×
BRCA2	HBOC	5–10%	6×
BRCA1	HBOC	2–3%	2×
PALB2	HBOC-like	2–3%	2–3×
ATM	ATM-related	5–10%	4–6×
CDKN2A	FAMMM (melanoma)	17%	13×
STK11	Peutz-Jeghers	11–36%	132×
MLH1/MSH2/MSH6	Lynch	3–4%	8×
PRSS1	Hereditary pancreatitis	40%	50–70×

Clinical actions per gene ▾

BRCA2: Olaparib maintenance (POLO trial). Screen from 50 (or 10 yrs before family case).
BRCA1: Platinum-sensitive; PARP under study.
PALB2: Same platinum/PARP biology as BRCA2.
ATM: Annual MRI/EUS screening eligible (CAPS consortium).
CDKN2A: Skin + pancreas surveillance from 40.
STK11: Highest pancreatic risk of any syndrome.
MLH1/MSH2/MSH6: MMR-deficient tumors respond to immunotherapy.
PRSS1: Lifetime smoking avoidance is mandatory.

The 27-year head start the tumor has on you

Hopkins/Iacobuzio-Donahue timing studies show that from the first KRAS mutation to the moment a patient feels sick, roughly 27 years pass — but metastatic seeding happens ~3 years before diagnosis. The window for early detection is real, but narrow.

Normal ductal cell

2+12 yrs

KRAS mutation — earliest PanIN-1 lesion

3+17 yrs

CDKN2A, TP53 loss — PanIN-2/3

4+21 yrs

SMAD4 loss — invasive PDAC, ~1 cm

5+24 yrs

Metastatic seeding

6+27 yrs

Clinical diagnosis (median)

Warning signs that should not wait

Painless jaundice — yellow eyes/skin, dark urine, pale stool. Most specific single sign of pancreatic head tumor.
New-onset diabetes after 50 with weight loss — get pancreatic imaging.
Persistent mid-back pain radiating from upper abdomen, worse lying flat.
Unexplained weight loss ≥5% in 6 months.
Steatorrhea — pale, greasy, floating stools from fat malabsorption.
Unprovoked blood clots (Trousseau's sign) — DVT or PE without obvious cause.

Treatment — what actually moves survival

Surgery (Whipple / distal) — the only cure, but only ~20% are resectable at diagnosis. Refer to a high-volume center (>20 cases/yr) — mortality drops 3×.
FOLFIRINOX — multi-drug chemotherapy; doubles median survival vs gemcitabine in fit patients (PRODIGE-24, PRODIGE-35).
Gemcitabine + nab-paclitaxel — standard for patients not fit for FOLFIRINOX.
Olaparib (PARP inhibitor) — maintenance for germline BRCA1/2 metastatic disease (POLO trial).
KRAS G12D / pan-KRAS inhibitors — RMC-6236, MRTX1133; first clinical responses in 2024–25 in the ~90% of tumors with mutant KRAS.
Pembrolizumab — only for the ~1% of tumors that are MSI-high (Lynch syndrome).

Who qualifies for surveillance today

There is no population screening for pancreatic cancer — the disease is too rare and current tests are too imperfect. But CAPS consortium guidelines recommend annual MRI or endoscopic ultrasound for:

• Germline carriers (BRCA2, PALB2, ATM, CDKN2A, STK11, MLH1/MSH2) with a family history
• Peutz-Jeghers carriers regardless of family history (132× risk)
• Familial pancreatic cancer kindreds: ≥2 first-degree relatives
• Hereditary pancreatitis (PRSS1) carriers from age 40

For everyone else, the single highest-yield action is to never smoke and to take new-onset diabetes after 50 seriously — ask for imaging if you've also lost weight.

Sources: SEER 2025 Cancer Statistics (Siegel et al., CA Cancer J Clin 2025); Rahib et al., "Projecting cancer incidence and deaths to 2040" (JAMA Netw Open 2021); Yachida & Iacobuzio-Donahue, "Distant metastasis occurs late during pancreatic cancer genetic evolution" (Nature 2010); Klein et al., "Genetic susceptibility to pancreatic cancer" (Mol Carcinog 2012); Goggins et al., "Management of patients with increased risk for familial pancreatic cancer: updated CAPS consortium" (Gut 2020); Conroy et al., PRODIGE-24/25 (NEJM 2018); Golan et al., POLO trial (NEJM 2019); Strickler et al., RMC-6236 ASCO 2024.

Pancreatic cancer · country comparison

How likely is pancreatic cancer where you live?

Pancreatic cancer is rare per year but has a meaningful lifetime probability. The age-standardized incidence rate (ASR, per 100,000 person-years) lets you compare countries fairly by stripping out age-structure differences. The lifetime-risk percentage is a rough ≈80-year cumulative proxy (ASR × 80 ÷ 100,000), not a formal cumulative incidence — use it for ordering, not for clinical counseling.

Source: WHO IARC GLOBOCAN 2022, both sexes, all ages.

Global average · ASR

4.8 / 100k

≈ 0.38% lifetime

United States · ASR

8.2 / 100k

≈ 0.66% lifetime (1 in 152)

Highest country

Uruguay 12.1

≈ 0.97% lifetime

Lowest tracked

Niger 0.6

≈ 0.05% lifetime

Region

Highlight country

United States ranks #29 of 82 tracked countries with an ASR of 8.2 per 100,000 person-years — roughly 0.66% lifetime probability (about 1 in 152), or 1.7× the global average.

Why the gap is so wide

• Aging populations — risk rises sharply after 60, so older countries report higher ASR even after standardization because of completeness of diagnosis.
• Smoking and heavy alcohol — two of the strongest modifiable PDAC risk factors, concentrated in Central/Eastern Europe and the Southern Cone.
• Obesity and type 2 diabetes — independent risk drivers, rising fastest in high-income and middle-income countries.
• Registry quality — low-income regions underreport because of limited cross-sectional imaging and post-mortem confirmation; true African and South Asian rates are likely higher than shown.

How to read the lifetime percentage

• ASR is an annual rate; the lifetime % uses an 80-year multiplier as a crude cumulative proxy.
• It ignores competing mortality, sex differences, and family history — actual personal risk varies severalfold.
• The US SEER formal lifetime risk is ~1.7% (≈1 in 64) — close to the ASR-derived ≈0.66% × ~2.5 adjustment for late-life concentration of cases.
• Use the chart for relative ordering; use SEER / national registries for clinical counseling.

Pancreatic cancer · early detection

Catching pancreatic cancer early — and why pancreatitis matters

Only about 12% of pancreatic cancers are found at a localized stage today, where 5-year survival jumps to ~44%. The score below shows who current guidelines say should be screened, what tests they use, and how often chronic inflammation of the pancreas (pancreatitis) precedes a cancer diagnosis.

5-yr survival · localized

44%

≈ Stage I, surgical candidates

5-yr survival · regional

16%

Spread to nearby nodes/vessels

5-yr survival · distant

Metastatic at diagnosis

Found at localized stage

12%

SEER 2014–2020

Who current guidelines screen (CAPS / ACG / NCCN)

There is no general-population screening for pancreatic cancer — the tests aren't accurate enough at low baseline risk. Screening is reserved for high-risk individuals, defined roughly as a 5%+ lifetime risk.

Hereditary pancreatitis (PRSS1, SPINK1)
≈ 40–55% lifetime risk
Start: Age 40 — or 20 years after pancreatitis onset
Peutz–Jeghers syndrome (STK11)
≈ 11–36% lifetime risk
Start: Age 35
CDKN2A / familial atypical mole-melanoma
≈ 10–17% lifetime risk
Start: Age 40
BRCA2 + family history of pancreatic cancer
≈ 5–10% lifetime risk
Start: Age 50, or 10 yrs before youngest affected relative
BRCA1, PALB2, ATM, MLH1/MSH2 (Lynch) + family history
≈ 5% lifetime risk
Start: Age 50
Familial pancreatic cancer (2+ first-degree relatives)
≈ 8–12% lifetime risk
Start: Age 50, or 10 yrs before youngest affected relative
New-onset diabetes after age 50 + weight loss
6–8× general population in the 3 yrs after onset
Start: Discuss imaging — not a formal screening indication yet

Sources: International Cancer of the Pancreas Screening (CAPS) Consortium 2020 update; ACG Clinical Guideline 2020; NCCN Genetic/Familial High-Risk Assessment v2.2024.

MRI / MRCP

Annual

Pros: No radiation. Best detection of small cystic lesions and main-duct changes.

Cons: Misses ~10% of solid lesions <1 cm. Requires gadolinium.

Endoscopic ultrasound (EUS)

Annual, alternating with MRI

Pros: Highest sensitivity for sub-centimeter solid masses; can biopsy in the same session.

Cons: Sedation, small risk of pancreatitis (~1%), operator-dependent.

CA 19-9 + fasting glucose / HbA1c

Every 6–12 months alongside imaging

Pros: Trend matters more than single value. New-onset diabetes can flag occult tumor.

Cons: CA 19-9 is not diagnostic; ~10% of people don't produce it (Lewis-negative).

Pancreatitis — the under-discussed risk multiplier

Chronic inflammation of the pancreas damages DNA repair and promotes KRAS-mutant clone expansion. The longer it lasts, the higher the cancer risk.

US acute pancreatitis cases / yr

275,000

Leading GI reason for hospital admission

Acute → chronic pancreatitis

~10%

After a single severe episode

Chronic pancreatitis · pancreatic cancer risk

13.3×

Pooled RR vs. general population (meta-analysis)

Hereditary pancreatitis · lifetime cancer risk

40–55%

By age 70 (PRSS1 mutations)

Gallstones40–70% of acute cases

Heavy alcohol use25–35% of acute · ~60% of chronic

Triglycerides > 1000 mg/dL2–4% of acute

Smoking2× risk of chronic pancreatitis; independent of alcohol

Genetic (PRSS1, SPINK1, CFTR)Most hereditary / early-onset cases

Post-ERCP1–5% of procedures

Sources: Yadav & Lowenfels (Gastroenterology 2013) — incidence; Raimondi et al. (Best Pract Res Clin Gastroenterol 2010) — chronic pancreatitis → cancer meta-analysis; Howes et al. (Clin Gastroenterol Hepatol 2004) — hereditary pancreatitis cohort; NIDDK Digestive Diseases Statistics 2023.

What you can actually do

Know your family history. Two or more first-degree relatives with pancreatic cancer, or any BRCA/PALB2/ATM/Lynch mutation in your family, qualifies most people for genetics referral.
Don't ignore a pancreatitis episode. Even one severe attack changes your long-term risk — ask about follow-up imaging at 6–12 months and address the cause (gallstones, alcohol, triglycerides).
Take new-onset diabetes seriously after age 50, especially with unexplained weight loss. The 3 years after onset carry the highest occult-tumor risk.
Stop smoking. It's the single largest modifiable risk for both pancreatitis and pancreatic cancer (RR ≈ 2.2 in current smokers).
Keep alcohol moderate. Risk of chronic pancreatitis rises sharply above ~4 drinks/day.

Pancreatic cancer vaccine pipeline

Vaccines being tested against the deadliest common cancer

PDAC is driven by somatic KRAS, TP53, CDKN2A and SMAD4 mutations that accumulate over decades. These trials don't prevent the random mutation events themselves — they train the immune system to recognize the resulting neoantigens (especially mutant KRAS) and clear residual or pre-clinical disease. Eligibility and status link directly to the trial record.

Who qualifies for prevention vaccines today?

Click a row to filter trials

A universal childhood vaccine doesn't work — somatic KRAS mutations don't exist yet, and targeting wild-type KRAS would cause pancreas autoimmunity. The trial design that does work: identify carriers whose lifetime PDAC risk is high enough that risk/benefit flips, then enroll them in surveillance + vaccine protocols. Baseline general-population lifetime risk is ~1.7% (≈1 in 64).

Germline marker	Lifetime PDAC risk	× baseline	Enrolls in
BRCA2	5–10%	≈5×	PancVAX (NCT05013216), autogene cevumeran (post-resection)
BRCA1	2–5%	≈2×	PancVAX, surveillance + PARP studies
PALB2	5–8%	≈4×	PancVAX, CAPS surveillance + vaccine arms
ATM	5–9%	≈4×	PancVAX, mKRAS peptide registries
CDKN2A (FAMMM)	15–20%	≈10×	PancVAX (priority cohort), CAPS5
STK11 (Peutz-Jeghers)	11–36%	≈15–20×	PancVAX (high-priority), CAPS5 lifetime surveillance
PRSS1 (hereditary pancreatitis)	~40% by 70	≈25×	PancVAX (priority), pancreatitis registries
Lynch (MLH1/MSH2/MSH6/PMS2)	4–6%	≈3×	PancVAX, KRAS + MMR-deficient combo trials
TP53 (Li-Fraumeni)	2–7%	≈2–4×	PancVAX, whole-body MRI + vaccine protocols
Familial PDAC (≥2 affected FDRs)	8–12%	≈5–7×	PancVAX, CAPS5 surveillance
General population (no marker)	~1.7%	1× (baseline)	Not eligible for prevention vaccines — risk/benefit unfavorable

Risk ranges from NCCN Genetic/Familial High-Risk Assessment Guidelines (Pancreatic v2.2024), CAPS Consortium consensus, and Hu et al. JAMA 2018 (multi-gene panel testing in PDAC). Trial enrollment based on ClinicalTrials.gov records — always confirm with the listed NCT and a genetic counselor.

Phase

Setting

Autogene cevumeran (BNT122 / RO7198457)

Phase IIAdjuvant

BioNTech + Genentech + MSKCC · mRNA neoantigen

Mechanism: Individualized mRNA encoding up to 20 tumor neoantigens identified from the resected pancreatic tumor; primes neoantigen-specific CD8+ T cells, given with atezolizumab + mFOLFIRINOX after Whipple.
Eligibility: Resected PDAC (R0/R1), ECOG 0–1, tumor tissue available for neoantigen prediction, recovered from surgery within ~9 weeks, no prior chemo for PDAC.
Status: Randomized Phase II enrolling (~260 patients) after Phase I showed neoantigen-specific T-cell responses in 8/16 patients with longer recurrence-free survival in responders (Nature 2023).
Readout: Primary RFS readout expected 2027–2028.
Trial ID: NCT05968326

↗ ClinicalTrials.gov · NCT05968326

ELI-002 7P (amphiphile mKRAS vaccine)

Phase IIAdjuvant

Elicio Therapeutics · Peptide (KRAS)

Mechanism: Lymph-node-targeted amphiphile peptide cocktail against 7 mutant KRAS variants (G12D/R/V/C/A/S, G13D) plus CpG adjuvant; trains T cells to surveil residual mKRAS+ disease after surgery.
Eligibility: Resected PDAC or CRC harboring a covered mKRAS mutation, ctDNA- or serum-tumor-marker-positive minimal residual disease after standard adjuvant therapy.
Status: AMPLIFY-7P Phase II ongoing after Phase I (AMPLIFY-201) showed T-cell responses in 84% and biomarker reduction in 77% of evaluable patients (Nat Med 2024).
Readout: Interim RFS data 2025–2026.
Trial ID: NCT05726864

↗ ClinicalTrials.gov · NCT05726864

GVAX Pancreas + nivolumab + CRS-207

Phase IIMetastatic

Johns Hopkins / Sidney Kimmel CCC · Whole-cell (GVAX)

Mechanism: Irradiated allogeneic pancreatic tumor cells engineered to secrete GM-CSF, primed with low-dose cyclophosphamide, boosted by Listeria-vectored mesothelin (CRS-207), combined with PD-1 blockade.
Eligibility: Previously treated metastatic PDAC, ECOG 0–1, adequate organ function, no active autoimmune disease, no steroid >10 mg prednisone equivalent.
Status: STELLAR and follow-on combinations active; prior Phase II (ECLIPSE) missed OS but signaled benefit in vaccine-induced mesothelin-specific T-cell responders.
Readout: Ongoing combination cohorts; biomarker-driven enrichment under study.
Trial ID: NCT03190265

↗ ClinicalTrials.gov · NCT03190265

Algenpantucel-L (HyperAcute Pancreas)

Phase IIIAdjuvant

NewLink Genetics (legacy) · Algenpantucel (HyperAcute)

Mechanism: Allogeneic pancreatic cancer cells engineered to express α-Gal epitopes, triggering hyperacute rejection–style immunity that cross-primes anti-tumor T cells.
Eligibility: Historical: resected PDAC after Whipple, ECOG 0–1, given with adjuvant gemcitabine ± chemoradiation.
Status: IMPRESS Phase III (722 patients) did NOT improve OS vs standard adjuvant chemo (JAMA Oncol 2020). Listed here for context — program discontinued.
Readout: Negative — informs design of next-generation allogeneic vaccines.
Trial ID: NCT01072981

↗ JAMA Oncology 2020 · IMPRESS

Mesothelin-targeted DC vaccine

Phase I/IIMaintenance

Multiple academic centers · Dendritic cell

Mechanism: Autologous monocyte-derived dendritic cells pulsed with mesothelin peptides or WT1, reinfused to drive a tumor-antigen-specific CTL response in patients with stable or minimal-residual disease.
Eligibility: PDAC with stable disease or no measurable disease after first-line chemo, adequate leukapheresis yield, HLA typing where required, no active immunosuppression.
Status: Several investigator-initiated trials across Japan, EU, and US; durable T-cell responses reported, OS benefit unproven outside small series.
Readout: Heterogeneous; awaiting larger randomized data.
Trial ID: NCT03114631

↗ ClinicalTrials.gov · NCT03114631

KRAS G12D / G12V peptide vaccine (PancVAX-style)

Phase IPrevention

Johns Hopkins / MD Anderson · Peptide (KRAS)

Mechanism: Mutant-KRAS long peptides plus poly-ICLC adjuvant in high-risk individuals (familial PDAC, germline carriers) to generate KRAS-specific T-cell memory before tumor formation.
Eligibility: Germline BRCA1/2, PALB2, ATM, CDKN2A, STK11/PRSS1, or Lynch carriers with ≥2 affected first-degree relatives; or IPMN under surveillance. ECOG 0–1, no active cancer in 5 years.
Status: Phase I safety/immunogenicity ongoing; first true 'prevention vaccine' attempt in pancreatic oncology.
Readout: Immune-response endpoints 2025–2026; clinical benefit will need decades-long follow-up.
Trial ID: NCT05013216

↗ ClinicalTrials.gov · NCT05013216

Listeria-vectored mesothelin (CRS-207) monotherapy

Phase IIMetastatic

Aduro / Bristol Myers Squibb (legacy) · Listeria-vectored

Mechanism: Live-attenuated Listeria monocytogenes engineered to secrete mesothelin; activates both innate (STING/IFN) and adaptive (mesothelin-specific T-cell) responses.
Eligibility: Metastatic PDAC after ≥1 prior line, ECOG 0–1, no active infection, no Listeria allergy, not pregnant, no significant valvular disease (Listeria endocarditis risk).
Status: Combination strategies continue (with GVAX, anti-PD-1, or chemo); monotherapy benefit modest.
Readout: Used as a backbone in combination protocols.
Trial ID: NCT02004262

↗ ClinicalTrials.gov · NCT02004262

VXM01 (DNA plasmid · VEGFR-2)

Phase I/IIMetastatic

VAXIMM · DNA plasmid

Mechanism: Oral Salmonella-vectored DNA vaccine encoding VEGFR-2; targets tumor vasculature rather than tumor cells, combined with checkpoint blockade.
Eligibility: Advanced PDAC progressing on standard therapy, ECOG 0–1, no severe cardiovascular disease, no chronic immunosuppression.
Status: Phase I/II completed in PDAC and glioblastoma; immune responses observed, clinical benefit being explored in combinations.
Readout: Combination data with anti-PD-L1 reported in select cohorts.
Trial ID: NCT03750071

Breast cancer risk per birth

Lancet pooled analysis, 47 studies, 150,000 women

−4.3%

Breast cancer risk per 12 months breastfeeding

Lancet 2002; independent of parity

−20%

Ovarian cancer per full-term pregnancy

Collaborative Group reanalysis, 2012

−30 to −40%

Endometrial cancer in parous vs nulliparous women

Epidemiologic Reviews, multiple cohorts

Interactive estimate

See how your reproductive history shifts your risk

Estimates apply the published relative risks above. Educational only — not a clinical tool, and absolute lifetime risk depends on many other factors.

Have you had children?

Why pregnancy is protective

Terminal differentiation of breast tissue. A full-term pregnancy drives undifferentiated Lobule Type 1 cells into mature Lobule Type 4 cells, which are far less susceptible to carcinogen-induced mutation (Russo & Russo, landmark work at Fox Chase).
Fewer ovulations. Each ovulation creates a small wound on the ovarian surface that must be repaired. Pregnancy and lactation suppress ovulation for ~12–18+ months per child, lowering cumulative ovarian epithelial damage — the leading mechanistic theory for ovarian cancer reduction.
Progesterone exposure. High pregnancy progesterone opposes unopposed estrogen in the endometrium, dramatically reducing endometrial hyperplasia and downstream cancer risk.
Permanent gene-expression changes. Post-pregnancy breast tissue shows lasting epigenetic reprogramming (p53 activity, immune-cell infiltration patterns) that persists for decades.

Age at first birth matters

The protective effect is strongest when the first full-term pregnancy happens early. After ~30–35, a first pregnancy can transiently increase short-term breast cancer risk before lifetime risk converges.

Age at first birth	Lifetime breast cancer risk vs nulliparous
< 20	~50% lower
20–24	~30% lower
25–29	~10% lower
30–34	~similar
≥ 35 or nulliparous	~20–40% higher

MacMahon et al., WHO Bulletin (foundational); confirmed by CARE Study and the Nurses' Health Study cohorts.

Breastfeeding: a dose-response curve

The 2002 Lancet collaborative reanalysis pooled data from 47 studies across 30 countries (150,000 women). For every 12 months of cumulative breastfeeding, breast cancer relative risk fell by 4.3% — on top of the 7% reduction per birth. A woman with 3 children who breastfed each for ~12 months would see roughly a ~30% lower lifetime breast cancer risk versus a nulliparous peer.

Mechanisms: prolonged amenorrhea (fewer ovulatory cycles), terminal duct lobular shedding of damaged cells during weaning, lower lifetime estrogen exposure.

Key studies

Breast cancer and breastfeeding (Lancet 2002)

Pooled 47 studies, 50,302 cases. RR ↓ 4.3% per 12mo breastfeeding + 7.0% per birth.

pubmed.ncbi.nlm.nih.gov ↗

Parity & ovarian cancer (Collaborative Group, 2012)

Reanalysis of 45 studies; each pregnancy ↓ ovarian risk ~20%, plateau after 3.

pubmed.ncbi.nlm.nih.gov ↗

Russo & Russo — pregnancy & breast differentiation

Identified Lobule Type 1→4 maturation as the protective mechanism in animal and human breast tissue.

pubmed.ncbi.nlm.nih.gov ↗

Endometrial cancer & parity (Epidemiologic Reviews)

Each birth ↓ endometrial risk ~15%; nulliparity is one of the strongest single risk factors.

pubmed.ncbi.nlm.nih.gov ↗

Transient breast cancer risk after first birth

Pre-menopausal Breast Cancer Collaborative — first pregnancy after 35 raises risk for ~20 years before convergence.

pubmed.ncbi.nlm.nih.gov ↗

Million Women Study — parity & multiple cancers

UK cohort of 1.3M women: parity protective for breast, ovarian, endometrial; neutral/slight ↑ for cervical.

pubmed.ncbi.nlm.nih.gov ↗

Honest caveats

Not all cancers. Parity slightly increases cervical cancer risk (more HPV exposure opportunity) and has a small transient ↑ in breast cancer risk in the first 5–10 years postpartum before long-term protection dominates.
BRCA1/2 carriers are different. Parity does not reliably reduce breast cancer risk in BRCA1 carriers; in BRCA2, effects are smaller than in the general population. Discuss with a genetic counselor.
Reproductive choices are personal. This is data about biology, not a prescription. The same protection comes from understanding the mechanisms — minimizing lifetime ovulatory cycles (e.g. combined oral contraceptives ↓ ovarian cancer ~50% after 10 years of use) and avoiding unopposed estrogen.

Social epidemiology

Marital status and cancer outcomes

Across nearly every major cancer, unmarried patients are diagnosed at later stages, receive curative treatment less often, and die from their disease at higher rates than married patients — even after adjusting for age, sex, race, income, insurance, and tumor biology. The effect rivals or exceeds the survival benefit of many modern chemotherapy regimens. The leading explanation is the "social support" mechanism: a partner notices symptoms earlier, drives to appointments, helps adhere to therapy, and supports recovery. Separated patients consistently fare worst.

Average cancer-mortality excess

+19.4% vs married, across 10 cancers

Cancer-specific mortality — hazard ratio vs married (HR = 1.00)

Pooled SEER + meta-analytic estimates

HRs > 1 mean higher death rate than married patients with the same cancer, after adjustment for age, sex, race, stage, and treatment. Separated patients show the largest gap on every site. Source: Aizer 2013 (JCO); Wang 2020 meta-analysis.

Diagnosed at metastatic stage

% of patients presenting with distant-stage disease

Received definitive treatment

% receiving curative-intent therapy when eligible

Earlier detection

Partners notice unexplained weight loss, a new lump, blood in stool, persistent cough — and push for a workup. Solo patients are more likely to wait, normalize symptoms, or skip a follow-up.

Treatment adherence

Chemo and radiation are physically brutal. Having someone to drive you, manage nausea, and enforce the schedule materially raises the share of patients who complete a curative course.

Recovery & mental health

Depression rates after a cancer diagnosis are 2–3× higher in unpartnered patients; depression in turn worsens immune function, treatment compliance, and survival. Loneliness is itself a measured mortality risk factor.

What this is — and isn't

Marriage is a marker of social support, not a treatment. A close family member, adult child, friend network, or caregiver can provide the same benefit.
Most studies adjust for age, race, income, and insurance — so the gap is not mainly a wealth or coverage story. It survives even within Medicare-only cohorts.
Effect size differs by cancer: largest in cancers with curative options (prostate, head & neck, colorectal), smaller in uniformly fatal cancers (pancreatic).
Same-sex partnered, cohabiting, and remarried patients track with the "married" group in studies that capture them — the active ingredient is the partner, not the paperwork.

Social determinants

Income, education, and cancer

Cancer mortality follows a steep socioeconomic gradient. Americans without a high-school diploma die of cancer at more than 2× the rate of those with a graduate degree, and the poorest income quintile carries roughly 30% higher cancer mortality than the richest — even though incidence is similar. The gap is not mainly biological. It is built from differences in smoking and obesity, screening uptake, time-to-diagnosis, insurance status, and the share of patients who can complete a full course of curative treatment. The gap has widened over the last three decades as the post-1991 cancer-mortality decline accrued disproportionately to the college-educated.

Poorest quintile mortality

188 / 100k

Richest quintile mortality

142 / 100k

Excess mortality, Q1 vs Q5

+32%

Cancer mortality by household-income quintile — All cancers

Age-adjusted, per 100,000 / yr

The gradient is steepest for cancers driven by tobacco (lung) and prevented by routine screening (cervical, colorectal). Cervical cancer mortality is 2.6× higher in the poorest quintile — almost entirely because Pap and HPV screening uptake is lower. Source: NCI SEER; Siegel 2024.

Mortality by education level (25+ adults)

Age-adjusted per 100,000 / yr — all cancers

Men without a high-school diploma die of cancer at 2.5× the rate of men with a graduate degree. The gap is wider in men because smoking is more steeply patterned by education.

The gap is widening, not closing

All-cancer mortality, US adults 25–74, by education

College-educated Americans have captured most of the modern cancer-mortality decline: −37% since 1995. The least-educated have improved only −12% over the same period. Source: CDC NCHS multiple-cause file.

Screening uptake by income quintile

% up-to-date with USPSTF-recommended screening — BRFSS / NHIS 2022

The lung-cancer screening gap is the most striking — lung LDCT is the screening test eligible patients in the poorest quintile need most, and use the least. Only ~4% of eligible low-income smokers are screened, vs ~9% of the richest quintile (both well below the public-health target of 50%+).

Risk-factor patterning

Smoking is now ~3× more prevalent among adults without a high-school diploma than among college graduates. Obesity and physical inactivity follow the same gradient. These behaviors explain roughly half the mortality gap.

Screening & early detection

Lower-income patients are less likely to be up-to-date on Pap, mammography, colonoscopy, and lung LDCT. They present at later stage, when curative options shrink and mortality rises.

Insurance & access

Medicaid and uninsured patients have longer time-to-diagnosis, are referred to comprehensive cancer centers less often, and receive guideline-concordant therapy at lower rates — even within the same hospital system.

Treatment completion

Lost wages, childcare, and transportation barriers mean low-income patients are more likely to miss radiation sessions, delay chemo cycles, or stop early — measurably reducing 5-year survival.

What this is — and isn't

This is a mortality gradient, not an incidence gradient. For many cancers (breast, prostate, melanoma) higher-income groups are actually diagnosed more — they get screened more. But they die less, because they are caught earlier and treated more completely.
Education is a stronger predictor than income for some cancers because it also captures health literacy, smoking initiation in adolescence, and lifetime occupational exposure.
The gap is not destiny: Medicaid expansion, employer-paid screening leave, and patient-navigator programs have measurably narrowed the gradient in states and health systems that adopted them.
Race and geography are correlated with income and education but contribute independent effects — see the regional and race/ethnicity sections.

Men's health · germ cell tumors

Testicular cancer — what actually causes it

Testicular cancer is the most common solid tumor in men aged 15–39, with ~10,000 new US cases a year. Unusually for a cancer, it is overwhelmingly a developmental disease: the seeds are laid down in fetal life, and the tumor surfaces decades later in young adulthood. Smoking, diet, and most "lifestyle" levers play almost no role. The dominant drivers are an undescended testicle, family history, prior testicular cancer, ancestry, and the broader "testicular dysgenesis syndrome" linking poor semen quality, hypospadias, and germ-cell tumors to in-utero endocrine disruption. The good news: cure rates exceed 95% even with metastatic disease, thanks to cisplatin-based chemotherapy.

Peak incidence

Age 25–29

~13.2 per 100,000 men/year (US)

Strongest known risk

Cryptorchidism

~4–5× lifetime risk; orchidopexy by age 1 helps

5-yr survival, all stages

95%

99% if caught localized — self-exam matters

Relative risk vs general male population

RR = 1.0 means average risk; higher = greater

A second tumor in the remaining testicle carries the highest relative risk (~12×), but absolute risk is still modest (≈2–5% over 15 years). Cryptorchidism and family history are the practical screening flags.

Incidence by age (US)

New cases per 100,000 men per year — unusual peak in young adulthood.

Rising incidence, 1975–2022

Age-standardized rate per 100,000 — incidence has roughly doubled in most of the West. Endocrine-disruptor exposure in pregnancy is the leading hypothesis.

Fetal origin

Germ cell tumors arise from primordial germ cells that fail to mature in fetal life. The precursor lesion — "germ cell neoplasia in situ" — is laid down before birth and dormant for ~20 years.

Endocrine disruption

Maternal exposure to phthalates, pesticides, and other anti-androgens during the masculinization window (gestation weeks 8–14) is the leading explanation for the post-WWII rise in incidence.

Genetics

Heritability is among the highest of any cancer (~37%). Common variants near KITLG, SPRY4, and BAK1 account for much of the familial risk; no single high-penetrance gene dominates.

Cryptorchidism

An undescended testicle sits in the warmer abdomen, which both reflects and worsens the underlying dysgenesis. Surgical fix (orchidopexy) before age 1 roughly halves later cancer risk.

5-year relative survival by stage

SEER 2014–2020

Testicular cancer is the model case for "chemo-curable" solid cancer. Cisplatin-based regimens (BEP) introduced in the late 1970s by Lawrence Einhorn turned a near-uniformly fatal disease into a 95%+ cure rate.

Signs worth a same-week urology visit

A painless lump, swelling, or firm area in one testicle (most common presentation).
A dull ache or heaviness in the scrotum or lower abdomen.
A sudden collection of fluid (hydrocele) in the scrotum.
Breast tenderness or enlargement (β-hCG–secreting tumors).
Back pain, cough, or shortness of breath in a young man — can signal retroperitoneal or lung metastases.

Self-exam (a slow roll of each testicle between thumb and fingers in a warm shower, monthly) is free and catches most early tumors. Population screening is not recommended — but men with cryptorchidism, a family history, or prior testicular cancer should examine themselves and have a low threshold for ultrasound.

What chemotherapy actually feels like

How long chemo takes — and how painful it really is

Chemotherapy isn't one experience. Duration ranges from a few weeks to lifelong daily pills, and the pain comes mostly from side effects (neuropathy, mucositis, bone pain from growth-factor support) rather than the infusion itself. Pain ratings below summarize typical patient-reported intensity at worst — not every patient experiences them.

Sort

Pain level

Pancreas (resectable)

mFOLFIRINOX

AdjuvantPain 5/5 · Very severe

Total duration6 months (12 cycles)

Bar scaled to 1 year. Cycle: Every 2 weeks (46-hour pump) · Route: IV infusion

Pain profile: Considered one of the harshest regimens. Severe abdominal cramping, mucositis, and oxaliplatin neuropathy are common; many patients reduce dose or stop early.
Side effects: Diarrhea, neuropathy, neutropenia, fatigue, weight loss.

↗ PRODIGE 24 (NEJM 2018)

Breast (early HER2−)

AC-T (doxorubicin/cyclophosphamide → paclitaxel)

AdjuvantPain 4/5 · Severe

Total duration~4–5 months (8 cycles)

Bar scaled to 1 year. Cycle: Every 2–3 weeks · Route: IV infusion

Pain profile: Infusions are not painful themselves, but taxane-induced neuropathy (burning/tingling in hands and feet) and bone pain from growth-factor support (pegfilgrastim) are commonly rated 6–8/10.
Side effects: Hair loss, fatigue, nausea, neutropenia, neuropathy, mouth sores.

↗ NCCN Breast Cancer Guidelines v4.2024

Colon (stage III)

FOLFOX (5-FU / leucovorin / oxaliplatin)

AdjuvantPain 4/5 · Severe

Total duration3 or 6 months (6 or 12 cycles)

Bar scaled to 1 year. Cycle: Every 2 weeks (46-hour pump) · Route: IV infusion

Pain profile: Oxaliplatin causes intense cold-triggered throat and hand pain within hours of infusion, and cumulative neuropathy that can persist for years. Port pain is mild.
Side effects: Cold dysesthesia, neuropathy, diarrhea, fatigue, low platelets.

↗ IDEA Collaboration (NEJM 2018)

Lung (NSCLC, stage III)

Carboplatin + paclitaxel + concurrent radiation

CurativePain 4/5 · Severe

Total duration~6–7 weeks chemoradiation + 1 year durvalumab

Bar scaled to 1 year. Cycle: Weekly during radiation · Route: IV infusion

Pain profile: Esophagitis from radiation is the dominant pain (swallowing rated 7–9/10 for weeks). Chemo itself adds neuropathy and fatigue rather than acute pain.
Side effects: Esophagitis, pneumonitis, neuropathy, fatigue, low blood counts.

↗ PACIFIC trial (NEJM 2017)

Testicular (good-risk)

BEP (bleomycin/etoposide/cisplatin)

CurativePain 4/5 · Severe

Total duration~9 weeks (3 cycles)

Bar scaled to 1 year. Cycle: Every 3 weeks · Route: IV infusion

Pain profile: Severe nausea and mucositis dominate. Cisplatin can cause painful neuropathy and ringing in the ears; bleomycin can trigger painful lung inflammation.
Side effects: Nausea/vomiting, tinnitus, neuropathy, neutropenia, hair loss.

↗ NCCN Testicular Cancer Guidelines v1.2024

Acute lymphoblastic leukemia (pediatric)

Multi-phase ALL protocol (induction → consolidation → maintenance)

CurativePain 4/5 · Severe

Total duration2.5–3.5 years total

Bar scaled to 1 year. Indigo = treatment continues beyond 1 year.

Cycle: Continuous phases · Route: Intrathecal + IV

Pain profile: Lumbar punctures for intrathecal methotrexate, steroid-induced bone pain, and vincristine jaw/neuropathy pain are the main complaints. Maintenance phase is mostly oral and far easier.
Side effects: Bone pain, mood changes, neuropathy, infection risk, hair loss.

↗ Children's Oncology Group AALL protocols

Breast (HER2+)

TCHP (docetaxel/carboplatin/trastuzumab/pertuzumab)

NeoadjuvantPain 3/5 · Moderate

Total duration~4–5 months (6 cycles) + 1 year HER2 antibody

Bar scaled to 1 year. Cycle: Every 3 weeks · Route: IV infusion

Pain profile: Severe diarrhea and mouth pain are the dominant complaints; infusion reactions occur but acute pain is uncommon. HER2-only maintenance is well tolerated.
Side effects: Diarrhea, mucositis, neutropenia, alopecia, cardiac monitoring.

↗ APHINITY trial (NEJM 2017)

Diffuse large B-cell lymphoma

R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)

CurativePain 3/5 · Moderate

Total duration~4–5 months (6 cycles)

Bar scaled to 1 year. Cycle: Every 3 weeks · Route: IV + Oral

Pain profile: Generally better tolerated than solid-tumor regimens. Bone pain from growth-factor support and vincristine-related neuropathy are typical; severe pain is uncommon.
Side effects: Fatigue, neuropathy, neutropenia, alopecia, steroid effects.

↗ NCCN B-cell Lymphomas v5.2024

Multiple myeloma

VRd (bortezomib/lenalidomide/dexamethasone)

CurativePain 3/5 · Moderate

Total duration8–12 months induction + maintenance for years

Bar scaled to 1 year. Cycle: Every 3–4 weeks · Route: IV + SC

Pain profile: Bortezomib commonly causes painful peripheral neuropathy (burning feet); subcutaneous injections sting. Existing bone-lesion pain often improves as disease responds.
Side effects: Neuropathy, fatigue, low counts, insomnia from steroids.

↗ SWOG S0777 (Lancet 2017)

Ovarian (advanced)

Carboplatin + paclitaxel

AdjuvantPain 3/5 · Moderate

Total duration~4–5 months (6 cycles) + PARP maintenance

Bar scaled to 1 year. Cycle: Every 3 weeks · Route: IV infusion

Pain profile: Paclitaxel-induced muscle and joint aches days 2–5 of each cycle are common (rated 5–7/10). Neuropathy accumulates with cycles.
Side effects: Myalgia, neuropathy, alopecia, fatigue, low platelets.

↗ NCCN Ovarian Cancer Guidelines v2.2024

Prostate (metastatic hormone-sensitive)

Docetaxel + ADT

PalliativePain 2/5 · Mild

Total duration~4–5 months (6 cycles)

Bar scaled to 1 year. Cycle: Every 3 weeks · Route: IV infusion

Pain profile: Among the gentler IV regimens. Nail changes, mild neuropathy, and short-lived fatigue dominate; many patients continue working.
Side effects: Fatigue, neuropathy, nail changes, hot flashes from ADT.

↗ CHAARTED trial (NEJM 2015)

Chronic myeloid leukemia

Imatinib (or 2nd-gen TKI)

MaintenancePain 1/5 · Minimal

Total durationIndefinite (often lifelong)

Bar scaled to 1 year. Indigo = treatment continues beyond 1 year.

Cycle: Daily oral pill · Route: Oral

Pain profile: Not traditional chemo. Most patients have mild muscle cramps and occasional GI upset; pain is rarely a feature. Many live decades on treatment.
Side effects: Cramps, mild nausea, fluid retention, fatigue.

↗ IRIS trial 10-year follow-up (NEJM 2017)

Evidence-based symptom management

Coping strategies for the most common side effects

Tactics below are drawn from ASCO, MASCC/ESMO, NCCN Supportive Care, and Cochrane reviews. They reduce — not eliminate — symptoms; combine with the medications your oncology team prescribes.

Nausea & vomiting

Strong

Triggered by chemo acting on the gut and brain's chemoreceptor trigger zone; worst in the first 24–72h after infusion.

Take prescribed antiemetics on a schedule for the first 3 days, not just when nauseated.
Eat small, cool, bland meals every 2–3h; cold food has less odor.
Ginger 1–1.5 g/day (capsules or tea) reduces nausea in RCTs.
Acupressure wristbands (P6/Nei-Guan point) show modest benefit.

Call the team if: vomiting >24h, can't keep fluids down, or signs of dehydration.

↗ ASCO Antiemetic Guideline 2020

Fatigue

Strong

Multi-factorial: anemia, inflammation, sleep disruption, deconditioning. Often the most disabling symptom.

Aerobic + resistance exercise 3–5×/week is the single most effective intervention (Cochrane).
Short daytime naps <30 min; protect a consistent sleep window at night.
Cognitive behavioral therapy and mindfulness reduce fatigue scores by ~20%.
Treat reversible causes: iron, B12, thyroid, depression.

Call the team if: sudden severe fatigue, chest pain, or shortness of breath at rest.

↗ NCCN Cancer-Related Fatigue v2.2024

Peripheral neuropathy

Moderate

Platinums, taxanes, vincristine, bortezomib damage sensory nerves; can be permanent if not caught early.

Report tingling early — dose reduction is the only proven prevention.
Duloxetine 30–60 mg/day is the only drug ASCO endorses for painful CIPN.
Cooling gloves/socks during taxane infusions reduce incidence by ~30%.
Balance and strength exercises lower fall risk; avoid barefoot walking.

Call the team if: weakness, foot drop, loss of bladder/bowel control, or rapid worsening.

↗ ASCO CIPN Guideline 2020

Mouth sores (mucositis)

Strong

Rapidly dividing mouth-lining cells are damaged by 5-FU, methotrexate, anthracyclines, and radiation.

Oral cryotherapy (ice chips 5 min before, during, 30 min after 5-FU bolus) cuts severe mucositis ~50%.
Brush with soft toothbrush 4×/day; floss gently; alcohol-free rinses.
Salt + baking soda rinses (¼ tsp each in 8 oz water) 4–6×/day.
Avoid acidic, spicy, crunchy foods; try cold, soft, high-protein options.

Call the team if: can't swallow saliva, white patches, fever, or bleeding ulcers.

↗ MASCC/ISOO Mucositis Guidelines 2020

Diarrhea

Strong

Irinotecan, 5-FU, capecitabine, and tyrosine-kinase inhibitors injure intestinal lining.

Start loperamide 4 mg at first loose stool, then 2 mg after each — up to 16 mg/day.
Replace fluids with oral rehydration (electrolyte solutions, not plain water alone).
BRAT diet (banana, rice, applesauce, toast) and low-fiber foods short-term.
Avoid dairy, caffeine, sugar alcohols, and high-fat foods during flares.

Call the team if: >6 stools/day, blood, fever ≥38°C, or signs of dehydration.

↗ ESMO Diarrhea Guidelines 2018

Infection risk (neutropenia)

Strong

Chemo lowers neutrophils 7–14 days after infusion; fever then is a medical emergency.

Check temperature any time you feel unwell; ≥38.0°C = call the on-call team immediately.
Hand hygiene before eating; avoid sick contacts and crowded indoor spaces at the nadir.
Skip raw oysters, unwashed produce, soft unpasteurized cheeses, and undercooked eggs/meat.
Take prescribed pegfilgrastim/G-CSF as scheduled; don't skip due to bone pain.

Call the team if: fever ≥38°C, shaking chills, or new cough/burning urination — go to ED.

↗ NCCN Prevention & Treatment of Infections v3.2024

Hair loss (alopecia)

Moderate

Chemo attacks rapidly dividing hair follicles; starts 2–3 weeks in, regrows 3–6 months after.

Scalp cooling caps during infusion preserve >50% of hair in ~50–65% of breast-cancer patients.
Cut hair short before shedding — less traumatic, less mess.
Use mild sulfate-free shampoo, soft brush, avoid heat/dye/tight styles.
Sun protection: SPF 30+ on scalp, soft cotton head covering.

Call the team if: scalp pain, sores, or signs of infection where the skin is exposed.

↗ SCALP trial (JAMA 2017)

Chemo-brain (cognitive fog)

Emerging

Inflammation, fatigue, hormone shifts, and direct neuronal effects impair memory and focus in ~30% of patients.

Aerobic exercise 150 min/week improves processing speed and memory.
Cognitive rehab apps (BrainHQ, Lumosity) with structured weekly programs show small gains.
Sleep hygiene: 7–9h, fixed schedule, screens off 60 min before bed.
Externalize memory: calendars, lists, single-task, do hard work at your peak hour.

Call the team if: sudden confusion, severe headache, vision change, or word-finding loss — call 911.

↗ ASCO Survivorship Care 2022

Anxiety & low mood

Strong

Up to 40% of patients meet criteria for clinical anxiety or depression during treatment.

Mindfulness-based stress reduction (8-week MBSR) reduces distress scores ~30%.
Brief CBT (6–12 sessions) is first-line for moderate anxiety/depression.
Peer support groups (in-person or moderated online) improve coping and reduce isolation.
Ask about SSRIs early — escitalopram and sertraline are well-tolerated alongside chemo.

Call the team if: thoughts of self-harm or hopelessness — call 988 (US) or local crisis line immediately.

↗ ASCO Anxiety & Depression Guideline 2023

Pain ratings are typical worst-case patient-reported intensity compiled from NCCN guidelines, pivotal trial toxicity tables, and patient-reported-outcome studies. Individual experience varies widely with dose, age, comorbidities, and supportive care. Always discuss expectations with the treating oncology team. Coping strategies are educational and not a substitute for personalized medical advice.

Pharmacologic prevention

Preventive drugs that lower the odds of genetic disruption

Chemoprevention uses approved drugs and vaccines to interrupt the steps that turn DNA damage into cancer — blocking inflammation, hormone-driven proliferation, or the viral infections that drive mutation in the first place.

Reduction in colorectal cancer

≈30%

10+ years low-dose aspirin (Rothwell, Lancet 2010)

Reduction in ER+ breast cancer

≈49%

5y tamoxifen or anastrozole, durable 10+ years

Reduction in cervical cancer

≈88%

HPV vaccine before age 17 (NEJM 2020)

Stack the effects

Toggle drugs you’d be a candidate for to see combined relative risk reduction.

Not medical advice. This page is for education only and is not a substitute for professional medical advice, diagnosis, or treatment. Chemoprevention is a clinical decision. Every drug here has real harms (bleeding, bone loss, endometrial cancer, sexual side effects, B12 deficiency). The right answer depends on your personal risk, age, and what you’re willing to trade. Talk to a licensed clinician — preferably one who knows your family history — before starting anything for prevention alone.

Action levers

Cancer risks — and the behaviors that de-risk them

Tell us your current profile and we'll narrow the list to only the de-risk behaviors that actually apply to you — and call out the ones you've already covered.

Personalize to me

Your profile

Smoking

BMI

Alcohol

Exercise

Diet

UV / tanning

HPV vaccine

Hepatitis B

Hepatitis C

H. pylori

Sleep / shift

Mood

Age

Sex assigned at birth

Colon screening current

Mammography current

LDCT current

Your risk-score summary

100/ 100 modifiableHigh modifiable risk

Based on the levers below that apply to you and aren't already addressed. Lower is better — addressing the top items has the largest expected effect on lifetime risk.

Do these first

#1 · HPV-93%
HPV vaccine (Gardasil 9)
#2 · Stomach (H. pylori)-91%
Test-and-treat eradication
#3 · Colorectal screening-69%
Colonoscopy or annual FIT

5 actions apply to you8 already addressed

HPV-93% net risk

Your risk

Unvaccinated, high-risk HPV exposure

×1.50

HPV causes ~5% of all cancers worldwide — cervical, anal, oropharyngeal, vulvar, vaginal, penile.

What to do

HPV vaccine (Gardasil 9)

×0.10

Real-world data: ~90% reduction in cervical cancer when vaccinated before age 17; near-elimination of HPV-16/18 lesions.

Lei et al. Swedish cohort, NEJM 2020; Falcaro et al. UK cohort, Lancet 2021.

Stomach (H. pylori)-91% net risk

Your risk

Untreated H. pylori infection

×6.00

Causes most non-cardia gastric adenocarcinoma; classified IARC Group 1.

What to do

Test-and-treat eradication

×0.55

Meta-analyses: eradication cuts gastric cancer incidence ~45% in high-prevalence populations.

Ford et al. Cochrane review 2020.

Colorectal screening-69% net risk

Your risk

Never screened after age 45

×1.30

Most colorectal cancers arise from adenomas detectable years before invasion.

What to do

Colonoscopy or annual FIT

×0.40

Colonoscopy with polypectomy lowers colorectal mortality ~60% over 15 years; annual FIT ~30%.

Nordic-European NordICC trial 2022; Zauber et al. (NEJM 2012).

Breast screening-40% net risk

Your risk

No mammography after age 50

×1.25

Late-stage diagnosis is the main driver of breast cancer mortality.

What to do

Biennial mammography 50–74

×0.75

Meta-analyses show ~22–25% lower breast-cancer mortality with regular screening.

USPSTF 2024 evidence review; Marmot Independent Review (Lancet 2012).

Diet-28% net risk

Your risk

Daily red & processed meat

×1.18

Processed meat IARC Group 1; red meat Group 2A. Mostly colorectal cancer.

What to do

Mediterranean / high-fiber diet

×0.85

≥25 g fiber/day cuts colorectal risk ~10%; Mediterranean pattern ~13% lower overall cancer incidence.

IARC Monograph Vol 114; PREDIMED trial; EPIC cohort.

Already covered ✓

Levers where your current profile already matches the recommended de-risk state.

Tobaccocovered
You've never smoked.
Body weightcovered
Your BMI is in the healthy range.
Alcoholcovered
≤7 drinks/week — already below the high-risk threshold.
Physical activitycovered
You meet WHO activity guidelines.
UV exposurecovered
Low UV exposure — keep using SPF.
Hepatitis B/Ccovered
Sleep & circadiancovered
Healthy sleep pattern.
Mental healthcovered
Mood reported as stable.

Net risk = derisk RR ÷ risk RR. "Applies to you" filters out levers where your current state already matches the recommendation, or where eligibility (age, sex, smoking history) excludes you. Educational, not clinical — pair with a primary-care visit.

Hematologic malignancies

Blood cancers: who gets diagnosed, when, and why

Leukemias, lymphomas, and myeloma look like one category but behave like seven different diseases. Age, sex, inherited mutations, and pre-existing blood or immune disorders each pull the odds in very different directions.

~187,000

New US blood-cancer diagnoses each year

ACS Facts & Figures 2024 (leukemia + lymphoma + myeloma)

10%

Of all new US cancer diagnoses are hematologic

SEER 2017–2021

Median age at diagnosis (NHL, CLL, myeloma)

SEER

1.4×

Average male-to-female incidence ratio

SEER pooled hematologic malignancies

Incidence by age group

Rate per 100,000 per year (SEER 2017–2021). ALL spikes in childhood; CLL, NHL, and myeloma are diseases of older adults; AML climbs steadily after 50. Hodgkin lymphoma is the rare bimodal cancer — peaks in young adulthood and again after 65.

Male vs female

Every major blood cancer is more common in men. CLL has the strongest skew — nearly 2 men diagnosed for every woman. Hodgkin lymphoma is the closest to even.

Likely drivers: X-linked tumor-suppressor dosage, androgen signaling on lymphoid progenitors, and higher cumulative occupational/benzene exposure.

Why age matters so much

Clonal hematopoiesis (CHIP) is found in ~10% of people over 70 — a pre-malignant pool of mutated stem cells that drives the AML and MDS curves upward.
Thymic involution after puberty changes the T-cell repertoire and contributes to the Hodgkin/NHL shifts across decades.
Childhood ALL is a distinct biology — most cases trace to a prenatal initiating translocation (ETV6-RUNX1) plus a postnatal immune trigger (Greaves' delayed-infection hypothesis).
Myeloma is almost never seen under 30 — it requires decades of plasma-cell evolution through MGUS and smoldering disease.

Inherited / germline drivers

Most blood cancers arise from acquired (somatic) mutations, but a recognized minority — and almost all childhood ALL surges — trace to germline syndromes. Family-history screening matters.

Germline driver	Cancers	Effect size
Down syndrome (trisomy 21)	ALL, AML (esp. AMKL)	10–20× ALL risk in children; 500× AMKL <5y
Li-Fraumeni (TP53)	ALL, lymphoma	Elevated childhood ALL; broad solid-tumor spectrum
Fanconi anemia	AML, MDS	~30% cumulative AML risk by age 40
Ataxia-telangiectasia (ATM)	Lymphoma, CLL	~25% lifetime lymphoid malignancy
CEBPA / RUNX1 / DDX41 germline	AML, MDS	Familial AML; often presents 40–60y
Bloom, Nijmegen breakage	Leukemia, lymphoma	Defective DNA repair → high lymphoid risk
Family hx of CLL (1st-degree)	CLL	~7× risk; strongest familial signal of any blood cancer
MGUS (monoclonal gammopathy)	Multiple myeloma	1% per year progression to myeloma

Antecedent & co-occurring disorders

A large fraction of adult blood cancers are downstream of an earlier hematologic, infectious, autoimmune, or iatrogenic condition. Surveillance of these states is one of the highest-yield prevention strategies in hematology.

Pre-existing condition	Leads to	Magnitude
MDS (myelodysplastic syndrome)	AML	~30% transform to AML within 5 years
MGUS	Myeloma	1%/yr progression; lifetime ~25%
Smoldering myeloma	Myeloma	10%/yr for first 5 years
Polycythemia vera / ET / MF (MPN)	AML	5–20% lifetime leukemic transformation
Aplastic anemia	AML/MDS	~15% at 10 years post-diagnosis
HIV	NHL, Hodgkin	60–200× NHL; 10× Hodgkin
EBV infection	Hodgkin, Burkitt, NK/T-cell	Drives ~40% of classical Hodgkin; nearly all endemic Burkitt
H. pylori	Gastric MALT lymphoma	Eradication cures ~75% of early MALT
Hepatitis C	Splenic marginal zone, DLBCL	2–3× NHL; antiviral cure ↓ risk
Autoimmune (Sjögren, RA, celiac, Hashimoto)	NHL	Sjögren 15–20× MALT lymphoma; RA 2× DLBCL
Prior chemo/radiation	t-AML / t-MDS	5–10% within 10 years of alkylators or topo-II inhibitors

Sources: SEER 2017–2021 age-specific incidence; ACS Cancer Facts & Figures 2024; Leukemia & Lymphoma Society Facts 2023–24; Greaves M., Nature Reviews Cancer (childhood ALL); Landgren O. et al. on MGUS progression (NEJM 2009); Jaiswal S. et al. on CHIP (NEJM 2014). Educational only.

AI disruption index

How ready is each cancer for the AI era?

A 0–10 readiness score for every major cancer across five dimensions: screening, biomarkers, imaging, AI pathology models, and AI-designed drugs in clinical trials. Every rating links to its primary source so you can verify it.

Readiness score (0–10)

Click a bar to inspect the breakdown. Score = sum of 5 dimensions (None = 0, Partial = 1, Mature = 2).

Lung — 10/10

Each rating links to its primary source.

Screening available

Mature

Annual LDCT for eligible smokers

↗ USPSTF: Lung Cancer Screening (2021)

Biomarkers available

Mature

EGFR, ALK, ROS1, KRAS-G12C, PD-L1, ctDNA

↗ NCCN NSCLC Guidelines

Imaging effective

Mature

AI nodule detection mature (Optellum, Riverain, Aidence)

↗ Optellum Virtual Nodule Clinic — FDA cleared

AI pathology models

Mature

PD-L1 quantification, TMB scoring

↗ PathAI PD-L1 product

AI-designed drugs in trials

Mature

Insilico ISM001, BenevolentAI, Recursion oncology in trials

↗ Insilico Medicine pipeline

Cancer	Screening available	Biomarkers available	Imaging effective	AI pathology models	AI-designed drugs in trials	Score
Lung	Mature ↗	Mature ↗	Mature ↗	Mature ↗	Mature ↗	10/10
Breast	Mature ↗	Mature ↗	Mature ↗	Mature ↗	Partial ↗	9/10
Colorectal	Mature ↗	Mature ↗	Partial ↗	Mature ↗	Partial ↗	8/10
Prostate	Partial ↗	Mature ↗	Mature ↗	Mature ↗	Partial ↗	8/10
Melanoma / Skin	Partial ↗	Partial ↗	Mature ↗	Mature ↗	Partial ↗	7/10
Liver (HCC)	Partial ↗	Partial ↗	Mature ↗	Partial ↗	Partial ↗	6/10
Leukemia / Lymphoma	None ↗	Mature ↗	Partial ↗	Mature ↗	Partial ↗	6/10
Cervical	Mature ↗	Mature ↗	None ↗	Partial ↗	None ↗	5/10
Gastric	Partial ↗	Partial ↗	Partial ↗	Partial ↗	Partial ↗	5/10
Brain (Glioma)	None ↗	Partial ↗	Mature ↗	Partial ↗	Partial ↗	5/10
Ovarian	None ↗	Partial ↗	Partial ↗	Partial ↗	Partial ↗	4/10
Bladder	None ↗	Partial ↗	Partial ↗	Partial ↗	Partial ↗	4/10
Thyroid	None ↗	Partial ↗	Mature ↗	Partial ↗	None ↗	4/10
Pancreatic	None ↗	None ↗	Partial ↗	Partial ↗	Partial ↗	3/10

Source policy: ratings prefer (1) USPSTF / NCCN / WHO / NCI guidelines for screening & biomarkers, (2) FDA cleared-device records or peer-reviewed validation studies for imaging & AI pathology, and (3) FDA approvals or company pipelines listed on ClinicalTrials.gov for AI-designed drugs. Educational only — not clinical advice.

DNA damage & repair

How DNA damage accumulates with age

Every cell takes on roughly 60,000 DNA lesions per day. Almost all are repaired — but the small fraction that escape accumulate linearly with age, and repair capacity itself declines after midlife. That two-sided curve is the engine of cancer incidence.

~70,000

DNA lesions per cell per day

Lindahl Nature 1993; Tubbs Cell 2017

~40

Mutations fixed per year, intestinal stem cell

Blokzijl Nature 2016

~150

Mutations per year, bronchial cell (smoker)

Alexandrov Science 2016

~60%

Drop in repair capacity, age 20 → 80

Gorbunova Aging Cell 2007

Somatic mutation burden by age

Mutations per cell, by tissue — toggle to filter.

Bronchial: smoker (≈150/yr)Skin: heavy UV exposure (≈180/yr)

What's actually breaking the DNA

Daily lesions per cell, by source. Oxidative damage dominates — it's the everyday cost of breathing — followed by replication errors and spontaneous base loss.

Oxidative damage (8-oxoG, ROS)40%

Hydrolytic depurination20%

Cytosine deamination1%

Replication errors30%

Alkylation (endogenous + diet)5%

Double-strand breaks0.1%

UV photoproducts (skin only)4%

Repair capacity falls with age

The DNA-damage response (BER, NER, MMR, HR, NHEJ) loses efficiency with age — chromatin gets stiffer, sirtuins drop, NAD+ falls. By 80, repair operates at roughly 40% of young-adult capacity.

Source: Gorbunova et al., Aging Cell 2007 (NER decline); Pan et al., Cell Metab 2016 (NAD+/sirtuin axis); Vermeij Nature 2016.

Damage source	~Lesions/cell/day	Share	Mechanism	Repair pathway
Oxidative damage (8-oxoG, ROS)	24,000	40%	Mitochondrial respiration byproducts; chronic inflammation amplifies it.	Base excision repair (OGG1, MUTYH)
Hydrolytic depurination	12,000	20%	Spontaneous loss of bases from the sugar-phosphate backbone.	Base excision repair (APE1)
Cytosine deamination	600	1%	C → U conversion; if unrepaired creates C→T transitions.	Base excision repair (UDG)
Replication errors	18,000	30%	DNA polymerase slip; ~1 error per 10⁹ bases per division × 3×10⁹ bp.	Mismatch repair (MLH1, MSH2/6)
Alkylation (endogenous + diet)	3,000	5%	Methylation by SAM, nitrosamines, processed meat.	Direct reversal (MGMT), BER
Double-strand breaks	50	0.1%	Replication-fork collapse, ionizing radiation, V(D)J recombination.	HR (BRCA1/2, RAD51), NHEJ (KU70/80, DNA-PK)
UV photoproducts (skin only)	2,350	4%	Sun exposure: cyclobutane pyrimidine dimers, 6-4 photoproducts.	Nucleotide excision repair (XPA-G)

Sources: Lindahl T., Nature 1993 (instability of DNA); Hoeijmakers J., NEJM 2009 (DNA damage, aging, and cancer); Blokzijl F. et al., Nature 2016 (mutational landscapes of adult stem cells); Lee-Six H. et al., Nature 2018 (HSC mutations); Alexandrov L. et al., Science 2016 (smoking mutagenesis); Cagan A. et al., Nature 2022 (somatic mutation rates across mammals). Educational only.

Genomic Defense

Slowing the mutation clock — and catching it early in blood

The DNA-damage section above shows mutations stack up linearly with age. Two practical levers exist: agents that reduce the rate of damage across tissues, and blood tests that can flag mutational activity before a tumor is visible. Every entry links to its source.

Broad-spectrum anti-mutation agents

Metformin

Cohort

Activates AMPK, lowers insulin/IGF-1, reduces 8-oxoG oxidative DNA lesions.

Dose: Start 500 mg/day with food, titrate to 1500–2000 mg/day (divided BID) over 4 weeks. XR form better tolerated.
Eligibility: Type 2 diabetes, prediabetes (A1c 5.7–6.4%), PCOS, BMI ≥30 with insulin resistance. Off-label longevity/prevention use is investigational.
Renal: eGFR ≥45: full dose. eGFR 30–44: max 1000 mg/day, reassess q3mo. eGFR <30 or dialysis: contraindicated.
Hepatic: Avoid in active liver disease or cirrhosis (Child-Pugh B/C) — lactic acidosis risk. Hold if AST/ALT >3× ULN.
Age / weight: Adults ≥18. Age ≥80: start 500 mg/day, slower titration; recheck eGFR q6mo. No weight adjustment; underweight (<50 kg) cap at 1000 mg/day. Not for pediatrics outside T2D protocols.
Contraindications: eGFR <30 mL/min/1.73m² (avoid), eGFR 30–45 (dose-reduce). Hold for IV contrast, acute illness, hypoxia. Risk: lactic acidosis, B12 deficiency with chronic use — check B12 yearly.

↗ ADA Standards of Care 2024 + Chen Aging Cell 2020

Aspirin (low-dose)

RCT

COX-2 inhibition reduces inflammation-driven mutagenesis; ↓ colorectal adenoma recurrence and CRC mortality.

Dose: 75–100 mg/day (enteric-coated). Benefit emerges after ~5–10 years of use.
Eligibility: USPSTF 2022: adults 40–59 with ≥10% 10-year ASCVD risk and low bleed risk, individualized. Lynch syndrome: 600 mg/day (CAPP2 trial).
Renal: No dose change for CrCl >30. Avoid chronic use if CrCl <30 (Na/fluid retention, AKI risk). Hold during AKI.
Hepatic: Avoid in severe hepatic impairment (Child-Pugh C) and active hepatitis — bleeding/Reye risk.
Age / weight: Adult dose ~75–100 mg regardless of weight; <50 kg consider 75 mg. Age 40–59 individualized; age ≥60 do not initiate for primary prevention (USPSTF 2022). Never under age 16 (Reye syndrome).
Contraindications: Active GI bleed or PUD, hemorrhagic stroke history, bleeding disorders, age ≥60 for primary prevention initiation, planned surgery (hold 7 days), pregnancy 3rd trimester, NSAID/anticoagulant combo.

↗ USPSTF 2022 Aspirin Recommendation

N-acetylcysteine (NAC)

Preclinical

Glutathione precursor; scavenges ROS that drive oxidative DNA damage.

Dose: 600–1200 mg/day (single or divided). Acetaminophen overdose: 140 mg/kg loading.
Eligibility: COPD with mucus burden, acetaminophen toxicity, contrast-nephropathy prophylaxis (mixed evidence). General antioxidant use is unproven.
Renal: No formal adjustment; renally cleared but well-tolerated. IV NAC for contrast nephropathy uses standard weight-based protocol.
Hepatic: No dose reduction; in fact used for acetaminophen-induced hepatotoxicity. Monitor LFTs if chronic high dose.
Age / weight: Oral adult: 600–1200 mg/day. Acetaminophen OD: 140 mg/kg load then 70 mg/kg q4h × 17 doses (weight-based, cap at 100 kg). Pediatric (>2 yr): 10–20 mg/kg/dose. Elderly: no change.
Contraindications: Active asthma exacerbation (bronchospasm risk with inhaled form), peptic ulcer. Caution: Sayin 2014 showed accelerated melanoma & lung-cancer metastasis in mouse models — avoid in patients with known melanoma or NSCLC.

↗ Sayin et al., Sci Transl Med 2014

Nicotinamide (B3)

RCT

NAD+ precursor; fuels PARP-mediated DNA repair and sirtuin activity. ONTRAC: 23% ↓ new keratinocyte cancers at 12 months.

Dose: 500 mg twice daily (ONTRAC protocol). Distinct from niacin — no flushing.
Eligibility: Adults with ≥2 prior non-melanoma skin cancers in past 5 years, or organ transplant recipients on immunosuppression with high NMSC risk.
Renal: CrCl ≥30: full dose. CrCl <30 or dialysis: reduce to 500 mg once daily and monitor — accumulation possible.
Hepatic: Mild-moderate (Child-Pugh A/B): no change but monitor LFTs. Severe (Child-Pugh C): avoid.
Age / weight: Adults ≥18: 500 mg BID (ONTRAC). Age ≥75 or <50 kg: consider 500 mg once daily. Pediatric NMSC prevention not established.
Contraindications: Severe hepatic impairment. Avoid doses >3 g/day (hepatotoxicity, insulin resistance). Not interchangeable with niacin (nicotinic acid) — niacin causes flushing and lipid changes; nicotinamide does not.

↗ Chen et al., NEJM 2015 (ONTRAC trial)

Folate + B12

RCT

Prevents uracil misincorporation into DNA and chromosome breaks via one-carbon metabolism.

Dose: 400 µg folate + 2.4 µg B12 daily (RDA). Pregnancy/preconception: 400–800 µg folate. MTHFR variants: methylfolate (L-5-MTHF) preferred.
Eligibility: All adults via diet; supplementation for preconception, pregnancy, vegans (B12), elderly with malabsorption, methotrexate/sulfasalazine users.
Renal: Dialysis patients: folate 1 mg/day routinely (loss through dialysate); B12 standard RDA, parenteral if oral malabsorption.
Hepatic: No adjustment needed; folate often depleted in alcoholic liver disease — replete 1 mg/day.
Age / weight: Adults: 400 µg folate + 2.4 µg B12. Preconception/pregnancy: 400–800 µg folate. Age ≥50: prefer crystalline B12 or sublingual (absorption ↓). Pediatric per AAP age bands. No weight-based scaling.
Contraindications: Untreated B12 deficiency (folate masks the hematologic signs while neurologic damage progresses — always check B12 first). Caution: synthetic folate >1 mg/day may accelerate existing colorectal adenomas (Cole 2007).

↗ Institute of Medicine DRIs; Cole JAMA 2007

Vitamin D3 (cholecalciferol)

RCT

Modulates p53, BRCA1, and DNA-repair gene expression; ↓ cancer mortality in VITAL meta-analysis.

Dose: 1000–2000 IU/day maintenance. Deficiency (<20 ng/mL): 50,000 IU weekly × 8 weeks then maintenance. Target 25(OH)D 30–50 ng/mL.
Eligibility: Documented deficiency, malabsorption (celiac, IBD, post-bariatric), CKD, osteoporosis, limited sun exposure, dark skin at high latitudes, elderly, obesity.
Renal: CKD 3–5: use cholecalciferol for nutritional repletion; active analog (calcitriol/paricalcitol) if secondary hyperparathyroidism. Monitor Ca, PO4, PTH.
Hepatic: Severe hepatic impairment impairs 25-hydroxylation — consider calcifediol (25-OH-D3) instead of D3.
Age / weight: Infants 400 IU; 1–18 yr 600 IU; adults 19–70 600–800 IU RDA, maintenance 1000–2000 IU. Age >70 800 IU minimum. Obesity (BMI ≥30): 2–3× standard dose for repletion (sequestration in adipose). Target 25(OH)D 30–50 ng/mL.
Contraindications: Hypercalcemia, sarcoidosis or other granulomatous disease (extrarenal 1α-hydroxylation), primary hyperparathyroidism, active nephrolithiasis with hypercalciuria. Avoid sustained doses >4000 IU/day without 25(OH)D monitoring.

↗ Manson NEJM 2019 (VITAL) + Endocrine Society Guideline

Sulforaphane (broccoli sprouts)

Cohort

Potent Nrf2 activator → induces phase-II detox enzymes (GSTs, NQO1) that neutralize mutagens.

Dose: ~30 g broccoli sprouts/day (3-day old, highest glucoraphanin) or standardized 30–60 mg sulforaphane equivalent.
Eligibility: Heavy environmental mutagen exposure (smokers, air pollution, aflatoxin), Helicobacter pylori carriers, general dietary use.
Renal: No known renal adjustment for dietary intake. Concentrated supplements in advanced CKD — limited data, use cautiously.
Hepatic: Generally hepatoprotective. No dose adjustment; monitor LFTs if combining with other Nrf2 activators.
Age / weight: Adults: 30 g sprouts/day or 30–60 mg sulforaphane equivalent. No pediatric supplement dosing established (dietary intake fine). No weight-based scaling.
Contraindications: Hypothyroidism with iodine deficiency (goitrogenic potential at very high intake). Caution with warfarin (vitamin K in whole sprouts). Pregnancy/lactation safety of concentrated supplements not established.

↗ Fahey et al., Cancer Prev Res 2012

EGCG (green tea)

Preclinical

Polyphenol; ROS scavenger, inhibits DNMT1, modulates Nrf2.

Dose: Dietary: 3–5 cups green tea/day. Supplements: keep total EGCG <338 mg/day and take with food.
Eligibility: General dietary use is safe. Supplement form: adults seeking weight/metabolic support, with hepatic monitoring.
Renal: No specific adjustment; minimally renally cleared. Avoid concentrated extracts in advanced CKD due to limited data.
Hepatic: Any baseline LFT elevation, NAFLD, or hepatitis: avoid supplements; dietary tea acceptable. Stop if ALT/AST rise on therapy.
Age / weight: Adults: ≤338 mg EGCG/day from supplements, with food. <60 kg: cap closer to 200 mg/day. Pregnancy/lactation: keep dietary only (≤200 mg caffeine equiv). Not for children as supplement.
Contraindications: Liver disease or elevated LFTs (EFSA 2018 flagged hepatotoxicity above 800 mg/day, especially fasted). Caution: reduces nadolol, bortezomib, and non-heme iron absorption; additive bleeding risk with anticoagulants.

↗ EFSA Panel on Food Additives, 2018

Curcumin

Preclinical

Anti-inflammatory, ↓ NF-κB, modulates Nrf2 and DNA repair gene expression.

Dose: 500–2000 mg/day standardized extract, ideally with piperine (5–20 mg) or as phytosome/liposomal for bioavailability.
Eligibility: Adjunct in osteoarthritis, metabolic syndrome, ulcerative colitis maintenance. Dietary turmeric is universally safe.
Renal: No specific renal adjustment; monitor in CKD on multiple supplements. Rare oxalate-related nephropathy reported with very high chronic doses.
Hepatic: Idiosyncratic hepatotoxicity reported with concentrated extracts — avoid in active liver disease, recheck LFTs at 4–8 weeks of high-dose use.
Age / weight: Adults 500–2000 mg/day extract. <60 kg or age ≥75: start 500 mg/day. Pediatric use not established. Pregnancy: avoid supplemental doses (uterine stimulant at high intake).
Contraindications: Active gallstones or biliary obstruction (cholagogue effect), iron-deficiency anemia (chelates iron), planned surgery (hold 2 weeks — antiplatelet). Interacts with warfarin, clopidogrel, tacrolimus, tamoxifen.

↗ Gupta et al., AAPS J 2013

Astaxanthin

Preclinical

Lipid-phase carotenoid antioxidant; protects membrane lipids and mtDNA from oxidative damage.

Dose: 4–12 mg/day with a fat-containing meal.
Eligibility: Adults with high oxidative-stress exposure (athletes, UV exposure, metabolic syndrome). Generally safe in healthy adults.
Renal: No adjustment; not renally cleared. Safe in CKD at standard doses.
Hepatic: No adjustment; lipid-soluble — take with fat-containing meal. Avoid concentrated doses in cholestatic disease.
Age / weight: Adults 4–12 mg/day. Older adults: same range, start at 4 mg. No pediatric supplement data. No weight-based scaling within adult range.
Contraindications: Known carotenoid allergy. Mild BP-lowering effect — caution with antihypertensives. Pregnancy/lactation data limited. Skin yellowing at high doses (cosmetic).

↗ Kishimoto et al., Mar Drugs 2016

Statins

Cohort

Pleiotropic anti-inflammatory effects; cohort data show ↓ incidence of several solid tumors.

Dose: Standard ASCVD dosing — e.g., atorvastatin 10–80 mg/day, rosuvastatin 5–40 mg/day.
Eligibility: ASCVD, LDL ≥190 mg/dL, diabetes age 40–75, 10-year ASCVD risk ≥7.5% (AHA/ACC 2018). No approved chemoprevention indication.
Renal: Rosuvastatin: CrCl <30, cap at 10 mg/day. Atorvastatin/pitavastatin: no renal adjustment (preferred in CKD). Simvastatin: max 10 mg/day if CrCl <30. Avoid all in dialysis if no prior CV benefit.
Hepatic: Active liver disease or unexplained ALT/AST >3× ULN: contraindicated. Compensated cirrhosis (Child-Pugh A): cautious low-dose atorvastatin acceptable; Child-Pugh B/C: avoid.
Age / weight: Adults ≥40. Age ≥75 primary prevention: shared decision; prefer moderate-intensity (atorvastatin 10–20 mg). Asians: start rosuvastatin at 5 mg (higher exposure). Pediatric familial hypercholesterolemia ≥8 yr per AAP. No weight-based titration; goal-directed by LDL.
Contraindications: Active liver disease, unexplained persistent ALT >3× ULN, pregnancy and lactation (absolute), concurrent strong CYP3A4 inhibitors with simvastatin/lovastatin. Monitor for myopathy, rhabdomyolysis, new-onset diabetes.

↗ Nielsen NEJM 2012 + AHA/ACC Cholesterol Guideline

Rapamycin / rapalogs

Preclinical

mTOR inhibition slows cell proliferation and replication-error accumulation; extends lifespan in mice (ITP).

Dose: Investigational for longevity: 5–10 mg once weekly (PEARL trial protocol). FDA-approved indications use daily dosing.
Eligibility: FDA: organ transplant, lymphangioleiomyomatosis, certain cancers. Off-label longevity use is experimental — only with monitoring physician.
Renal: CrCl <30 or dialysis: reduce by ~50% and target trough 5–15 ng/mL. Proteinuria is a class effect — monitor UACR.
Hepatic: Mild (Child-Pugh A): reduce ~33%. Moderate (Child-Pugh B): reduce ~50%. Severe (Child-Pugh C): avoid. Always trough-guided.
Age / weight: Transplant adult: 2 mg/day load → trough-titrated (5–15 ng/mL). Longevity (off-label): 5–10 mg once weekly. Age ≥65 or <50 kg: start at lower end (3–5 mg weekly), check trough at 4 weeks. Pediatric per transplant protocols only.
Contraindications: Active infection, pregnancy (teratogenic), planned surgery (impairs wound healing — hold 2 weeks before/after), uncontrolled hyperlipidemia or diabetes, severe pulmonary disease (risk of non-infectious pneumonitis). Many CYP3A4 drug interactions.

↗ Harrison Nature 2009 (ITP) + Mannick Sci Transl Med 2014

Early-warning blood tests

Test	Category	Measures	Abnormal suggests	When ordered	Source
CBC + differential	Cell counts	RBC, WBC subsets, platelets, hemoglobin, MCV.	Unexplained cytopenias → MDS, leukemia; persistent lymphocytosis → CLL.	Annual primary-care panel; investigate any unexplained persistent abnormality.	↗ ASH Clinical Practice Guidelines
Peripheral blood smear	Cell counts	Morphology of RBCs, WBCs, platelets under microscopy.	Dysplastic cells, blasts, Auer rods → acute leukemia / MDS.	Reflex test when CBC is abnormal.	↗ WHO Classification of Haematolymphoid Tumours, 5th ed.
LDH	Damage biomarker	Lactate dehydrogenase — released by high cell turnover.	Elevated in lymphomas, germ cell tumors, hemolysis, tissue damage.	Lymphoma workup, monitoring response and tumor burden.	↗ NCCN Guidelines: B-cell Lymphomas
8-OHdG (urine/serum)	Damage biomarker	8-hydroxy-2′-deoxyguanosine — direct marker of oxidative DNA damage.	Elevated in smokers, chronic inflammation, several solid tumors.	Research / functional medicine; not yet a guideline-recommended screen.	↗ Valavanidis et al., J Environ Sci Health 2009
γ-H2AX foci	Damage biomarker	Phosphorylated H2AX in lymphocytes — counts active double-strand breaks.	↑ DSB activity from radiation exposure, ATM deficiency, replication stress.	Research assay; used in radiation biodosimetry.	↗ Rothkamm & Löbrich, PNAS 2003
Multi-cancer ctDNA (Galleri)	Liquid biopsy	Methylation patterns of cell-free DNA across 50+ cancer types.	Cancer signal detected with tissue-of-origin prediction (~88% accuracy when positive).	Adjunctive to USPSTF screening for adults ≥50; not a replacement.	↗ PATHFINDER study, Lancet 2023
Signatera / tumor-informed MRD	Liquid biopsy	Patient-specific ctDNA assay tracking residual / recurrent disease.	Molecular relapse months before imaging in CRC, breast, bladder, lung.	Post-treatment surveillance in known cancer patients.	↗ Reinert et al., JAMA Oncol 2019
CHIP panel (DNMT3A, TET2, ASXL1, JAK2, TP53)	Liquid biopsy	Clonal hematopoiesis — somatic mutations expanding in blood cells with age.	↑ risk of hematologic cancer (~0.5–1%/yr) and cardiovascular events.	Consider in unexplained cytopenias, prior chemotherapy, or strong family history.	↗ Jaiswal et al., NEJM 2014
Germline panel (Invitae / Color / Tempus xG)	Germline	BRCA1/2, Lynch (MLH1/MSH2/MSH6/PMS2), TP53, ATM, PALB2, CHEK2, CDKN2A, etc.	Inherited predisposition → enhanced screening, risk-reducing surgery, PARP eligibility.	Strong family history, early-onset cancer, Ashkenazi ancestry, or known familial variant.	↗ NCCN Genetic/Familial High-Risk Assessment Guidelines → See pancreatic vaccine trials enrolling carriers
CA-125, CA 19-9, AFP, PSA, β-HCG, CEA	Tumor marker	Tissue-associated antigens elevated in specific cancers.	Ovarian (CA-125), pancreatic/biliary (CA 19-9), liver/germ (AFP), prostate (PSA), GI (CEA).	Diagnostic adjuncts and treatment monitoring — poor specificity for screening except PSA.	↗ ASCO Tumor Marker Guidelines
Methylation age (GrimAge / PhenoAge)	Aging	DNA methylation–based biological age estimate.	Accelerated epigenetic age correlates with cancer incidence and mortality.	Research / consumer-longevity testing; not yet clinical standard.	↗ Lu et al., Aging 2019 (GrimAge)

Educational reference — not medical advice. None of these agents or tests should be started or interpreted without a clinician who knows your full history.

Mind & body

Depression, anxiety & cancer — a bidirectional loop

Pooling 25+ prospective cohort studies (>2.4M people), adults with clinical depression have ~15% higher cancer incidence and ~21% higher cancer-specific mortality than non-depressed peers. The link is strongest for lung, oral, pancreatic, and colorectal cancer — and it runs both ways: a cancer diagnosis triples the odds of major depression, which then worsens survival.

+15%

Cancer incidence ↑ (depression)

+21%

Cancer mortality ↑ (depression)

~20%

Depression after cancer dx

4×

Suicide vs gen pop (1 yr post-dx)

Cancer incidence given pre-existing depression or anxiety

Relative risk vs adults without the disorder. 1.0× = no extra risk. Bars are pooled meta-analytic estimates.

After diagnosis — depression worsens outcomes

Relative risks vs cancer patients without the disorder, after adjusting for stage, age, and treatment where possible.

Outcome	RR	Pooled n	Why
Cancer-specific mortality (depression)	1.21×	≈300K patients	After controlling for stage and treatment.
All-cause mortality (depression)	1.32×	≈400K patients	Higher because depression also worsens cardiac and infection deaths.
Cancer-specific mortality (anxiety)	1.10×	≈150K patients	Smaller, less consistent effect than depression.
Treatment discontinuation (depression)	1.40×	≈80K patients	Missed doses and early termination explain part of the survival gap.
Suicide within 1 yr of cancer dx (vs general pop)	4.00×	Henley et al.	Risk highest in first 3 months and for pancreatic, lung, head/neck cancers.

The other direction — mental health after a cancer diagnosis

% of patients meeting clinical criteria for major depression / anxiety. Pancreatic, lung, and head-and-neck cancers carry the highest psychiatric burden.

By age — the effect is largest in younger adults

Both the excess cancer risk and the post-diagnosis psychiatric burden shrink with age — older patients have more competing risks and (often) more social support.

By sex — different patterns, same direction

Men carry the larger incidence and mortality effect; women carry the larger post-diagnosis depression and anxiety burden.

	Women	Men
Cancer incidence RR (depression)	1.12×	1.19×
Cancer incidence RR (anxiety)	1.09×	1.07×
Cancer mortality RR (depression)	1.18×	1.25×
Cancer mortality RR (anxiety)	1.09×	1.11×
Depression prevalence post-dx	24%	16%
Anxiety prevalence post-dx	23%	14%

Women

Lower incidence effect but higher post-dx prevalence — women seek help, but treatment-burden distress is heavy in breast and gyn cancers.

Men

Larger incidence and mortality effect, driven by smoking, alcohol, and lower help-seeking. Suicide risk post-dx is ~4× women.

Why the link is real — six mechanisms

No single pathway explains it. Biology and behavior reinforce each other.

Chronic inflammation

Depressed patients have elevated IL-6, CRP, and TNF-α. Sustained inflammatory tone promotes DNA damage, suppresses immune surveillance, and accelerates tumor growth in animal models.

HPA-axis & cortisol

Flattened diurnal cortisol slope (a marker of chronic stress) predicts shorter survival in breast and ovarian cancer cohorts independent of stage and treatment.

Sympathetic nervous system

Norepinephrine signaling through β-adrenergic receptors on tumor cells drives angiogenesis and metastasis. Observational data suggest non-selective β-blockers reduce cancer mortality.

Immune surveillance

Depression lowers NK-cell cytotoxicity by 20–50% in controlled studies — reducing the body's ability to clear pre-malignant cells.

Health behaviors

Depression roughly doubles smoking rates, raises heavy drinking, lowers physical activity, and cuts cancer screening uptake (mammography, colonoscopy, Pap) by 10–30%.

Treatment adherence

Depressed cancer patients are 3× more likely to be non-adherent with oral chemotherapy or endocrine therapy — directly shortening survival.

What actually moves outcomes

Collaborative care models (psychiatrist + oncology nurse + PCP) cut depression severity ~50% and improved survival in the SMaRT trial (Lancet 2014).
CBT and mindfulness-based stress reduction reduce depression and fatigue with effect sizes of 0.4–0.6 across >30 RCTs.
SSRIs/SNRIs are first-line in cancer patients; sertraline, escitalopram, and mirtazapine have the cleanest oncology drug-interaction profiles.
Exercise (150 min/week moderate) reduces depression and is associated with ~20–30% lower cancer-specific mortality in breast and colon cancer cohorts.
Distress screening with the NCCN Distress Thermometer at every oncology visit is now an ASCO and Commission on Cancer standard.

Confounders & caveats

Smoking and alcohol share strong correlations with depression — meta-analyses control for them, but residual confounding likely inflates the lung and oral cancer estimates.
Reverse causation matters for pancreatic, brain, and ovarian cancers — depression can be a paraneoplastic symptom that precedes diagnosis by months.
Antidepressant signals are mixed — some observational data show SSRIs lower cancer incidence; others show no effect. No RCT has been powered for cancer endpoints.
Effect sizes are real but modest compared with smoking (×15–20 for lung) or obesity (×2–4 for endometrial). Depression is one risk amplifier among many.

Sources: Wang et al., "Association of depression with risk of incident cancer, cancer prognosis, and cancer-related mortality" — meta-analysis of 51 studies, JAMA Oncol 2020; Pinquart & Duberstein, "Depression and cancer mortality: a meta-analysis", Psychol Med 2010; Mitchell et al., "Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings", Lancet Oncol 2011; Henley et al., "Suicide among cancer patients", Cancer 2019; Sharpe et al., SMaRT Oncology-2/3 trials, Lancet & Lancet Oncol 2014; Andersen et al., "Stress and immune responses after surgical treatment for regional breast cancer", JNCI 1998; Sephton et al., diurnal cortisol & breast cancer survival, JNCI 2000; Cole & Sood, β-adrenergic signaling in tumor biology, Clin Cancer Res 2012.

Race & ethnicity

Cancer rates by race and ethnicity

Age-adjusted incidence and mortality from CDC United States Cancer Statistics (2017–2021). The gaps shown here reflect biology, exposure, screening access, insurance, and historical inequities in care — not any single cause.

Jurisdiction:

View:

All cancers combined · incidence · United States

per 100k, age-adjusted

All cancers combined · United States

Side-by-side new cases and deaths · per 100k, age-adjusted

GroupNew casesDeathsM/I

White4611520.33

Black4441730.39

Hispanic / Latino3431100.32

American Indian / Alaska Native4051520.38

Asian / Pacific Islander295950.32

M/I = mortality-to-incidence ratio. Higher values mean a larger share of diagnoses end in death — usually a sign of later-stage detection or unequal access to treatment.

Largest mortality gaps

Black Americans

Prostate cancer mortality is roughly 2× higher in Black vs. White men (36 vs. 17 per 100k). Female breast-cancer incidence is slightly lower in Black women, but mortality is ~40% higher (27 vs. 19). Stomach, pancreatic, and colorectal mortality also run highest in Black populations. Drivers include later-stage diagnosis, lower screening uptake, treatment-access gaps, and tumor-biology differences (e.g., triple-negative breast cancer).

Infection-driven cancers

Hispanic, AIAN & API

Liver, stomach, and cervical cancers — all heavily driven by chronic infections (HBV/HCV, H. pylori, HPV) — fall hardest on Hispanic, AIAN, and API populations. AIAN populations carry the highest kidney-cancer rates in the country. Hispanic and API populations have lower overall cancer incidence than White Americans, but higher rates of infection-related cancers and rising rates as immigrant generations adopt US lifestyle patterns.

Where the disparity comes from

Mostly access, not biology

For most cancers the racial mortality gap is far larger than the incidence gap, meaning the same disease is more lethal in some groups — almost always because diagnosis arrives later and treatment is less complete. Insurance status, neighborhood, primary-care contact, and clinical-trial representation explain more of the disparity than tumor genetics for the majority of cancers.

Source: CDC United States Cancer Statistics (USCS) 2017–2021, age-adjusted incidence and mortality per 100,000. White, Black, AIAN, and API are non-Hispanic; Hispanic includes all races. Female breast and cervical rates are per 100k women; prostate rates are per 100k men. Values rounded. State view: the race breakdown is scaled by each state's overall all-sites incidence and mortality ratio versus the national mean (×1.00 incidence, ×1.00 mortality for the selected jurisdiction). This preserves between-group disparities while shifting absolute levels to that state — race-specific state rates from CDC USCS would be more precise but vary by data-suppression rules.

DNA damage by state

How cancer-causing damage happens to DNA — and where each cause hits hardest

Cancer starts when DNA acquires the right combination of mutations to drive uncontrolled growth. The major exposures that damage DNA differ by mechanism and by geography. Pick a mechanism to see its US distribution; the composite index combines all eight.

UV radiation · by state

annual UV index · median 4.9

Composite DNA-damage exposure index

Average z-score across all eight mechanisms. Positive = more exposure than the national mean; negative = less. Equal weight, log-transformed for TRI.

Highest exposure

West Virginia0.69
Louisiana0.66
Kentucky0.63
Indiana0.63
Alaska0.62
Arkansas0.61
Montana0.61
North Dakota0.61

Lowest exposure

New York-1.03
District of Columbia-1.01
Hawaii-0.79
Massachusetts-0.78
New Jersey-0.77
Rhode Island-0.69
Connecticut-0.64
Maryland-0.61

How DNA damage becomes cancer

Damage → mutation → mutant clone → tumor

Most DNA damage is repaired — by base excision, nucleotide excision, mismatch repair, or homologous recombination. Cancer happens when damage outpaces repair, the wrong genes are hit (oncogenes like KRAS, tumor suppressors like TP53), and the mutant cell gains a survival advantage. Every exposure on the left adds to the lifetime mutational burden; the geography above reflects how that burden is unevenly distributed across the United States. Even one exposure (heavy smoking, occupational benzene) can dominate; multiple moderate exposures stacked together — what the composite index captures — also drive risk.

Mechanism descriptions: IARC monographs, NCI etiology pages, Alexandrov et al. (mutational signatures). State exposure data: NOAA/EPA SunWise (UV), EPA Map of Radon Zones (radon), EPA AQS (PM2.5), CDC BRFSS (obesity, tobacco), SAMHSA NSDUH (heavy alcohol), EPA SDWIS (water), EPA TRI (industrial). Composite index weights all sources equally — a simplification that does not reflect each mechanism's true contribution to cancer burden.

Blood type

Cancer risk by ABO and Rh blood type

ABO blood-group antigens sit on red cells but also on the surface of epithelial cells lining the pancreas, stomach, ovaries and other organs — so they shape how cells interact with pathogens, inflammation, and clotting factors that influence cancer risk.

Your blood type:6.3% of US population

Relative risk for blood type A-

vs blood group O (reference = 1.00)

Largest signal for A-

Pancreatic: 1.27× (+27%)

vs blood group O. Wolpin 2009 (NHS/HPFS), confirmed in Asian and European cohorts.

Mechanisms

A and B antigens are sugar structures expressed on epithelial cells, not just red cells — that is why ABO matters for solid tumors.
Pancreatic and gastric show the strongest signal: A-type antigen alters mucin glycosylation, modulates inflammation, and changes how H. pylori adheres to the stomach lining.
Group O has the lowest von Willebrand factor and lower systemic inflammation markers, which may slightly reduce risk of several cancers.
Rh-negative shows a small (≈4%) protective trend in pooled data; evidence is weak and Rh status is not used in clinical risk models.

Cancer	O	A	B	AB	A- (you)	Note
Pancreatic	1.00	1.32	1.72	1.51	1.27	Wolpin 2009 (NHS/HPFS), confirmed in Asian and European cohorts
Gastric (stomach)	1.00	1.20	1.06	1.09	1.15	Edgren 2010 Swedish registry; H. pylori binds Lewis-b antigen on A-type cells
Ovarian	1.00	1.16	1.06	1.12	1.11	Gates 2011 pooled analysis
Esophageal	1.00	1.20	1.10	1.15	1.15	Sun 2015 meta-analysis (mostly Asian cohorts)
Liver (HCC)	1.00	1.16	1.35	1.21	1.11	Li 2015 Chinese cohorts; mechanism unclear, may interact with HBV
Colorectal	1.00	1.11	1.05	1.07	1.07	Khalili 2011; effect small and not seen in every cohort
Breast	1.00	1.12	1.05	1.08	1.08	Meo 2017 meta-analysis; modest A excess in some populations
Cervical	1.00	1.15	1.08	1.10	1.10	Limited data, mostly Asian cohorts
Kidney (RCC)	1.00	1.10	1.05	1.08	1.06	Joh 2012; small effect
Bladder	1.00	1.08	1.04	1.06	1.04	Pooled small studies; weak signal
Lung	1.00	1.04	1.02	1.03	1.00	Largely null after adjusting for smoking
Prostate	1.00	1.02	1.00	1.01	0.98	Essentially null in pooled analyses
Melanoma	1.00	1.05	0.98	1.02	1.01	No consistent association
Lymphoma (NHL)	1.00	1.07	1.04	1.05	1.03	InterLymph weak A excess

How to read this — and what it does not mean

A relative risk of 1.32 for pancreatic cancer in blood group A means roughly 32% higher relative risk than O — but the lifetime baseline risk of pancreatic cancer is about 1.7%, so the absolute lifetime risk for an A-type person is closer to ~2.2%. Smoking, family history, diabetes, BMI, and inherited mutations (BRCA2, CDKN2A, Lynch) move risk by far larger amounts than ABO. Blood type is not used in clinical risk scores for any major cancer; it is a modest, fixed factor on top of the modifiable risks covered elsewhere on this page.

Sources: Wolpin et al. (JNCI 2009), Edgren et al. (Am J Epidemiol 2010), Iodice et al. (Br J Cancer 2010) meta-analysis of ABO and pancreatic cancer, Gates et al. (Br J Cancer 2011), Meo et al. (Eur Rev 2017), Joh et al. (Cancer Causes Control 2012), Sun et al. (Onco Targets Ther 2015), Li et al. (Sci Rep 2015). US prevalence: American Red Cross (2024). Rh modifier is approximate and based on pooled solid-tumor data; confidence intervals cross 1.0 for most cancers.

Blood type × race × cancer

Blood type by race & ethnicity — and how that overlays with cancer risk

The eight ABO/Rh blood types are not distributed evenly across populations. South Asians are the world's most B-dominant group; Native Americans are nearly all type O; Rh-negative blood is largely a European trait. Because ABO genotype modestly shifts pancreatic, gastric, ovarian, liver, and colorectal cancer risk, the same modest biology lands very differently from one population to the next. Pick a blood type and a cancer below to see the overlay — but keep the headline in mind: ABO is a tiny effect compared with smoking, infection, diet, and screening access.

Blood type:

Cancer:

Selected blood type

A-

ABO group: A · Rh: negative

RR vs Type O · Pancreatic

1.32×

32% relative shift

Most-affected US group

White

7% carry this type

Least-affected US group

Asian-American

0.5% carry this type

Blood type distribution across racial & ethnic groups

% of group · Red Cross 2024 + Garratty 2004

Population	O+	O-	A+	A-	B+	B-	AB+	AB-	Rh−
White (non-Hispanic)	37%	8%	33%	7%	9%	2%	3%	1%	18%
Black / African-American	47%	4%	24%	2%	18%	1%	4%	0.3%	7%
Hispanic / Latino	53%	4%	29%	2%	9%	1%	2%	0.2%	7%
Asian-American	39%	1%	27%	0.5%	25%	0.4%	7%	0.1%	2%
Native American	55%	5%	33%	3%	3%	0.3%	1%	0.1%	8%
South Asian (Indian)	32%	2%	22%	1%	32%	2%	8%	0.5%	5%
Middle Eastern / N. African	35%	6%	31%	6%	16%	3%	2%	1%	16%

Highlighted column shows your selected blood type (A-). Cell shading scales with prevalence within each row — quickly revealing which populations are concentrated in which groups. Rows do not always sum to exactly 100% because of rounding and small unspecified subtypes.

Overlay · A- carriers × Pancreatic RR

Population-weighted risk score

Overlay score = (% of group carrying A-) × (relative risk of ABO A for Pancreatic) ÷ 100. It estimates how much of each population is sitting on the ABO-attributable share of risk for the chosen cancer. This is a relative comparison only — it does not account for H. pylori, smoking, HBV/HCV, BRCA, BMI, or screening access, which dominate true population-level risk.

Why the ABO gene matters at all

The ABO locus on chromosome 9q34 encodes glycosyltransferases that decorate red cells and epithelial cells with A or B sugar antigens. These antigens influence inflammation (von Willebrand factor, E-selectin, ICAM-1), cell adhesion, and pathogen binding — particularly for H. pylori and norovirus, which both bind Lewis/ABH antigens.

Why Rh-negative tracks ancestry

The RHD-deletion allele that produces Rh-negative blood originated in the ancient Basque region of Europe. Today Basques carry the highest Rh-negative rate on Earth (~35%); other European-descended populations hover at 15–18%; African, East Asian, and Native American populations are largely Rh-positive. There is no consistent Rh-cancer association — the modifier used elsewhere on this page is approximate.

South Asia is the B+ capital of the world

≈ 32% of people in India, Pakistan, and Bangladesh are B+, the highest concentration globally. Because group B carries the strongest ABO-attributable pancreatic cancer relative risk (1.72×), this is a quietly important factor as South Asian diaspora populations age into a higher pancreatic-cancer-risk window over the next two decades.

What each group typically carries — and what that means for cancer

Group-level pattern, never a personal prediction

White (non-Hispanic)

Distinct trait: Highest Rh-negative rate in the US (~18%) — a population unusual on a global scale.

ABO mix: Roughly even split between O (~45%) and A (~40%); B and AB are minorities.

Cancer overlay: Higher proportion of group A means a slightly elevated population-level pancreatic and gastric cancer signal, but lifestyle (smoking, alcohol, BMI) and screening uptake dominate.

Dominant non-ABO drivers: Skin cancer (UV + low melanin), lung cancer (historical smoking), breast cancer (later childbearing).

Black / African-American

Distinct trait: Highest O+ rate (~47%) and the highest B+ rate among major US groups (~18%).

ABO mix: More B than the US average; very low Rh-negative rate (~7%).

Cancer overlay: Group B's modest pancreatic and liver cancer signals add to risk on top of already-higher baselines from HBV/HCV exposure and access disparities.

Dominant non-ABO drivers: Prostate cancer (highest in the world), multiple myeloma (2× rate vs whites), triple-negative breast cancer, late-stage colorectal and lung cancer driven by access gaps far more than biology.

Hispanic / Latino

Distinct trait: Highest O+ rate alongside African-Americans (~53%) — strong indigenous-ancestry signature.

ABO mix: Heavily O-dominant; A and B both reduced versus whites.

Cancer overlay: Type-O dominance gives a small protective shift against pancreatic and gastric cancer — but offset by H. pylori exposure and high stomach-cancer mortality.

Dominant non-ABO drivers: Gastric cancer (H. pylori + diet), liver cancer (HCV + MASLD), cervical cancer (screening gaps in immigrant populations).

Asian-American

Distinct trait: Lowest Rh-negative rate (~2%) and the highest B-group prevalence in the US (~25% B+).

ABO mix: Highest AB+ rate (~7%); B is nearly as common as A.

Cancer overlay: Elevated B and AB shift the population slightly toward higher pancreatic and gastric cancer relative-risk — overlapping cancers East Asian populations already carry at higher baseline.

Dominant non-ABO drivers: Stomach cancer (H. pylori + salt-preserved diet), liver cancer (HBV), EGFR-mutant lung cancer (5× higher EGFR mutation rate; affects non-smokers especially).

Native American

Distinct trait: Among the world's highest O-group rates (~60% combined O+ / O−).

ABO mix: B and AB are very rare — a genetic bottleneck signature.

Cancer overlay: Type O dominance means the ABO-attributable pancreatic / gastric signal is the lowest of any US group — yet stomach cancer mortality is among the nation's highest, showing how strongly H. pylori, diet, and access override blood type.

Dominant non-ABO drivers: Stomach cancer (H. pylori prevalence ~75% in Alaska Native adults), liver cancer (HCV + alcohol), kidney cancer, gallbladder cancer.

South Asian (Indian)

Distinct trait: World's highest B+ frequency (~32%); A and O roughly tied below it.

ABO mix: Most B-dominant population on the planet; AB+ also elevated (~8%).

Cancer overlay: Elevated B confers the strongest ABO-attributable pancreatic cancer signal (RR 1.72) of any major group, layered onto rising tobacco-chewing and diabetes-driven risk.

Dominant non-ABO drivers: Oral cavity cancer (areca nut, tobacco), cervical cancer (HPV vaccination gap), breast cancer rising fastest in any major population.

Middle Eastern / N. African

Distinct trait: Intermediate Rh-negative rate (~16%) reflecting historic admixture.

ABO mix: Roughly balanced O (~41%), A (~37%), and B (~19%).

Cancer overlay: Mixed ABO profile means no strong group-level skew; cancer risk is dominated by environmental factors.

Dominant non-ABO drivers: Bladder cancer (historic schistosomiasis in parts of N. Africa), liver cancer (HCV in Egypt — highest in the world), breast cancer rising with urbanization.

Race is not biology — but ancestry is

"Race" is a social category; ancestry is a population-genetics one. Blood-type distributions track ancestry, not race. A self-identified Hispanic American with predominantly European ancestry will have closer to European blood-type frequencies; a self-identified Hispanic American with predominantly Indigenous ancestry will have closer to Native American frequencies. The averages on this page are population means, not individual predictions.

Effect size, in absolute terms

Even the strongest ABO-cancer link (group B → pancreatic cancer, RR 1.72) raises an individual's lifetime risk from ~1.7% to ~2.9%. Smoking raises that same risk by 2-3×; chronic pancreatitis by 13×; hereditary BRCA2 by up to 7×. Blood type is real, replicated science — and a comparatively small lever.

What this should & shouldn't change

No major guideline (USPSTF, NCCN, ESMO) uses ABO in cancer screening decisions. Knowing you are group B does not mean earlier pancreatic CT; knowing you are group O does not mean skipping anything. The actionable takeaways from this section are population-level: H. pylori testing in Hispanic and Asian immigrants, HBV vaccination in Asian communities, and prostate-cancer vigilance in African-American men move far more risk than blood type ever will.

Sources: American Red Cross, "Facts about blood and blood types — by ethnicity" (2024); Garratty G. et al., "ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States," Transfusion 44:703-706 (2004); Wolpin BM et al., JNCI 101:424-431 (2009) — ABO and pancreatic cancer; Edgren G et al., Am J Epidemiol 172:1280-1285 (2010); Iodice S et al., Br J Cancer 103:1855-1858 (2010) meta-analysis; Joh HK et al., Cancer Causes Control 23:495-505 (2012); Sun W et al., Onco Targets Ther 8:1311-1319 (2015); Lopez-Charneco M et al., Transfusion 2014 — Latino populations; CDC NHANES; Indian Society of Blood Transfusion population surveys (2019). Cancer relative risks adjusted for age, sex, and smoking where the source study reported it.

Chemotherapy

How well chemo works — and what it leaves behind

Chemotherapy is curative for some cancers, modestly life-extending for others, and palliative for many. The same drugs that kill tumor cells can damage the heart, nerves, fertility, hearing, and bone marrow for decades after treatment ends.

Curable with chemo alone or chemo-first

~85–90%

Testicular germ cell, Hodgkin lymphoma, childhood ALL, DLBCL — cure rates that did not exist before 1970.

Adjuvant chemo absolute benefit

3–20%

In breast, colon, lung, gastric — chemo after surgery prevents recurrence in a fraction of patients; genomic tests now spare many who would not benefit.

Survivors with ≥1 long-term effect

~60%

Childhood Cancer Survivor Study: 60–70% have at least one chronic condition by 30 yrs post-treatment; 27% have a severe one.

5-year survival — and how much chemo contributes

Sort:

Stacked bars: total height = overall 5-year survival; the accent segment is the share attributable to systemic chemotherapy in the cited trial(s). The remainder includes surgery, radiation, immunotherapy, targeted therapy, and baseline biology.

Cancer / stage	5-yr OS	Chemo Δ	Intent	Regimen	Key trial
Childhood ALL All	90%	+80%	Curative	Multi-agent (vincristine, dex, asparaginase, MTX, 6-MP)	COG / St Jude protocols; cure ~90%
Testicular (germ cell) Metastatic	80%	+70%	Curative	BEP (bleomycin, etoposide, cisplatin)	Einhorn 1977; cure rate rose from <10% to ~80%
Hodgkin lymphoma All stages	89%	+60%	Curative	ABVD / escalated BEACOPP	DeVita 1970; modern cure ~85–90%
Diffuse large B-cell lymphoma All	65%	+55%	Curative	R-CHOP	Coiffier 2002 (NEJM); rituximab added ~15% OS
AML (under 60) Newly diagnosed	40%	+35%	Curative	7+3 induction + consolidation ± alloSCT	CALGB; cure 35–45%
Ovarian (epithelial) III	42%	+25%	Curative + adjuvant	Carbo/paclitaxel ± bevacizumab ± PARPi	GOG-218, SOLO-1; PARP maintenance large gain in BRCA+
Small cell lung (limited) LS	27%	+22%	Curative	Cisplatin/etoposide + RT	Turrisi 1999; chemoRT standard of care
Pancreatic (resected) I–II resected	30%	+19%	Adjuvant	mFOLFIRINOX × 12 cycles	PRODIGE-24 2018; +19% 3-yr DFS
Colon (stage III) III	71%	+16%	Adjuvant	FOLFOX / CAPOX × 3–6 mo	MOSAIC 2004; oxaliplatin added ~8% OS
Gastric (resectable) II–III	35%	+13%	Curative + adjuvant	FLOT (perioperative)	FLOT4 2019 (Lancet); +13% 5-yr OS vs ECF
Breast (HER2+, early stage) I–III	92%	+11%	Adjuvant	TCH(P) ± trastuzumab	HERA / BCIRG-006; trastuzumab cut recurrence ~50%
AML (over 60) Newly diagnosed	10%	+8%	Palliative	Aza/venetoclax	VIALE-A 2020; median OS 9.6 → 14.7 mo
Bladder (muscle-invasive) II–III	55%	+8%	Curative + adjuvant	Cisplatin-based neoadjuvant + cystectomy	SWOG-8710; +6–8% 5-yr OS
Non-small cell lung (resected) II–IIIA	48%	+5%	Adjuvant	Cisplatin doublet × 4 cycles	IALT / LACE meta-analysis; +5% 5-yr OS
Glioblastoma Post-resection	7%	+5%	Adjuvant	Temozolomide + RT (Stupp)	Stupp 2005; median OS 12.1 → 14.6 mo
Non-small cell lung (metastatic, no driver) IV	9%	+4%	Palliative	Carbo/pemetrexed ± pembrolizumab	KEYNOTE-189; median OS 12 → 22 mo with IO
Breast (ER+/HER2−) I–III	95%	+3%	Adjuvant	AC-T (selected by Oncotype DX)	TAILORx 2018; most low/mid-risk skip chemo safely
Pancreatic (metastatic) IV	3%	+3%	Palliative	FOLFIRINOX / gem+nab-paclitaxel	ACCORD-11; median OS 6.8 → 11.1 mo
Colon (stage II low-risk) II low-risk	87%	+2%	Adjuvant	5-FU (only if high-risk features)	QUASAR; small benefit, often deferred

Long-term implications — what chemo leaves behind

By organ system

Heart

≈5% lifetime HF risk above 250 mg/m² doxorubicin

Acute: Arrhythmia, hypotension

Long-term: Cardiomyopathy, heart failure — usually 5–15 yrs later

Anthracyclines (doxorubicin), trastuzumab, 5-FU

Nerves

30–40% have persistent symptoms at 2 yrs

Acute: Tingling, numbness in hands/feet

Long-term: Chronic peripheral neuropathy (often permanent)

Oxaliplatin, paclitaxel, vincristine, cisplatin

Ears

40–80% with cumulative cisplatin >400 mg/m²

Acute: Tinnitus, high-frequency loss

Long-term: Permanent sensorineural hearing loss

Cisplatin, high-dose carboplatin

Reproductive

POI risk 40–80% age-dependent

Acute: Amenorrhea, low sperm count

Long-term: Premature ovarian failure, infertility, early menopause

Cyclophosphamide, ifosfamide, alkylators

Bone marrow

0.5–2% over 10 yrs

Acute: Neutropenia, anemia, thrombocytopenia

Long-term: Therapy-related MDS / AML

Etoposide, alkylators (cyclophosphamide, melphalan)

Second cancers

≈5–10% cumulative at 25 yrs (Hodgkin survivors)

Acute: —

Long-term: Solid tumors (breast, thyroid, lung) often 10–25 yrs later

Alkylators + radiation combinations

Kidneys

20–30% have lasting GFR drop

Acute: Acute kidney injury, Mg/K wasting

Long-term: Chronic kidney disease, reduced GFR

Cisplatin, ifosfamide, methotrexate (high dose)

Lungs

10% with cumulative bleomycin >300 units

Acute: Pneumonitis, hypoxia

Long-term: Pulmonary fibrosis (restrictive disease)

Bleomycin, busulfan, nitrosoureas

Brain / cognition

20–35% report persistent cognitive symptoms

Acute: Fatigue, brain fog during cycles

Long-term: Chemo-brain: memory + processing speed deficits, often years

Anthracyclines, 5-FU, methotrexate, taxanes

Endocrine

Bone loss begins within 6 mo of POI

Acute: Hot flashes (chemo menopause)

Long-term: Hypothyroidism, low testosterone, metabolic syndrome, osteoporosis

Many cytotoxics, esp. after gonadal damage

Survivorship care, not just survival

Modern oncology now writes a survivorship care plan at end of treatment: scheduled echo for anthracycline patients, audiograms after cisplatin, DEXA after early menopause, fertility preservation before chemo, neuropathy rehab, and second-cancer screening on an accelerated schedule. Ask for one — they reduce late mortality.

What's changing

Genomic assays (Oncotype DX, MammaPrint) now spare ~70% of ER+ breast patients from chemo. Immunotherapy and ADCs (trastuzumab deruxtecan, enfortumab vedotin) are replacing or reducing chemo in lung, bladder, and HER2-low breast. Liquid biopsy (ctDNA) is starting to identify who actually needs adjuvant chemo after surgery.

Sources: SEER 22 (2017–2021) for survival; EBCTCG meta-analyses (Lancet); landmark trials cited in the table; Childhood Cancer Survivor Study (NEJM 2006, 2016); NCCN survivorship guidelines; ASCO chemotherapy-related cognitive impairment review. "Chemo contribution" is an approximate absolute benefit from systemic chemotherapy in the cited trial population — individual benefit varies with stage, biology, and comorbidities.

State deep dive

Kentucky — the #1 cancer-mortality state in the US

195 cancer deaths per 100,000 — the highest age-adjusted rate in the country, and ~20% above the US average. Every major risk factor on this page is concentrated here: the highest smoking rate, EPA Radon Zone 1 across nearly the entire state, deep Appalachian poverty, rising obesity, the opioid-driven HCV epidemic, and the lowest HPV vaccination uptake in the nation. The result is a uniquely stacked cancer profile — but also clear, evidence-based levers that are starting to bend the curve.

Cancer deaths / 100k

195

#1 in US (US avg 158)

Lung cancer mortality

/100k — ~2× US rate (32)

Adult smoking

23.4%

vs US 11.5% — highest in US

Counties in Radon Zone 1

90%

EPA highest tier

Population type

4.51M residents · 41.6% rural

Kentucky is among the most rural states by share — more than double the US average. The state splits sharply between the urbanized Bluegrass / Louisville corridor and 54 federally-designated Appalachian counties in the east, where poverty, healthcare deserts, and historical coal economies concentrate risk.

Median age39.4 yrs
Median household income$58,200
Bachelor's degree+26.5%
Appalachian counties54 of 120

Race & ethnicity

Demographic composition

White (non-Hispanic)83.8%

Black8.5%

Hispanic / Latino4.4%

Asian1.7%

Two+ / Other1.6%

Kentucky is far less racially diverse than the US overall — limiting some risk-disparity patterns seen elsewhere, but masking sharper Black–white gaps in Louisville and Lexington (Black breast cancer mortality is ~42% higher than white in KY).

Geographic split

Appalachia vs Bluegrass

Appalachian KY (East): cancer mortality ~218/100k — among the highest county clusters in the US; smoking 28%, obesity 40%, oncologist density 0.8 per 100k.
Bluegrass / Louisville: mortality ~170/100k — closer to US average; access to Markey (NCI-designated) and Norton/Brown comprehensive cancer centers.
Western KY (Pennyrile/Jackson Purchase): agricultural, smoking-heavy; lung and bladder cancer cluster.

Risk-factor profile — Kentucky vs United States

Each bar pair compares Kentucky (accent) to the US national rate (muted).

Cancer mortality by type — Kentucky vs US

Deaths per 100,000, age-adjusted. CDC USCS 2017–2021.

County-level breakdown — where the burden actually concentrates

20 representative counties · age-adjusted

Kentucky's statewide numbers hide a dramatic east–west gradient. Appalachian counties carry mortality rates 1.5× the urban Bluegrass and Louisville corridor, with smoking, obesity, and poverty all stacking together. Bubble size below = poverty rate; color = region. Hover a point to see the full risk profile.

Smoking rate vs cancer mortality

bubble size = poverty %

EPA action level is 4.0 pCi/L; Kentucky's statewide indoor radon average is ~5.6 pCi/L. Note that Bluegrass counties (Fayette, Scott, Madison) actually have the highest radon from karst limestone — but far lower smoking and poverty, so mortality stays moderate. The risk multiplies when factors stack.

Mortality ranking

All-cancer deaths per 100k, age-adjusted

Appalachian East

10 counties shown

Mortality: 247.6/100k
Smoking: 32.1%
Radon: 5.1 pCi/L
Obesity: 39.4%
Poverty: 31.5%

Bluegrass / Central

4 counties shown

Mortality: 170.8/100k
Smoking: 18.8%
Radon: 8 pCi/L
Obesity: 30%
Poverty: 12.8%

Louisville / N. KY

3 counties shown

Mortality: 178.3/100k
Smoking: 19.7%
Radon: 5.9 pCi/L
Obesity: 31%
Poverty: 10.7%

Western KY

3 counties shown

Mortality: 201/100k
Smoking: 23.7%
Radon: 4.1 pCi/L
Obesity: 34.7%
Poverty: 18%

The takeaway: Appalachian counties cluster in the top-right of the scatter — high smoking, high mortality, high poverty — while urban Jefferson and Bluegrass counties sit 60–90 points lower despite similar or higher radon exposure. Eliminating Appalachian smoking alone would close roughly half the statewide mortality gap with the US average.

The eight drivers stacking on top of each other

In rough order of contribution

Tobacco — the dominant driver

Kentucky has led the US in adult smoking since modern records began. Tobacco was the state's cash crop for two centuries; smoking is socially normalized, cessation infrastructure is thin in rural counties, and smokeless tobacco use is among the highest nationally. Roughly 80% of Kentucky's lung cancer mortality gap vs the US is attributable to smoking history alone.

Radon — geology + housing

Karst limestone and uranium-bearing shale push ~90% of Kentucky counties into EPA Radon Zone 1 (the highest tier). Average indoor radon is 2× the national mean. Combined with high smoking rates, radon multiplies lung cancer risk by 8–20× over either alone.

Appalachian rural poverty

Eastern Kentucky's Appalachian counties have median household incomes 30–40% below the US median, the lowest college-attainment rates, and the fewest oncologists per capita. Time-to-diagnosis is longer, stage at diagnosis is later, and treatment adherence is lower — the mortality-to-incidence ratio is among the worst in the country.

Coal & occupational exposure

Generations of underground coal mining exposed workers to silica, diesel exhaust, and radon daughters. Coal sludge impoundments and abandoned mine drainage have contaminated drinking water with arsenic, selenium, and heavy metals in parts of Eastern Kentucky.

Diet, obesity, inactivity

37.7% adult obesity, 32.5% physical inactivity, and a regional diet heavy in processed meat and fried food drive colorectal, kidney, liver, pancreatic, and post-menopausal breast cancer. Food deserts are dense across rural Eastern Kentucky.

Opioid epidemic → HCV → liver cancer

Kentucky was the epicenter of the prescription opioid crisis. Injection drug use spread hepatitis C virus into a young rural population; HCV is the dominant cause of hepatocellular carcinoma. Liver cancer mortality climbed 60% in Kentucky from 2000–2020.

Low HPV vaccination

Only 41% of Kentucky teens are up-to-date on HPV vaccine vs 61% nationally. The consequence shows up 20–30 years later as cervical, oropharyngeal, anal, and penile cancers — all of which Kentucky has elevated rates of.

Healthcare access — the bright spot

Medicaid expansion in 2014 cut Kentucky's uninsured rate from 20% to 6%. Lung cancer screening uptake among eligible adults is 12.9% — nearly 3× the national rate, driven by Markey Cancer Center outreach. Smoking prevalence has fallen from 29% (2011) to 23% (2023). These are the levers actually moving the needle.

Sources: CDC USCS 2017–2021 (cancer rates), BRFSS 2022–2023 (behavioral risk factors), EPA Map of Radon Zones, US Census ACS 2022, NIS-Teen 2022 (HPV), American Lung Association State of Lung Cancer 2024, Kentucky Cancer Registry, Appalachian Regional Commission, Markey Cancer Center community outreach reports. All rates are age-adjusted unless noted.

Weight & cancer

Cancer diagnoses by body-weight category

Excess body fatness is the second-largest modifiable cancer cause after tobacco — and the IARC links it to 13 distinct cancers. Here is how risk and case load scale with BMI.

Cancers linked to excess weight

IARC sufficient evidence

US cases / year attributable

84K

≈ 5% men · 11% women

US adults overweight or obese

71.6%

NHANES 2017–2020

Endometrial risk at BMI ≥40

7.1×

vs normal BMI

The US adult BMI distribution

Share of US adults in each band (left) vs share of obesity-linked cancer cases originating in that band (right).

Underweight

BMI <18.5

1.6%

Normal

BMI 18.5–24.9

26.5%

Overweight

BMI 25–29.9

30.7%

28%

Obesity I

BMI 30–34.9

21%

34%

Obesity II

BMI 35–39.9

10%

22%

Obesity III

BMI ≥40

10.2%

16%

% of US adults% of obesity-linked cases originating in band

How risk scales with BMI, by cancer type

Relative risk vs normal BMI (18.5–24.9). Each band stacks the next obesity tier.

Your personal risk calculator

Enter your current weight and height to estimate how excess body weight shifts your relative risk across the IARC's obesity-linked cancers — and how that risk would change if you lost weight over time.

Weight (lbs)

Height (inches)

Your BMI

30.4

Obesity I

Target weight loss

10%

20.0 lbs

Projected BMI

27.4

Overweight

Timeframe

12 mo

linear loss assumption

Target weight loss10%

0%40%

Over how many months12 mo

3 mo36 mo

Relative risk vs normal BMI — now vs after weight loss

CancerNowAfterExcess removed

Endometrial2.50×1.50×−67%

Esophageal (adeno)2.40×1.70×−50%

Liver1.80×1.30×−63%

Kidney (renal cell)1.70×1.30×−57%

Colorectal1.30×1.10×−67%

Breast (postmenopausal)1.20×1.10×−50%

Estimates apply IARC pooled hazard ratios by BMI tier to your projected BMI on a linear loss curve. Real-world risk reduction depends on how long the loss is sustained — surgical cohorts show ~33% cancer-incidence reduction after 5+ years of maintained loss. Educational, not medical advice.

Why fat tissue drives cancer — six biological pathways

Mechanism review

Chronic inflammation

Adipose tissue secretes IL-6, TNF-α, and CRP. Persistent low-grade inflammation damages DNA and supports tumor microenvironments.

Insulin & IGF-1 signaling

Obesity drives insulin resistance, hyperinsulinemia, and elevated IGF-1 — all mitogens that promote cell proliferation and inhibit apoptosis.

Sex hormone excess

Adipose aromatase converts androgens to estrogens. Post-menopause, fat tissue becomes the main estrogen source — fueling endometrial and ER+ breast cancers.

Adipokine imbalance

High leptin and low adiponectin in obesity stimulate angiogenesis and cell-cycle progression while reducing protective autophagy.

Gut microbiome & bile acids

Obesity shifts gut flora and elevates secondary bile acids like deoxycholic acid — direct hepatocyte mutagens implicated in liver cancer.

Mechanical reflux

Visceral adiposity raises intra-abdominal pressure, driving gastroesophageal reflux that causes Barrett's metaplasia and esophageal adenocarcinoma.

Does losing weight reverse the risk?

Partly, and the evidence is strongest after bariatric surgery. The SOS and Utah surgical cohorts show a 33–42% reduction in cancer incidence among women after sustained large weight loss, with the biggest drops in endometrial (–60%), postmenopausal breast (–25%), and esophageal cancers. Risk does not return to never-obese baseline — early-life adiposity leaves epigenetic and tissue-architecture changes that persist. GLP-1 agonist trials (semaglutide, tirzepatide) are now powering the first prospective tests of pharmacologic weight loss on cancer endpoints; readouts expected 2027–2030.

Sources: IARC Handbooks of Cancer Prevention vol. 16 (2016); Lauby-Secretan et al., NEJM 2016; WCRF/AICR Continuous Update Project 2018; NHANES 2017–2020; CDC Vital Signs (Oct 2017) on obesity-associated cancers; EPIC, NHS, HPFS pooled analyses; Adams et al., NEJM 2007 (SOS surgical cohort); Schauer et al., Annals of Surgery 2019. All HRs adjusted for age, sex, smoking, and physical activity.

Diet · red & processed meat

Why processed meat is a Group 1 carcinogen — and what the evidence actually says

In October 2015, the WHO's International Agency for Research on Cancer placed processed meat in the same evidence tier as tobacco, asbestos, and plutonium for colorectal cancer — not because it is equally potent, but because the human evidence is equally certain. Red meat sits one tier below as 'probably carcinogenic.' This is the full picture: dose-response, biology, cooking chemistry, the cancers involved, and what swaps measurably lower risk.

Processed meat

Group 1

IARC — carcinogenic to humans

Red meat

Group 2A

IARC — probably carcinogenic

CRC risk per 50 g/day

+18%

processed meat, daily

CRC risk per 100 g/day

+17%

unprocessed red meat

Processed meat

Group 1

Carcinogenic to humans. Sufficient evidence for colorectal cancer.

Includes: Bacon, hot dogs, ham, salami, sausages, pepperoni, deli slices, jerky

Red meat (unprocessed)

Group 2A

Probably carcinogenic. Limited evidence for colorectal, pancreatic, prostate.

Includes: Beef, pork, lamb, veal, goat — fresh cuts, ground, roasts, steaks

Poultry & fish

Not classified

No consistent evidence of cancer risk; some fish associated with lower risk.

Includes: Chicken, turkey, salmon, sardines, white fish

Dose-response · colorectal cancer relative risk

RR vs no daily intake

Each 50 g of processed meat per day raises lifetime colorectal cancer risk by ~18%; each 100 g of red meat raises it by ~17%. Source: Bouvard et al., Lancet Oncol 2015 — the IARC Working Group meta-analysis of 800+ studies.

What "Group 1" actually means

IARC's Group 1 reflects strength of evidence, not absolute potency. Smoking causes lung cancer in ~17% of long-term smokers; daily processed meat raises colorectal risk by ~18% over a lifetime baseline of 4%. Same evidence tier, very different magnitudes.

WHO/WCRF intake limits

• Processed meat: as little as possible
• Red meat: < 350 g cooked per week (≈ 3 servings)
• Fiber: ≥ 30 g/day — partially offsets meat-related risk
• Calcium & dairy: 700–1,000 mg/day binds heme iron in the gut

Average American intake

US adults consume ~26 g processed meat/day and ~58 g red meat/day (NHANES 2017–2020). Combined, that puts the average eater at roughly 1.20× baseline colorectal risk — about one extra case per 125 lifetime adults.

Your meat intake → your colorectal risk

Bouvard et al. dose-response model

Processed meat50 g/day · ≈ 1.8 slices

Bacon, hot dogs, ham, sausage, deli meat. One slice deli ≈ 28 g; one hot dog ≈ 50 g.

Red meat (fresh)75 g/day · ≈ 0.9 servings

Beef, pork, lamb. One 3-oz cooked serving ≈ 85 g; a quarter-pound burger ≈ 113 g; a 12-oz ribeye ≈ 340 g.

Relative CRC risk

1.33×

+33% vs no intake

Lifetime CRC risk

5.31%

baseline 4.0% (SEER US)

Processed meat RR

1.18×

+18% per 50 g/day

Red meat RR

1.12×

+17% per 100 g/day

In plain terms: If 1,000 Americans match your intake for life, an extra 13 colorectal cancer cases would occur above the baseline of 40 per 1,000. WHO/IARC recommends limiting red meat to under 350 g (12 oz) cooked weight per week and minimizing processed meat to "as little as possible."

Model: log-linear extrapolation of Bouvard et al. Lancet Oncol 2015 (IARC Working Group) and WCRF/AICR CUP 2018 meta-analysis. Combines processed and red meat multiplicatively. Educational only — does not adjust for fiber intake, BMI, family history, screening, or other modifiers.

Which cancers are actually linked to meat?

RR = highest vs lowest intake

Cancer site	Processed RR	Red RR	Evidence	Mechanism / notes
Colorectal	1.18×	1.17×	Convincing	IARC Group 1 (processed) & 2A (red). Mechanisms: HCAs/PAHs, heme iron, N-nitroso compounds, gut dysbiosis.
Stomach (non-cardia)	1.45×	1.16×	Probable	N-nitroso compounds and high-salt cured meats interact with H. pylori infection.
Pancreatic	1.19×	1.13×	Limited	Cooked-meat mutagens; well-done/grilled meat shows the strongest signal.
Prostate (advanced)	1.12×	1.12×	Limited	Heme iron and IGF-1 elevation linked to aggressive disease, not indolent tumors.
Breast (post-meno)	1.09×	1.06×	Limited	EPIC pooled analysis; mechanism likely heterocyclic amines + saturated fat.
Esophageal (SCC)	1.41×	1.18×	Probable	Combined with alcohol and hot beverages, multiplies risk in upper GI tract.
Endometrial	1.00×	1.03×	No clear link	Largely mediated by obesity, not red meat itself.
Lung	1.06×	1.05×	No clear link	Smoking dwarfs any dietary signal; small residual in non-smokers.

Cooking method · HCA/PAH formation index

Relative mutagen load · boiled = 1.0

How you cook matters as much as what you eat. A boiled beef stew and a charred ribeye are the same meat — but produce wildly different carcinogen loads. NCI cooked-meat database; Sinha et al., Mutat Res 2005.

Doneness scale

Going from medium-rare to well-done multiplies HCA content by ~3.5× in beef and ~5× in chicken. The visible brown crust is where the chemistry happens — Maillard browning and HCA formation share the same precursors (creatine + amino acids + sugar).

The smoke matters too

PAHs form in smoke when fat drips onto coals, flame, or hot metal. A single grilled steak with visible char can contain as many PAHs as 600 cigarettes' worth of smoke — concentrated on the surface you eat.

Six ways meat-derived compounds damage DNA

Biological mechanism review

Heterocyclic amines (HCAs)

Form when muscle meat (beef, pork, chicken) is cooked at high temperatures — pan-frying, grilling, broiling above 300°F. HCAs are metabolized by liver enzymes into DNA-binding adducts in colon, breast, and prostate tissue. Concentrations rise 10–100× from rare to well-done.

Polycyclic aromatic hydrocarbons (PAHs)

Created when fat drips onto open flames or hot surfaces, generating smoke that coats the meat. Same family of carcinogens found in tobacco smoke. Charred barbecue can contain PAH levels comparable to several cigarettes per serving.

N-nitroso compounds (NOCs)

Formed when nitrites/nitrates used to cure processed meats react with amines in stomach acid, or endogenously from heme iron in red meat. NOCs alkylate DNA at the O6 position of guanine — the same lesion caused by tobacco-specific nitrosamines.

Heme iron

The pigment that makes red meat red. In the colon, heme catalyzes lipid peroxidation and N-nitrosation, generating reactive aldehydes (4-HNE, MDA) that bind DNA. This is the leading proposed reason red meat raises colorectal risk even when not processed.

Advanced glycation end-products (AGEs)

Browned, seared, and grilled meats are concentrated sources. AGEs activate the RAGE receptor, driving chronic inflammation, oxidative stress, and tumor microenvironment remodeling — implicated in pancreatic and breast cancer progression.

TMAO from L-carnitine

Gut bacteria convert carnitine (abundant in red meat) into trimethylamine, which the liver oxidizes to TMAO. Elevated TMAO is linked to colorectal adenoma recurrence and is a leading hypothesis for the gut-microbiome arm of meat-related cancer risk.

Dietary patterns vs cancer risk

Relative risk vs typical Western diet

Mediterranean diet

Olive oil, fish, legumes, vegetables, low red meat. PREDIMED RCT + EPIC cohort.

Vegetarian

Adventist Health Study-2; 96,000 participants over 7 years.

Vegan

Strongest signal for prostate cancer (RR 0.65). AHS-2.

Pesco-vegetarian

Largest colorectal benefit in AHS-2 — likely omega-3 contribution.

DASH (high fiber, low Na)

Originally for blood pressure; cancer benefit shown in NHS + HPFS.

Typical Western diet

Baseline: high red/processed meat, refined grains, added sugar, low fiber.

Evidence-backed ways to cut risk without going vegan

Realistic harm-reduction swaps

Marinate before grilling

−70 to −90% HCAs

Smith et al., J Food Sci 2008 — vinegar, lemon, herbs (rosemary, thyme) block HCA formation.

Microwave 1–2 min before grilling

−90% HCAs

AICR — discards myoglobin precursors before flame exposure.

Avoid char, flip frequently

−50% PAHs

NCI — every 30s flipping prevents surface temperature spikes.

Add cruciferous vegetables

Detoxifies HCAs

Sulforaphane (broccoli, kale) induces glutathione-S-transferase clearance.

Replace one daily serving with legumes

−19% CRC risk

Pan et al., Arch Intern Med 2012 — Harvard pooled cohorts (n=121,000).

Replace one daily serving with fish

−7% mortality

Same study — substitution analysis, not just addition.

Replace one daily serving with poultry

−14% CRC risk

WCRF/AICR CUP 2018 meta-analysis.

Myth: "Grass-fed is risk-free"

Grass-fed beef has a better fatty-acid profile (more omega-3, CLA) but contains the same heme iron, same carnitine, and forms the same HCAs/PAHs when cooked hot. The cancer signal tracks total red meat, regardless of feed.

Myth: "Uncured / no-nitrate bacon is safe"

"Uncured" bacon uses celery powder — a natural nitrate source that converts to the same nitrites and nitrosamines. IARC classifies all processed meat together; the curing chemistry is identical.

Myth: "Carnivore diet has no cancer data"

True — no RCTs. But the all-meat pattern stacks every known risk factor (heme iron, NOCs, zero fiber, no polyphenols, gut dysbiosis) and removes every known protective factor. Mechanistic plausibility is overwhelming.

Sources: IARC Monograph 114 — Red Meat and Processed Meat (2018); Bouvard V. et al., "Carcinogenicity of consumption of red and processed meat," Lancet Oncology 16(16):1599-1600 (Oct 2015); WCRF/AICR Continuous Update Project Expert Report 2018; Sinha R. et al., Mutation Research 2005 (cooked-meat mutagens); Pan A. et al., Archives of Internal Medicine 172(7):555-563 (2012) — red meat consumption and mortality; EPIC cohort (n=521,000); NIH-AARP Diet and Health Study (n=545,000); Nurses' Health Study; Adventist Health Study-2; PREDIMED RCT (Mediterranean diet); NHANES 2017–2020 (US intake); SEER 2020 (US baseline incidence).

Stomach cancer · the bacterial cause

Helicobacter pylori — the only bacterium classified as a Group 1 human carcinogen

In 1982, two Australian researchers (Barry Marshall and Robin Warren) discovered a spiral bacterium thriving in the supposedly sterile stomach. By 1994, the WHO had classified H. pylori as a Group 1 carcinogen — the first and only bacterium on a list otherwise dominated by tobacco, asbestos, and ionizing radiation. Today it infects roughly half of humanity and causes ~75% of all stomach cancers, the world's fourth-deadliest malignancy. This is the complete picture of how a single microbe drives a global cancer epidemic.

Global prevalence

~50%

≈ 4.4 billion people infected

Stomach cancers caused

78%

non-cardia adenocarcinoma

MALT lymphoma cases

92%

cured by antibiotics alone

Annual deaths attributable

~650k

WHO IARC 2024 estimate

The discovery that overturned a century of medicine

Until the 1980s, the consensus was that no bacterium could survive stomach acid, and ulcers were caused by stress and spicy food. Barry Marshall drank a culture of H. pylori himself in 1984 to prove it caused gastritis — and then cured himself with antibiotics. He and Robin Warren won the 2005 Nobel Prize in Physiology or Medicine. The discovery transformed peptic ulcer disease from a chronic surgical condition into a one-week antibiotic course, and reframed ~75% of stomach cancer as a preventable infectious disease.

Global prevalence by region

% adults seropositive · Hooi et al. 2017

Prevalence inversely tracks sanitation, refrigeration, and household size — making H. pylori an ecological marker of childhood living conditions. The mismatch between African prevalence and stomach cancer rates remains an active research puzzle.

The childhood window

≥ 80% of infections are acquired before age 10, and most before age 5. Adult-onset infection is rare; what you carry as a child you typically carry for life unless treated.

Lifetime cancer risk if infected

~1–3% of carriers develop gastric cancer. The number sounds small until multiplied by 4.4 billion carriers — yielding the world's 4th-leading cancer killer.

Strain matters

East Asian CagA+ strains carry 5–10× the cancer risk of European CagA− strains. Same bacterial species, very different oncogenic potential.

The American story: a deep racial & socioeconomic divide

NHANES 1999–2018

US prevalence varies 4-fold between demographic groups — the largest infectious-disease gap of any common pathogen in the country. The pattern mirrors stomach cancer mortality almost exactly: Indigenous and Hispanic Americans have 2–3× the gastric cancer death rate of non-Hispanic whites, and H. pylori is the dominant explanation.

What drives whether a person becomes infected

Childhood environment dominates · adult behaviors barely move the needle

Risk factor	Relative weight	Mechanism
Childhood overcrowding	Risk-raising	Most transmission happens before age 5 within the household. Each additional sibling raises risk ~15%; sharing a bed during early childhood is among the strongest single predictors.
Unsafe drinking water	Risk-raising	H. pylori survives 1–3 weeks in chlorinated municipal water and longer in well water. Outbreaks traced to contaminated wells in Peru, Bangladesh, and rural US Appalachia.
Low socioeconomic status (childhood)	Risk-raising	The single best independent predictor in every cohort studied. Captures water, housing, nutrition, and healthcare access simultaneously.
Maternal infection	Risk-raising	Mothers transmit via pre-chewed food, shared utensils, and saliva during feeding. Vertical transmission is the dominant route in low-income settings.
Lack of refrigeration	Risk-raising	Refrigeration reduces both bacterial load on food and reliance on salt-preserved foods that synergize with infection to drive cancer.
Sharing food / utensils	Risk-raising	Saliva is a confirmed reservoir; H. pylori DNA found in dental plaque. Risk highest within nuclear family, modest between adults.
Daycare attendance	Risk-raising	Child-to-child fecal-oral and oral-oral spread; modest signal vs household contacts.
Antibiotic use (protective)	Protective	Repeated childhood antibiotics for ear/respiratory infections incidentally clear early colonization — partially explains falling Western prevalence.
Breastfeeding (protective)	Protective	Lactoferrin and secretory IgA in breast milk delay colonization; effect strongest beyond 6 months of exclusive nursing.

Not supported

No consistent evidence beyond shared oral contact (kissing).

Six ways H. pylori turns a stomach lining into a tumor

Molecular & cellular mechanisms

CagA injection (the 'oncoprotein syringe')

Virulent strains use a type IV secretion system — a molecular needle — to inject the CagA protein directly into gastric epithelial cells. Once inside, CagA hijacks SHP-2 phosphatase, disrupts cell polarity, and drives the 'hummingbird' morphology associated with malignant transformation. CagA+ strains carry 2–3× the gastric cancer risk of CagA− strains.

VacA pore-forming toxin

Vacuolating cytotoxin A inserts into mitochondrial membranes, induces autophagy, suppresses T-cell proliferation (immune evasion), and creates the cytoplasmic vacuoles that give the toxin its name. The s1m1 allele is the most carcinogenic variant.

Chronic inflammation → atrophic gastritis

Decades of low-grade neutrophil and lymphocyte infiltration destroy parietal cells, reduce stomach acid, and allow intestinal metaplasia — the precancerous lesion in the Correa cascade: normal → chronic gastritis → atrophy → metaplasia → dysplasia → adenocarcinoma. The full sequence takes 20–40 years.

Reactive oxygen / nitrogen species

Neutrophils recruited to fight H. pylori release ROS that damage epithelial DNA. Bacterial urease generates ammonia, which combines with nitrites from cured/preserved foods to form N-nitroso compounds — the same carcinogens implicated in processed-meat-driven cancer.

Methylation silencing of tumor suppressors

H. pylori infection induces aberrant CpG-island methylation of CDH1, p16, MLH1, and RUNX3. Even after eradication, this 'epigenetic field defect' persists and explains residual cancer risk in patients cleared late in life.

Gastric microbiome disruption

H. pylori dominates the gastric niche, suppressing protective Lactobacillus species. Loss of microbial diversity is now considered an independent risk factor for gastric MALT lymphoma and adenocarcinoma.

The Correa cascade · 20–40 years from infection to cancer

Normal mucosa

Age 0–5

→

Chronic gastritis

+5–10 yr

→

Atrophic gastritis

+10–20 yr

→

Intestinal metaplasia

+15–25 yr

→

Dysplasia

+20–30 yr

→

Adenocarcinoma

+25–40 yr

Pelayo Correa first described this stepwise progression in 1975. Eradication during the gastritis or atrophy stages can halt or reverse the cascade; intervention after metaplasia reduces but does not eliminate cancer risk — the "point of no return" appears to lie between metaplasia and dysplasia.

Diseases attributable to H. pylori

Population attributable fraction (PAF)

Disease	% attributable	Clinical note
Gastric adenocarcinoma (non-cardia)	78%	IARC Group 1 since 1994. Eradication before atrophy develops reduces incidence by ~50%.
Gastric MALT lymphoma	92%	Eradication alone induces complete remission in 60–80% of early-stage cases — the only cancer routinely cured by antibiotics.
Peptic ulcer disease (duodenal)	85%	Not cancer, but the discovery that ulcers are infectious won the 2005 Nobel Prize for Marshall & Warren.
Peptic ulcer disease (gastric)	70%	Eradication cuts recurrence from ~70% to <5% within 1 year.
Iron-deficiency anemia (refractory)	30%	H. pylori sequesters iron and impairs absorption; eradication restores ferritin in unexplained cases.
Immune thrombocytopenia (ITP)	25%	Molecular mimicry between CagA and platelet glycoproteins; eradication raises platelet count in ~50% of seropositive patients.
Vitamin B12 deficiency	20%	Atrophic gastritis destroys intrinsic-factor-producing parietal cells.

How H. pylori is detected

Diagnostic test performance

Urea breath test (¹³C)

Non-invasive

Gold standard non-invasive test. Detects active infection. Must stop PPIs 2 weeks prior.

Stool antigen test

Non-invasive

Excellent alternative; preferred for children. Detects active infection.

Serology (IgG antibody)

Non-invasive

Detects past or present exposure — cannot confirm eradication. Largely obsolete in high-prevalence areas.

Endoscopic biopsy (histology)

Invasive

Allows direct visualization, staging of atrophy/metaplasia, and culture for antibiotic susceptibility.

Rapid urease (CLO) test

Invasive

Performed on biopsy during endoscopy; result in 1 hour.

Molecular PCR

Invasive

Detects resistance mutations (clarithromycin 23S rRNA) — increasingly important as resistance rises.

Does treatment actually prevent cancer? The trial evidence.

Randomized eradication studies

Shandong intervention trial (China)

n = 3,365•Follow-up: 22 yr

−39% gastric cancer incidence

Largest RCT to date. Pan et al., Gut 2020.

Taiwan Matsu Islands mass eradication

n = 4,121•Follow-up: 14 yr

−53% incidence; −25% mortality

Population-wide screen-and-treat program. Chiang et al., Gut 2021.

Japan post-endoscopic resection cohort

n = 544•Follow-up: 3 yr

−66% metachronous cancer

After early gastric cancer removal. Fukase et al., Lancet 2008.

Ford BMJ meta-analysis (asymptomatic)

n = 8,323•Follow-up: various

−34% gastric cancer incidence

Pooled 7 RCTs. Ford et al., BMJ 2014.

First-line treatment in 2025

Standard bismuth quadruple therapy (PPI + bismuth subsalicylate + tetracycline + metronidazole for 14 days) achieves > 90% eradication and is preferred in regions where clarithromycin resistance exceeds 15% — which now includes most of North America, Europe, and East Asia. Older "triple therapy" (PPI + amoxicillin + clarithromycin) has slipped to ~70% eradication and is no longer first-line per the Maastricht VI / ACG 2024 guidelines. Confirmation of clearance with breath or stool antigen test ≥ 4 weeks post-treatment is mandatory.

The African enigma

Sub-Saharan Africa has ~79% H. pylori prevalence but among the world's lowest stomach cancer rates. Leading explanations: (1) co-infection with intestinal helminths shifts immune response toward Th2, reducing carcinogenic inflammation; (2) younger age structure — most carriers die of other causes before cancer emerges; (3) diet rich in cassava and low in salt; (4) less virulent strain mix. The puzzle remains partially unsolved.

Why screening isn't universal in the US

The USPSTF does not recommend population-wide H. pylori screening because US gastric cancer incidence (5/100k) is too low to justify mass treatment given antibiotic resistance and side-effect costs. Japan and South Korea, with 10–20× higher incidence, do offer national screening — and have driven gastric cancer mortality down by 50–60% over two decades. Targeted US screening is appropriate for first-generation immigrants from high-prevalence countries, patients with iron-deficiency anemia of unknown cause, and anyone with a first-degree relative with gastric cancer.

Sources: IARC Monograph 100B — Biological Agents (2012); Marshall BJ & Warren JR, Lancet 1984 (original discovery); Hooi JKY et al., Gastroenterology 153:420-429 (2017) — global prevalence systematic review; Plummer M et al., Lancet Global Health 4:e609-e616 (2016) — attributable fraction; Ford AC et al., BMJ 348:g3174 (2014) — eradication meta-analysis; Pan KF et al., Gut 70:243-252 (2020) — Shandong 22-year follow-up; Chiang TH et al., Gut 70:1909-1915 (2021) — Matsu Islands trial; Fukase K et al., Lancet 372:392-397 (2008); Correa P, Cancer Research 1992 (cascade model); Maastricht VI/Florence Consensus, Gut 2022; ACG Clinical Guideline on H. pylori 2024; CDC NHANES 1999–2018; WHO Global Cancer Observatory (GLOBOCAN 2022).

Screening & harms

Overdiagnosis from imaging — when finding cancer earlier doesn't save lives

The cleanest test for whether a screening program works is simple: does cancer mortality fall? For colonoscopy, cervical Pap, and low-dose lung CT in smokers, the answer is yes. For thyroid ultrasound, routine PSA testing, whole-body MRI marketing, and many incidental CT findings, the answer is no — incidence skyrockets while deaths stay flat. The difference is overdiagnosis: detecting disease that would never have caused harm. Every overdiagnosed cancer becomes overtreatment, with all its surgical, hormonal, financial, and psychological costs.

Overdiagnosed thyroid cancers

≈ 90%

of screen-detected papillary cases

South Korea thyroid surge

15×

incidence 1993 → 2011, mortality flat

Adults with occult cancer

~36%

autopsy series, thyroid alone

DCIS overdiagnosis rate

≈ 30%

Marmot UK breast review 2013

What overdiagnosis actually means

Overdiagnosis is not a false positive, a misdiagnosis, or a billing error. It is the histologically-correct detection of a cancer that would never have caused symptoms or death during the patient's lifetime — because the tumor was indolent, the patient died of something else first, or the diagnostic threshold simply caught microscopic disease that always existed in the population. The patient cannot personally know they were overdiagnosed; it is only visible at the population level, by comparing incidence with mortality over decades.

Estimated overdiagnosis by cancer type

% of screen-detected cases that would never have mattered

Sources: Welch & Black, JNCI 2010; Bleyer & Welch NEJM 2012; Marmot UK Independent Review 2013; Vaccarella NEJM 2016; NLST & NELSON trial reports.

Thyroid (papillary)

90% over-dx

Neck ultrasound

South Korea: thyroid cancer incidence rose 15× in 15 years after a 1999 screening campaign — mortality unchanged. Vaccarella, NEJM 2016.

Prostate (PSA-detected)

60% over-dx

PSA + MRI/biopsy

European ERSPC trial: ~1,400 men must be screened and 48 treated to prevent 1 death over 13 years.

Breast DCIS

30% over-dx

Screening mammography

DCIS detection rose from 5 to 50 per 100k after mammography spread; invasive breast cancer mortality unchanged from screening alone.

Lung (CT-detected nodules)

18% over-dx

Low-dose chest CT

NLST: 18% of screen-detected cancers would never have caused symptoms. NELSON trial confirms similar rate.

Case study: the global thyroid cancer epidemic that wasn't

Incidence multiplier · mortality change

South Korea

mortality: unchanged

1999 'comprehensive cancer screening' included neck US. Thyroid cancer became #1 cancer in Korean women within a decade.

United States

mortality: unchanged

Tripling of papillary thyroid cancer since 1975; almost all tumors < 2 cm.

Italy

mortality: unchanged

Similar pattern in regions where neck US adoption was earliest.

France

mortality: unchanged

Driven by incidental detection during carotid US for stroke risk.

Japan

mortality: unchanged

Fukushima pediatric screening found 100× expected rate — almost certainly overdiagnosis.

Vaccarella et al. (NEJM 2016) estimate that 470,000 women and 90,000 men were overdiagnosed with thyroid cancer between 1988 and 2007 in just 12 high-income countries. Most underwent total thyroidectomy and now require lifelong levothyroxine. Korean physicians who first raised the alarm in 2014 succeeded in cutting screening rates by ~35% — and the incidence curve began bending back down for the first time in two decades.

The cascade: one incidental finding → years of consequences

Six-step pathway from scan to overtreatment

Incidental finding

A scan ordered for an unrelated reason (back pain, headache, ER trauma) reveals a 1.2 cm thyroid nodule, lung micronodule, or renal cyst.

Diagnostic workup

Follow-up dedicated imaging, MRI with contrast, biopsy. Each step adds cost ($800–$5,000), radiation, anxiety, and rare procedural complications (1-3% biopsy bleeding/pneumothorax).

Histologic 'cancer' label

Pathology returns 'papillary microcarcinoma' or 'low-grade DCIS' — lesions that meet 1960s cancer criteria but behave indolently. The label itself is now a known harm.

Treatment

Surgery (thyroidectomy, lumpectomy, prostatectomy), radiation, or active surveillance. Each carries permanent risks: vocal cord injury, lifelong hormone replacement, incontinence, impotence, lymphedema.

Surveillance burden

Lifetime imaging follow-up, repeated biopsies, recurrent anxiety. Insurance, employment, and life-insurance consequences of a 'cancer survivor' label.

No mortality benefit

Population-level data: the cancers prevented from killing patients are vastly outnumbered by the indolent cancers treated unnecessarily. Net survival unchanged.

Why modern imaging finds more cancer than there is

The mechanics of overdetection

Resolution outpaced biology

Modern 256-slice CT and 3T MRI detect sub-centimeter lesions invisible to 1990s imaging. Autopsy studies show ~36% of adults have occult thyroid cancers, ~30% have prostate cancer, and ~22% have small renal masses they would have died with — not from.

The 'reservoir' of indolent disease

For most epithelial cancers, the pool of microscopic disease in the general population vastly exceeds the pool that will ever become symptomatic. Better imaging dips into the reservoir without distinguishing dangerous from inert.

Length-time and lead-time bias

Slow-growing tumors are over-represented in screen-detected cases (length bias) because they spend longer in the detectable-but-asymptomatic window. Survival appears better — but it's an artifact of when the clock starts, not when death occurs.

Pathology threshold creep

Diagnostic criteria for 'cancer' have expanded over 50 years. Encapsulated follicular variant of papillary thyroid carcinoma was reclassified as NIFTP (non-cancer) in 2016 — overnight reducing 'cancer' diagnoses by ~10,000/year in the US.

Incidentalomas are the new normal

Estimated frequency on routine imaging: thyroid nodules on neck US: 67%; pulmonary nodules on chest CT: 30%; adrenal nodules on abdominal CT: 5%; renal cysts on abdominal CT: 41%. Most are clinically meaningless.

Defensive medicine amplifies workup

Radiologists report every visible abnormality to avoid malpractice exposure. Ordering clinicians then feel obligated to investigate. The U.S. legal climate produces ~30% more incidental-finding workups per scan than European systems.

Lesions that were demoted from "cancer"

Pathology reclassifications in the last decade

Old name	New designation	Year	Population impact
Encapsulated follicular variant PTC	NIFTP (not cancer)	2016	≈ 10,000 fewer thyroid cancer diagnoses/year in US.
DCIS (ductal carcinoma in situ)	Proposed: IDLE lesion	Esserman 2014	Active surveillance trials (LORIS, LORD, COMET) testing watchful waiting.
Gleason 6 prostate cancer	Increasingly called 'low-grade neoplasia'	2022	Active surveillance now first-line for 60%+ of newly diagnosed US cases.
Borderline ovarian tumors	Tumors of low malignant potential	2014	Conservative surgery, fertility preservation.
Bethesda III thyroid nodules	Many monitored without surgery	ATA 2015	Molecular testing (ThyroSeq, Afirma) avoids 60–70% of unnecessary thyroidectomies.

Where screening genuinely saves lives

The honest comparison · NNT to prevent 1 death

Colonoscopy (CRC)

≈ 850 to 1,250 to prevent 1 death

NordICC + US polyp trials; removes adenomas before cancer forms — true prevention, not just detection.

HPV/Pap (cervical)

≈ 1,140 to prevent 1 death

Detects preinvasive CIN that can be ablated. Mortality dropped ~70% in screened populations.

Low-dose CT (lung, eligible smokers)

≈ 320 to prevent 1 death

NLST + NELSON. Benefit limited to high-risk eligible adults; harms balance benefits in low-risk groups.

Mammography (women 50–74)

≈ 1,150 to prevent 1 death

Real but modest mortality benefit; 19% of screen-detected cancers are overdiagnosed (Marmot review, UK).

Whole-body MRI marketing

Direct-to-consumer "executive scans" (Prenuvo, Ezra, Q Bio) detect incidentalomas in 30–70% of asymptomatic adults. No prospective trial has shown mortality benefit. The American College of Radiology and USPSTF both recommend against them for average-risk people. They are clinical experiments paid for out-of-pocket.

Active surveillance is now mainstream

For low-risk prostate cancer, papillary thyroid microcarcinoma (< 1 cm), and selected DCIS, watch-and-wait protocols match treatment outcomes with vastly less harm. Japanese Kuma Hospital data show < 1% progression at 10 years for < 1 cm thyroid cancers under surveillance.

Questions to ask before any scan

1. Will the result change what we do? 2. What is the chance of an incidental finding, and what would I do with it? 3. Is there a non-imaging alternative (blood test, clinical exam)? 4. What is the cumulative radiation dose if this becomes a yearly habit? 5. Is this scan recommended by USPSTF for my age/risk — or am I paying for marketing?

Sources: Welch HG & Black WC, "Overdiagnosis in Cancer," JNCI 102:605-613 (2010); Bleyer A & Welch HG, NEJM 367:1998-2005 (2012) — mammography; Vaccarella S et al., NEJM 375:614-617 (2016) — global thyroid epidemic; Marmot MG et al., Independent UK Breast Screening Review, Br J Cancer 108:2205-2240 (2013); Esserman LJ et al., Lancet Oncology 15:e234-e242 (2014) — redefining cancer; Brito JP et al., BMJ 347:f4706 (2013) — thyroid; National Lung Screening Trial Research Team, NEJM 365:395-409 (2011); de Koning HJ et al., NEJM 382:503-513 (2020) — NELSON; Bell KJL et al., BMJ 350:g7773 (2015); Welch HG, "Less Medicine, More Health" (2015); American College of Radiology Incidental Findings Committee white papers (2010–2023); USPSTF recommendation statements 2016–2024.

Where to get screened

Where to actually go — including if you have no insurance

Cancer screening only counts if you get it done. These programs cover the gap when insurance doesn't.

CDC NBCCEDP — free breast & cervical screening →

Uninsured & underinsured women 21–64 (cervical) or 40–64 (breast)

CDC CRCCP — free colorectal screening →

Adults 45–75 without insurance in funded states

NCI-designated cancer centers →

73 centers offering specialized screening, second opinion, trials

HRSA Find a Health Center (FQHC) →

Sliding-scale fees regardless of insurance status

American Lung Association — Saved By The Scan →

Find a low-dose CT lung screening site

Susan G. Komen — Free / low-cost screening helpline →

Call 1-877-465-6636 to find local mammography options

GO2 for Lung Cancer — screening center locator →

Centers of Excellence for lung screening

Survivorship

After diagnosis: the surveillance plan that follows

Treatment ends; the cancer doesn't stop being part of your medical story. Modern survivorship care is structured — written care plans, MRD where available, late-effect monitoring, and continued screening for second primaries.

1
Year 0–2 (active surveillance)
Cross-sectional imaging every 3–6 months for most solid tumors; ctDNA-based MRD every 3 months for colorectal/breast/bladder where validated.
Highest recurrence risk window — most relapses happen here.
2
Year 2–5
Imaging spaced to every 6–12 months; tumor markers per primary; physical exam every 3–6 months.
Late recurrence still common for ER+ breast (decade-long risk) and renal cell carcinoma.
3
Year 5+
Annual visit; shift focus to second-cancer screening and late effects (cardiotoxicity, secondary malignancies, fertility, bone health).
5-year survival ≠ cured: lifelong vigilance for late recurrence and treatment-related cancers.
4
Late effects
Cardio-oncology referral for anthracyclines/HER2/radiation. Endocrinology for thyroid post-neck radiation. Pelvic radiation: bladder/bowel/sexual health. Bone density on aromatase inhibitors.
Often under-managed — survivorship care plans should be written at end of treatment.
5
Second-cancer screening
Survivors of one cancer face elevated risk for second primaries — both treatment-induced and from shared risk factors. Continue all age/sex screens on schedule.
Up to 20% of new cancers diagnosed in the US are in someone with a prior cancer history.

Ask your oncology team for a written Survivorship Care Plan at the end of active treatment — it lists every drug you received, total doses, late-effect risks, and a year-by-year follow-up schedule. ASCO publishes templates if your team doesn't offer one.

Clinical trials

Find a clinical trial you might qualify for

ClinicalTrials.gov lists every registered trial in the US and most international ones — over 30,000 active cancer studies. Filter by cancer type and location; bring matches to your oncology team to assess eligibility.

Cancer typeLocation (city, state, country)

Search recruiting trials →All trials (incl. closed)

Other useful resources: NCI's trial finder, Lazarex (covers travel costs for trial participation), and your NCI-designated cancer center's research office.

A century in view

100 years of cancer — how rates, science, and survival have shifted

From the discovery of X-rays to mRNA cancer vaccines: a long arc where cases climbed (mostly because we live longer and detect more) while age-adjusted death rates first surged, peaked in 1991, and have fallen by a third since.

US mortality peak

215

per 100,000 · 1991

Today

144

per 100,000 · 2022

Mortality drop

−33%

since 1991 peak · ~4.1M lives saved

World cases / yr

~20.7M

1950: ~1.7M · 12× rise

United States · age-adjusted rate per 100,000 (1925–2022)

NCHS · CDC WONDER · SEER · ACS

Two stories collide on one chart. Incidence rises through most of the century — partly real (smoking, aging) and partly diagnostic (mammography, PSA, CT). Mortality climbed alongside until 1991, then bent sharply downward as tobacco use fell and treatment improved. Life expectancy rises the whole time, which is itself a major reason "more cancer" exists.

Worldwide cases & deaths · millions/year

WHO · IARC GLOBOCAN

World cancer cases rose ~12× since 1950. Population grew ~3×; the rest is aging, exposure shifts, and better registries.

What drove cancer, by era (share of cases)

Doll & Peto · IARC · GBD 2019 reconstruction

Infection-driven cancers (stomach, cervix, liver) dominated a century ago. Tobacco took over mid-century, peaked, and is now receding. Aging is the largest single driver today.

Milestones — click any year

discoverytreatmentpolicyscreeningtragedy

policy2024

33% mortality drop sustained

ACS confirms US cancer death rate down 33% since 1991 — an estimated 4.1 million deaths averted.

Why more cases — but fewer deaths?

Aging populations

US life expectancy rose from 57 in 1925 to 77 in 2025. Cancer is overwhelmingly a disease of age — half of all cancers occur after 66. More cancer is partly the price of not dying earlier of something else.

Better detection

Pap (1940s), mammography (1980s), colonoscopy (1990s), PSA (1990s), low-dose CT (2010s), and now liquid biopsies all find cancers earlier — or find cancers that would never have caused harm (see overdiagnosis).

Smoking's long shadow

Lung cancer rose for ~40 years after cigarette use peaked, then fell for ~40 years after smoking did. Cancer trends lag behavior change by a generation.

Treatment revolution

Combination chemo (1960s), targeted therapy (1998+), immunotherapy (2011+), and CAR-T (2017+) converted several fatal cancers into chronic or curable disease.

Prevention wins

HPV vaccination, hepatitis B vaccination, H. pylori eradication, and tobacco control have each prevented millions of cancers worldwide.

Global divergence

Incidence in high-income countries is plateauing; in low- and middle-income countries it's still climbing as populations age and adopt Western diets, tobacco, and obesity.

Sources: NCHS Vital Statistics of the US (1930–1999); CDC WONDER underlying-cause mortality (2000–2022); SEER 9 incidence (1975–2021); ACS Cancer Facts & Figures 1998–2026 editions; WHO/IARC GLOBOCAN 2008/2012/2018/2022; Doll & Peto, "The Causes of Cancer" JNCI 1981; GBD 2019 Cancer Collaboration, JAMA Oncol 2022; Siegel et al., "Cancer statistics, 2024" CA Cancer J Clin; Bray et al., "Global cancer statistics 2022" CA Cancer J Clin 2024; National Cancer Act of 1971; US Surgeon General's Report on Smoking and Health, 1964.

Inherited vs acquired

The genetic mutation atlas — by state and around the world

Roughly 5–10% of cancers run in families through inherited (germline) mutations; the other 90%+ are driven by acquired (somatic) mutations a cell collects during life. Both vary dramatically by ancestry, geography, and how much testing actually happens.

Cancers that are hereditary

5–10%

A high-penetrance germline mutation explains roughly 1 in 10–20 cancers.

US adults carrying a Tier-1 mutation

~2M

BRCA1/2 + Lynch + FH — most don't know it. >90% remain undiagnosed.

Risk reduction with surveillance

−70 to −95%

Prophylactic surgery / intensive screening for BRCA, Lynch, FAP.

Gene	Associated cancers	Carrier prevalence	Clinical note
BRCA1	Breast, ovarian, prostate, pancreatic	~1 in 400 (1 in 40 Ashkenazi)	Lifetime breast cancer risk 55–72%; ovarian 39–44%.
BRCA2	Breast, ovarian, prostate, pancreatic, melanoma	~1 in 400 (1 in 40 Ashkenazi)	Male breast cancer risk ~7%; aggressive prostate cancer.
TP53	Li-Fraumeni: sarcoma, breast, brain, adrenal, leukemia	~1 in 5,000	Near-100% lifetime cancer risk; multiple primaries common.
MLH1/MSH2/MSH6/PMS2	Lynch syndrome: colorectal, endometrial, ovarian, gastric, urothelial	~1 in 279	Most common hereditary cancer syndrome. CRC risk to age 70: 40–80%.
APC	Familial adenomatous polyposis (FAP) → colorectal	~1 in 8,000	Near-100% CRC by age 40 without colectomy.
CDH1	Diffuse gastric, lobular breast	Very rare	Often leads to prophylactic gastrectomy.
PTEN	Cowden: breast, thyroid, endometrial	~1 in 200,000	Macrocephaly and hamartomas are clinical clues.
STK11	Peutz-Jeghers: GI, breast, pancreatic	~1 in 50,000–200,000	Mucocutaneous pigmentation in childhood.
RET	MEN2 → medullary thyroid, pheochromocytoma	Rare	Prophylactic thyroidectomy in childhood for carriers.
VHL	Renal clear-cell, hemangioblastoma, pheo	~1 in 36,000	Lifelong imaging surveillance from childhood.
PALB2	Breast (~35–58% lifetime), pancreatic	~1 in 1,000	Risk comparable to BRCA2 in many families.
ATM	Breast, pancreatic	~1 in 200 (carrier)	Moderate-penetrance; radiation sensitivity.
CHEK2	Breast, colorectal, prostate	~1 in 100 (1100delC in N. Europe)	Moderate ~2× breast risk.

Founder mutations — geography hides in the genome

Ashkenazi Jewish

BRCA1 185delAG · BRCA1 5382insC · BRCA2 6174delT

Carrier rate: ~1 in 40

Cancers: Breast, ovarian, pancreatic, prostate

Iceland

BRCA2 999del5

Carrier rate: ~1 in 200

Cancers: Breast (esp. male), prostate, pancreatic

Poland

BRCA1 5382insC · C61G · 4153delA

Carrier rate: ~1 in 200

Cancers: Breast, ovarian

Norway

BRCA1 1675delA · 1135insA

Carrier rate: Regional clusters

Cancers: Breast, ovarian

Netherlands

BRCA1 large genomic rearrangements

Carrier rate: ~1 in 250

Cancers: Breast, ovarian

Quebec (French-Canadian)

BRCA1 C4446T · BRCA2 8765delAG

Carrier rate: Regional

Cancers: Breast, ovarian

Mexico (mestizo)

BRCA1 ex9-12del (large deletion)

Carrier rate: ~10–15% of BRCA+ in Mexico

Cancers: Breast, ovarian

South Africa (Afrikaner)

BRCA1 E881X · BRCA2 8162delG

Carrier rate: Founder effect

Cancers: Breast, ovarian

Pakistan / South Asia

BRCA1 4284delAG · 2080delA

Carrier rate: Regional

Cancers: Early-onset breast

Japan

BRCA1 L63X · BRCA2 5802del4

Carrier rate: Founder

Cancers: Breast, ovarian, pancreatic

Bahamas

BRCA1 943ins10

Carrier rate: ~23% of breast Ca patients

Cancers: Breast — highest BRCA rate worldwide

Finland

CHEK2 1100delC · TP53 R337H equivalents

Carrier rate: ~1.4%

Cancers: Breast, colorectal

Southern Brazil

TP53 R337H (Li-Fraumeni)

Carrier rate: ~1 in 300

Cancers: Adrenocortical, breast, sarcoma

Sources: NCCN Genetic/Familial High-Risk Assessment guidelines v3.2024; CDC Office of Public Health Genomics — Tier 1 conditions surveillance; The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas, Cell 2018; COSMIC v99 (Sanger); cBioPortal MSK-IMPACT 50,000-tumor cohort; Alexandrov et al., "The repertoire of mutational signatures in human cancer" Nature 578:94-101 (2020); Manolio et al., "Bedside Back to Bench" Nature 2019; Sirugo, Williams & Tishkoff, "The Missing Diversity in Human Genetic Studies" Cell 177:26-31 (2019); Manchanda et al., "Population testing for BRCA in Ashkenazi Jews" JAMA Oncol 2020; Petrucelli et al., GeneReviews BRCA1/2 (NCBI) 2023; Idos & Valle, Lynch Syndrome GeneReviews 2024; CAPP2 trial, Lancet 2020; NHGRI GWAS Catalog ancestry diversity report 2024; H3Africa Consortium publications; All of Us Research Program data brief 2024; National Society of Genetic Counselors workforce report 2023.

From mutation to medicine

Cures and treatments for genetic mutations

A generation ago, knowing your tumor's mutation rarely changed treatment. Today, a single DNA change can route you to a pill, an antibody, a vaccine, a prophylactic surgery — or, in a small but growing list of cancers, to a durable cure.

FDA-approved targeted oncology drugs

90+

2001 Gleevec → 2024. ~10 new each year.

Tissue-agnostic approvals

MSI-H, NTRK, TMB-high, RET, BRAF V600E, dMMR, HER2-IHC3+.

CML 10-yr survival

~90%

Was ~20% before BCR-ABL targeting. A genuine cure-or-near for many.

Patients sequenced annually (US)

~500k

FoundationOne, Tempus, Caris, Guardant. Still under 50% of eligible.

Targeted drug

EGFR (L858R, ex19del, T790M, C797S)

FDA 2015 · 1st-line 2018 · adjuvant 2020

Cancers: Non-small cell lung

Therapy: Osimertinib (Tagrisso) — 3rd-gen TKI

Outcome

ADAURA: 88% disease-free at 4 yr vs 78% placebo. FLAURA: median OS 38.6 mo vs 31.8 mo.

Caveat

Resistance via C797S, MET amplification within 1–3 years. 4th-gen drugs in trials.

Targeted drug

BRAF V600E/K

FDA 2014 (melanoma) · 2018 (thyroid) · 2022 (tumor-agnostic for V600E)

Cancers: Melanoma, papillary thyroid, hairy cell leukemia, colorectal

Therapy: Dabrafenib + trametinib (BRAF + MEK combo)

Outcome

Metastatic melanoma 5-yr OS ~34% (was <10% pre-2011). Hairy cell leukemia near-100% CR.

Caveat

Colorectal BRAF V600E needs triplet (encorafenib + cetuximab + ...) — biology differs by tissue.

Targeted drug

ALK fusions (EML4-ALK)

Crizotinib FDA 2011 · alectinib 2017 · lorlatinib 2018

Cancers: Non-small cell lung, anaplastic large-cell lymphoma

Therapy: Alectinib → lorlatinib (next-gen)

Outcome

CROWN trial: 5-yr PFS 60% with lorlatinib — unprecedented in metastatic lung cancer.

Caveat

CNS side effects (cognitive, mood) with lorlatinib; dose reduction common.

Targeted drug

KRAS G12C

FDA 2021 (sotorasib lung) · 2022 (adagrasib)

Cancers: Lung, colorectal, pancreatic

Therapy: Sotorasib (Lumakras), adagrasib (Krazati)

Outcome

First drugs to hit a 40-year 'undruggable' target. Lung ORR ~37%, median PFS ~6.8 mo.

Caveat

Modest vs EGFR/ALK. G12D and pan-KRAS inhibitors (RMC-6236) in trials and look stronger.

Targeted drug

HER2 (ERBB2) amplification / mutation

Trastuzumab FDA 1998 · T-DXd 2019 · HER2-low breast 2022 · tumor-agnostic 2024

Cancers: Breast, gastric, lung, colorectal, bladder

Therapy: Trastuzumab + pertuzumab · T-DXd (trastuzumab deruxtecan)

Outcome

HER2+ early breast: cure rates jumped from ~70% to ~90%. T-DXd in HER2-low: PFS doubled.

Caveat

Interstitial lung disease (~10–15%) with T-DXd; cardiotoxicity with trastuzumab.

Targeted drug

NTRK fusions

FDA 2018 (larotrectinib) — first tissue-agnostic targeted drug

Cancers: Tumor-agnostic — salivary, sarcoma, pediatric, thyroid, lung

Therapy: Larotrectinib, entrectinib, repotrectinib

Outcome

ORR ~75% across 17+ tumor types. Durable responses >5 years.

Caveat

NTRK fusions are rare (<1%) outside specific pediatric cancers; testing rates still low.

Targeted drug

RET fusions / mutations

FDA 2020

Cancers: Thyroid (medullary, papillary), lung

Therapy: Selpercatinib, pralsetinib

Outcome

Lung ORR 84% (treatment-naive). Medullary thyroid: durable responses, CNS activity.

Caveat

Hypertension, hepatotoxicity, QT prolongation.

Targeted drug

FGFR2/3 fusions

FDA 2019–2022

Cancers: Cholangiocarcinoma, urothelial

Therapy: Pemigatinib, erdafitinib, futibatinib

Outcome

Cholangiocarcinoma ORR ~35–42% — first targeted option for this near-untreatable cancer.

Caveat

Hyperphosphatemia, retinal pigment epithelial detachment, nail toxicity.

Targeted drug

IDH1 / IDH2

FDA 2017 (AML) · 2021 (cholangio) · 2024 (vorasidenib — first glioma targeted drug in 25 yr)

Cancers: Acute myeloid leukemia, cholangiocarcinoma, glioma

Therapy: Ivosidenib (IDH1), enasidenib (IDH2), vorasidenib (low-grade glioma)

Outcome

INDIGO trial: vorasidenib tripled PFS in IDH-mutant glioma (27 mo vs 11 mo).

Caveat

Differentiation syndrome in AML (potentially fatal if unrecognized).

PARP / synthetic lethal

BRCA1 / BRCA2 (germline or somatic), PALB2, ATM, HRD+

FDA 2014 (ovarian) · 2018 (breast) · 2020 (prostate, pancreatic)

Cancers: Ovarian, breast, prostate, pancreatic

Therapy: Olaparib, talazoparib, niraparib, rucaparib

Outcome

SOLO-1: maintenance olaparib in BRCA+ ovarian — 7-yr PFS 45% vs 21%. OlympiA: adjuvant olaparib in BRCA+ breast cut recurrence ~42%.

Caveat

MDS/AML in ~1–2%; anemia, fatigue. Resistance via BRCA reversion mutations.

Immunotherapy

MSI-H / dMMR (Lynch syndrome + sporadic)

FDA 2017 (first tissue-agnostic approval in history) · dostarlimab endometrial 2021

Cancers: Tumor-agnostic — colorectal, endometrial, gastric, etc.

Therapy: Pembrolizumab (Keytruda), dostarlimab (Jemperli)

Outcome

Cercek/Diaz 2022: dostarlimab in MSI-H rectal cancer — 100% clinical complete response (n=14 → 42 by 2024). No surgery, no chemo, no radiation needed.

Caveat

Only ~15% of CRC, ~30% of endometrial are MSI-H. Immune-related adverse events possible.

Immunotherapy

TMB-high (≥10 mut/Mb)

FDA 2020

Cancers: Tumor-agnostic

Therapy: Pembrolizumab

Outcome

KEYNOTE-158: ORR ~29% across 10 tumor types.

Caveat

Definition and cutoff still debated; assay-dependent.

Risk-reducing surgery

BRCA1 / BRCA2 carriers

Standard of care since 1990s

Cancers: Breast, ovarian (risk-reduction)

Therapy: Bilateral mastectomy ± risk-reducing salpingo-oophorectomy (RRSO)

Outcome

Bilateral mastectomy: ~90–95% breast cancer risk reduction. RRSO by 35–40: ~80% ovarian cancer mortality reduction; also halves breast cancer risk in BRCA1.

Caveat

Surgical menopause, body-image and psychological impact; not for everyone.

Risk-reducing surgery

MLH1/MSH2/MSH6/PMS2 (Lynch)

NCCN guideline

Cancers: Colorectal, endometrial

Therapy: Hysterectomy + BSO at completed childbearing; subtotal colectomy if cancer found

Outcome

Hysterectomy: ~100% endometrial cancer risk reduction. Colonoscopy every 1–2 yr starting age 20–25 cuts CRC mortality >70%.

Caveat

Hormonal and fertility consequences; lifelong follow-up.

Risk-reducing surgery

APC (Familial adenomatous polyposis)

Standard since 1980s

Cancers: Colorectal

Therapy: Prophylactic colectomy in late teens/early 20s

Outcome

Near-100% prevention of the otherwise inevitable CRC by age 40.

Caveat

Lifetime stoma or J-pouch; duodenal/desmoid surveillance continues.

Risk-reducing surgery

RET (MEN2A/2B)

Standard of care

Cancers: Medullary thyroid

Therapy: Prophylactic thyroidectomy in childhood (age 5 for MEN2A, infancy for MEN2B)

Outcome

Effectively eliminates lifetime medullary thyroid cancer risk if done before nodal spread.

Caveat

Lifelong thyroid hormone replacement.

Risk-reducing surgery

CDH1 (Hereditary diffuse gastric)

International CDH1 consortium guideline

Cancers: Diffuse gastric, lobular breast

Therapy: Prophylactic total gastrectomy

Outcome

Effectively eliminates gastric cancer risk (lifetime risk was 70%).

Caveat

Major lifestyle change — dumping syndrome, B12 deficiency, weight loss.

Chemoprevention

Lynch syndrome (MMR)

NICE 2020 · NCCN considers

Cancers: Colorectal

Therapy: Aspirin 600 mg/day (CAPP2 trial dose); newer trials testing lower doses

Outcome

CAPP2 20-yr follow-up: CRC incidence cut by ~50% with 2+ years of aspirin.

Caveat

GI bleeding risk; dose-optimization ongoing in CaPP3.

Chemoprevention

BRCA1/2 carriers

FDA 1998 (tamoxifen for prevention)

Cancers: Breast (risk-reduction)

Therapy: Tamoxifen / raloxifene / aromatase inhibitors

Outcome

Cuts ER+ breast cancer risk ~40–60% in high-risk women.

Caveat

VTE, endometrial cancer, hot flashes; uptake remains low (~5% of eligible).

Gene therapy

Various (TIL therapy, neoantigen)

FDA 2024 (first TIL therapy approved)

Cancers: Melanoma, cervical, solid tumors

Therapy: Lifileucel (Amtagvi) — tumor-infiltrating lymphocyte (TIL) therapy

Outcome

Advanced melanoma after checkpoint failure: ORR 31%, durable in many.

Caveat

Requires tumor harvest, lymphodepletion chemo, ICU-level care. ~$515,000 list price.

Gene therapy

CD19+ B-cell malignancies

FDA 2017 (tisagenlecleucel) — first gene therapy in US

Cancers: ALL, DLBCL, follicular, mantle cell

Therapy: CAR-T: tisa-cel, axi-cel, brexu-cel, liso-cel

Outcome

Pediatric ALL: ~80% remission at 3 months; many durable. DLBCL: ~40% long-term remission after chemo failure.

Caveat

Cytokine release syndrome, ICANS neurotoxicity, B-cell aplasia. Manufacturing 2–4 wk.

Gene therapy

BCMA (multiple myeloma)

FDA 2021–2022

Cancers: Multiple myeloma

Therapy: Ide-cel (Abecma), cilta-cel (Carvykti) BCMA CAR-T

Outcome

CARTITUDE-1: ORR 98%, median PFS ~35 mo in heavily pretreated patients.

Caveat

Parkinsonian-like delayed neurotoxicity reported with cilta-cel.

Gene therapy

p53 reactivation (investigational)

Investigational (Phase II/III); rezatapopt has FDA Breakthrough Designation

Cancers: TP53-mutant solid tumors (most of cancer)

Therapy: Eprenetapopt (APR-246), PC14586/rezatapopt, ATO derivatives

Outcome

Targets specific TP53 mutants (e.g., Y220C). Early signals in MDS, ovarian, sarcoma.

Caveat

TP53 has hundreds of mutation variants — likely needs allele-specific drugs.

Gene therapy

Sickle / β-thalassemia (precedent for cancer)

FDA 2023

Cancers: Not cancer — proof of concept

Therapy: Casgevy (CRISPR/Cas9 BCL11A edit), Lyfgenia (lentiviral)

Outcome

First CRISPR-edited therapy ever approved. ~95% of patients vaso-occlusion-free at 1 yr.

Caveat

Listed here because base-editing and CRISPR delivery platforms are the foundation of next-gen cancer cures (Verve, Beam, Intellia oncology pipelines).

FDA 2025 · SpotlightClass · Targeted small moleculeTrial-only

KRAS G12D / pan-KRAS agents

What changed

First clinical responses reported (RMC-6236, MRTX1133) — ~90% of pancreatic cancers carry a KRAS mutation.

For whom

Trial-only; pan-KRAS or G12D-mutant disease.

Why it matters

KRAS was called "undruggable" for 40 years. G12C inhibitors cracked it in 2021; G12D and pan-KRAS unlock the other ~85% of KRAS-mutant tumors — including pancreatic, the toughest adult cancer.

NCT05379985 · RMC-6236 →NCT05737706 · MRTX1133 →

Trial details · phase, status, key endpoints▼

Endpoints view

NCT05379985RMC-6236 (daraxonrasib)RecruitingPhase 1/1b

Revolution Medicines · Pan-RAS (G12X) solid tumors — pancreatic, NSCLC, CRC

Primary endpoints

• Safety, tolerability, adverse events
• MTD / RP2D determination

NCT05737706MRTX1133RecruitingPhase 1/2

Mirati / Bristol Myers Squibb · KRAS G12D-mutant advanced solid tumors (PDAC, CRC, NSCLC)

Primary endpoints

• Dose-limiting toxicities (DLTs)
• RP2D determination

Source: ClinicalTrials.gov registry records. Status and enrollment change frequently — confirm at the linked record before contacting a site.

The 2025–2030 frontier

Allele-specific TP53 reactivators

TP53 is mutated in ~50% of all human cancer but each mutation behaves differently. PC14586/rezatapopt (Y220C-specific) is the proof of concept; allele-by-allele drugs are coming.

Pan-KRAS and KRAS G12D inhibitors

RMC-6236 (pan-RAS), MRTX1133 (G12D), and Revolution Medicines' tri-complex inhibitors expand beyond G12C to ~90% of pancreatic and ~40% of colorectal.

Antibody-drug conjugates (ADCs)

T-DXd, Enhertu, Trodelvy, datopotamab-deruxtecan — chemo payloads delivered by an antibody to mutation-defined targets (HER2, TROP2, HER3). Replacing chemotherapy in multiple cancers.

mRNA neoantigen cancer vaccines

Moderna/Merck mRNA-4157 in BRAF/NRAS melanoma: ~44% reduction in recurrence in Phase II. Personalized to each tumor's mutations. Phase III readouts in 2025–2026.

Base & prime editing

Single-letter DNA edits without double-strand breaks. Verve, Beam, Prime Medicine pipelines now include oncology indications (CAR-T enhancements, in vivo edits).

In vivo CAR-T

Lipid nanoparticles deliver CAR mRNA directly into the body — no cell harvest, no manufacturing, ~$10,000s instead of $500,000+. Capstan, Umoja, Orna in trials.

Synthetic lethal beyond BRCA

WEE1, ATR, PRMT5/MAT2A (MTAP-deleted), USP1, Polθ inhibitors — exploiting one mutation to make a second pathway essential.

AI-designed oncology drugs

Insilico, Isomorphic, Recursion programs moving from in silico to clinic — first AI-designed cancer drug in trials (INS018_055 platform extended to oncology).

"Cure" is a careful word

CML, APL, pediatric ALL, Hodgkin lymphoma, choriocarcinoma, MSI-H rectal (Cercek 2022), HER2+ early breast — these are genuine cures or near-cures for most patients. Most metastatic solid tumors are turning into chronic disease, not cures (yet).

Resistance is the rule

Targeted drugs work brilliantly until a tumor evolves around them — often within 1–3 years. Cures usually require combinations, sequencing, or eradicating residual disease (CAR-T, vaccines, ADCs).

Access lags science

Comprehensive tumor sequencing reaches under half of eligible US patients and a small fraction worldwide. The best drug in the world doesn't help if no one ran the test that identifies its target.

Sources: FDA Oncology Center of Excellence approvals 2014–2024; NCCN Biomarker Compendium 2024; ASCO Annual Meeting plenary abstracts (CAPP2, OlympiA, SOLO-1, CROWN, ADAURA, INDIGO, CARTITUDE-1); Cercek et al., "PD-1 Blockade in Mismatch Repair–Deficient Rectal Cancer" NEJM 386:2363-2376 (2022); Burki, "Dostarlimab in mismatch-repair-deficient rectal cancer" Lancet Oncol 2024; Hodi et al., melanoma checkpoint long-term follow-up; Mok/Soria et al., FLAURA & ADAURA NEJM 2018/2020; Tutt et al., OlympiA NEJM 2021; Mateo et al., PROfound (olaparib in prostate) NEJM 2020; Maude et al., tisagenlecleucel in pediatric ALL NEJM 2018; Mehrling, "Antibody-drug conjugates in oncology" Nature Rev Drug Disc 2024; Weiss et al., CRISPR/Cas9 BCL11A editing for SCD NEJM 2023; Moderna/Merck KEYNOTE-942 mRNA-4157 ASCO 2023; Revolution Medicines RMC-6236 ESMO 2023; Mullard, "2024 FDA approvals" Nature Rev Drug Disc 2025; AACR Cancer Progress Report 2024; ACS Cancer Facts & Figures 2026.

Social determinants

Cancer by education level

Education is one of the strongest single predictors of cancer risk and death in the United States — stronger than income for many cancers, because it shapes smoking, screening, and care navigation across a lifetime.

1.33× mortality gap (<HS vs post-grad)

+10.2 yrs life expectancy gap

All cancers — age-adjusted rate per 100,000 adults 25+

Higher educational attainment is associated with lower overall cancer incidence and substantially lower mortality.

<HS

Incidence 512

Mortality 242

Life exp 73.5 yrs

Incidence 478

Mortality 206

Life exp 76.1 yrs

Some college

Incidence 448

Mortality 174

Life exp 78.4 yrs

College

Incidence 408

Mortality 134

Life exp 82.1 yrs

Post-grad

Incidence 384

Mortality 114

Life exp 83.7 yrs

By cancer type

Most cancers fall sharply with education. A few (breast, prostate, melanoma) rise — they track screening intensity and lifestyle.

Why: Steepest gradient — driven by smoking prevalence.

Smoking

Adults with <HS smoke at ~3× the rate of college graduates. Lung cancer alone explains a third of the education mortality gap.

Screening & early detection

Colonoscopy, mammography, and Pap test uptake all rise with education — meaning cancers found earlier, when curable.

Care navigation

Higher-education patients access clinical trials, second opinions, and academic centers more often, lifting survival even at the same stage.

Sources: NCI SEER + NHIS linked mortality files; CDC NCHS education-stratified life tables; Sasson & Hayward, "Educational inequalities in US mortality" (Demography 2019); Singh & Jemal, "Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the US, 1950–2014" (J Environ Public Health 2017). Rates are illustrative age-adjusted estimates for US adults 25+ and round published figures.

The partner effect

Cancer outcomes by marital status — married, single, divorced, widowed

Across nearly every major cancer, married patients live longer than unmarried patients with the same disease. The gap rivals what chemotherapy adds. Three drivers: earlier diagnosis, more treatment received, stronger adherence.

Death risk reduction if married

−20%

Aizer JCO 2013 · adjusted HR 0.80 across 10 cancers

More likely to present early

+17%

localized vs distant stage at diagnosis

More likely to get definitive Rx

+53%

curative-intent surgery, chemo, or radiation

Larger benefit in men

~2×

marital effect vs women in most sites

Cohort filters — compare like-for-like

Age group

SEER pooled baseline

Race / ethnicity

SEER pooled baseline

Cancer stage

pooled baseline

Diagnosis year

full SEER span

level ×1.00gap ×1.00Showing SEER pooled baseline. Pick a cohort to see how the marital gap shifts.

5-yr cause-specific survival (%) · by marital status

SEER · Aizer JCO 2013 (+updates)

Marital advantage (married − unmarried avg)

percentage-point gap

Head & neck+19 pts

Colorectal+13 pts

Bladder+12 pts

Lung (NSCLC)+11 pts

Esophageal+11 pts

Prostate+10.7 pts

Breast (female)+10 pts

Ovarian+9.7 pts

Melanoma+8.7 pts

Pancreatic+5 pts

Cancers where survival depends most on timely diagnosis and complex treatment (head & neck, esophageal, lung) show the largest marital gaps. Cancers with obvious early symptoms or indolent biology (melanoma in situ, low-grade prostate) show smaller gaps.

Why marriage seems to help — and the confounders

Men benefit more than women

The survival gap between married and unmarried patients is larger for men across nearly every cancer site (Aizer 2013, Ai 2020). The 'caregiver wife' hypothesis is one explanation; women's broader social networks may buffer the absence of a spouse.

Effect ≈ chemotherapy benefit

For several cancers (prostate, lung, head & neck) the adjusted survival improvement from being married exceeds the absolute benefit of receiving chemotherapy in the same population.

Stage at diagnosis

Married patients are 17% more likely to present at a localized (curable) stage. Spousal nudging to see a doctor about symptoms is a leading mechanism.

Treatment receipt

Married patients are 53% more likely to receive definitive (curative-intent) therapy after adjusting for stage, age, income, and comorbidities.

Depression & adherence

Unmarried cancer patients show ~30% higher rates of clinical depression during treatment and ~25% lower adherence to oral chemo/endocrine therapy (DiMatteo meta-analysis).

Cohabitation ≈ marriage

Recent SEER analyses find unmarried cohabiting partners capture most of the survival benefit — it's the partner, not the certificate.

Income confounder

Married households have ~2× median income. Adjusting for income and insurance shrank the marital effect ~30%, but it persisted.

Divorced > single > widowed

Divorced patients consistently outperform never-married and widowed patients. Widowhood after age 65 is the worst prognostic marital category.

It's the support, not the ring

The benefit appears to flow from a present, engaged partner — catching symptoms, attending appointments, driving to chemo, managing medications — not from marital status itself. Cohabiting partners and live-in family confer similar benefit.

A clinical signal, not a prescription

Oncologists use marital/support status as a flag for navigator referral, transportation help, and intensified follow-up — not as a reason to alter treatment. NCCN distress screening explicitly captures it.

Selection bias caveat

Healthier people are more likely to be married. SEER analyses adjust for stage, age, income, race, and insurance and the effect persists — but no observational study eliminates residual confounding.

Sources: Aizer AA et al., "Marital Status and Survival in Patients With Cancer" J Clin Oncol 31:3869-3876 (2013); Aizer AA et al. SEER updates 2019; Wang L et al., "Cohabitation, marriage and cancer outcomes" Cancer Med 2021; Kravdal & Syse, BMC Public Health 2011; DiMatteo MR, "Social support and patient adherence" Health Psychol 2004; Pinquart & Duberstein, Crit Rev Oncol Hematol 75:122-137 (2010); Ai AL et al., "Gender differences in the marital benefit of cancer survival" Support Care Cancer 2020; NCCN Distress Management Guidelines v2.2024.

Reproductive history

No births & cancer risk: breast, endometrial, ovarian and beyond

Pregnancy, age at first birth, and breastfeeding are among the largest modifiable hormonal influences on women's cancer risk. The protective effects are strongest for endometrial and ovarian cancer, real but more nuanced for breast cancer, and reversed for cervical cancer. Below is what the pooled literature actually says — and where it gets messy.

Relative risk by cancer type

RR = 1.0 is the reference (parous woman). Values <1.0 mean lower risk; >1.0 mean higher risk. "Per birth" is the multiplicative change for each additional full-term pregnancy.

Endometrial×2.00 nullip

Strongest single signal — unopposed estrogen exposure.

Ovarian (epithelial)×1.55 nullip

Each pregnancy suppresses ~9 months of ovulation.

Breast (overall)×1.30 nullip

Late first birth (>30) carries similar risk to nulliparity.

Breast (ER+ post-menopausal)×1.35 nullip

Long-term protection dominates after age 50.

Breast (triple-negative)×0.85 nullip

Inverse pattern — parity slightly raises TNBC; breastfeeding strongly protects.

Pancreatic×1.10 nullip

Small, inconsistent signal across cohorts.

Thyroid×0.95 nullip

Essentially neutral; pregnancy may transiently raise risk.

Colorectal×1.05 nullip

Weak protection per birth in pooled analyses.

Cervical×0.70 nullip

Reversed — higher parity raises risk via HPV persistence and trauma.

Breast cancer by age at first birth

Reference: first birth at 25–29. Early first birth is the single most protective reproductive variable.

Breast cancer by number of births

Reference: 2 births. Each additional birth lowers lifetime breast risk ~7%.

Breast cancer by lifetime breastfeeding

Lancet 2002 reanalysis: ~4.3% lower risk per 12 months of breastfeeding, independent of parity.

Why pregnancy changes the math

Lobular maturation (breast)

Full-term pregnancy before ~30 drives terminal differentiation of breast lobules (Type 1/2 → Type 4), shrinking the pool of stem-like cells most vulnerable to carcinogenic hits.

Ovulatory suppression (ovary)

Each pregnancy halts ~9 months of ovulation; lactation adds more. Fewer ovulatory cycles = fewer surface-epithelium repair events and lower fallopian-tube inflammatory exposure.

Progesterone shielding (endometrium)

Pregnancy floods the endometrium with progesterone, which opposes estrogen-driven proliferation. Nulliparous women accumulate decades of relatively unopposed estrogen exposure.

Hormonal milieu reset

Pregnancy lowers long-term levels of IGF-1, estradiol, and prolactin in many women — sustained changes detectable a decade later in cohort studies.

Transient post-partum spike

Risk of breast cancer rises modestly for ~5–10 years after a first birth, especially after age 35, before the long-term protective effect takes over.

Immune & involution biology

Post-partum mammary involution involves inflammatory remodeling that can promote occult tumors short-term but clears damaged epithelium long-term.

What it means in practice

• A nulliparous woman's lifetime endometrial risk is roughly double a multiparous woman's — the largest reproductive signal in oncology.
• Combined oral contraceptives for ≥5 years cut endometrial risk ~25% and ovarian risk ~30% — protection persists decades after stopping, and partially offsets nulliparity.
• For breast cancer the pattern is biphasic: a small risk bump for ~5–10 years after a first birth (especially after 35) followed by long-term protection. Aggregate effect is net protective by age 70.
• BRCA1/2 carriers see less benefit from parity than the general population — early prophylactic salpingo-oophorectomy remains the dominant risk-reducing intervention.
• Tubal ligation and salpingectomy independently cut ovarian risk 30–65%, on top of any parity effect.

Caveats & confounders

• Age at menarche and menopause: independent risk factors, often correlated with reproductive history.
• Hormonal contraceptive and HRT use: oral contraceptives lower ovarian/endometrial risk and slightly raise breast risk.
• BMI and insulin resistance: amplify endometrial and post-menopausal breast risk regardless of parity.
• Socioeconomic patterning: education and income correlate with later first birth and with screening uptake — partially confound observed risk.
• Infertility itself: some infertility causes (PCOS, endometriosis) carry their own cancer risks distinct from nulliparity.

Sources: Collaborative Group on Hormonal Factors in Breast Cancer (Lancet 2002, n=150,000); Setiawan et al., Type-I/II endometrial cancer pooled analysis (Am J Epidemiol 2013); Wu et al., parity & ovarian cancer (Int J Cancer 2015); Million Women Study (BMJ 2007); Lambertini et al., parity & TNBC meta-analysis (Cancer Treat Rev 2016); IARC Handbook Vol 15 (combined oral contraceptives); SEER 2025 baseline incidence.

Personal estimate

Reproductive history risk calculator

Estimate your relative risk for breast, endometrial, ovarian, and cervical cancer based on parity, age at first birth, breastfeeding, and a few modifiers. Reference woman = 2 full-term births, first birth at 25–29, no breastfeeding, no oral contraceptives (RR = 1.00).

Number of full-term births

Age at first birth

Locked while births = 0.

Total lifetime breastfeeding (months)

0 mo

Years on combined oral contraceptives

0 yr

Menopause status

Known BRCA1 or BRCA2 carrierTubal ligation or salpingectomy

Breast cancer

×1.30

~30% higher

Nulliparous (no births)×1.30

Endometrial cancer

×2.00

~100% higher

Nulliparous (no births)×2.00

Ovarian cancer

×1.55

~55% higher

Nulliparous (no births)×1.55

Cervical cancer

×0.70

~30% lower

Nulliparous (no births)×0.70

Method: multiplicative model anchored to a 2-birth, first-birth-25–29, no-breastfeeding reference woman. Per-birth, age-at-first-birth, breastfeeding, oral contraceptive, BRCA, and tubal-ligation effects derived from Collaborative Group on Hormonal Factors in Breast Cancer (Lancet 2002), Setiawan et al. (Am J Epidemiol 2013), Wu et al. (Int J Cancer 2015), Million Women Study (BMJ 2007), and IARC Handbook Vol 15. Output is a relative risk — multiply by population lifetime risk (~13% breast, ~3% endometrial, ~1.2% ovarian, ~0.7% cervical in the US) for an absolute estimate. Educational only; not a clinical prediction tool.

By region

A disease without borders

High-income regions detect more cases — but lower-income regions carry a heavier share of deaths, because diagnosis often comes late and treatment is harder to reach.

Asia

55% mortality

Europe

45% mortality

North America

28% mortality

Latin America

46% mortality

Africa

62% mortality

Oceania

22% mortality

Treated & in remission

Millions are living after cancer

A cancer diagnosis is no longer the same as it was a generation ago. More people than ever are completing treatment and living for years — many cancer-free — thanks to earlier detection, better therapies, and ongoing follow-up care.

Cancer survivors · United States

19.8M

ACS 2026 · projected 22.5M by 2032

5-year survivors · worldwide

56.5M

2025 · IARC projection

US survivors in remission

68%

≈ 12M no longer in active treatment

Curable when caught early

90%

for many common cancers · NCI SEER

US cancer survivors (millions)

ACS / NCI

5-year survival by cancer type (US)

SEER 2014–2020

A word on "remission". Remission means signs and symptoms of cancer have decreased or disappeared. Complete remission means no detectable disease; partial remission means significant shrinkage. Doctors typically reserve the word "cured" for people who remain cancer-free for many years.

The arc of progress

Survival is rising. Deaths are falling.

Decades of research, earlier screening, and better treatments have meaningfully changed the prognosis. In the US, the cancer death rate has dropped about a third since its 1991 peak — an estimated 4 million lives saved.

5-year survival, all cancers (US)

SEER, NCI

US cancer death rate · per 100,000

ACS / CDC

What helps

Roughly 4 in 10 cancers are preventable

No single habit can eliminate risk, but research consistently points to a handful of choices that meaningfully shift the odds.

Don't smoke

Tobacco causes ~22% of cancer deaths worldwide — the single largest preventable cause.

Move daily

Just 150 minutes of moderate activity a week lowers risk for at least 13 cancers.

Screen on schedule

Mammograms, colonoscopies and HPV tests catch disease when it's most treatable.

Vaccinate

HPV and hepatitis B vaccines prevent the infections behind cervical and liver cancers.

Signs to watch for

Early signs that get cancer detected sooner

Most of these symptoms are caused by something other than cancer — but when they linger, getting checked early is one of the most powerful things a person can do. Detection at an early stage can raise survival from single digits to over 90% for many cancers.

Unexplained weight loss

Losing 10+ pounds without trying can be an early sign of pancreatic, stomach, esophageal, or lung cancer.

No diet changeLasting > a few weeks

Persistent fatigue

Tiredness that doesn't improve with rest may signal leukemia or some colon and stomach cancers from internal blood loss.

Rest doesn't helpInterferes with daily life

A new lump or thickening

Any new lump in the breast, testicle, lymph nodes, or soft tissue that persists deserves a check — even painless ones.

BreastNeck / armpitTesticle

Skin changes

A mole that changes in size, shape, or color — or a sore that won't heal — can point to skin cancer. Yellowing skin or eyes may signal liver or pancreatic cancer.

AsymmetryColor changeWon't heal

Changes in bowel or bladder habits

Long-term constipation, diarrhea, blood in stool, or changes in urination can be signs of colorectal, prostate, or bladder cancer.

Blood in stool/urinePersistent change

Persistent cough or hoarseness

A cough lasting more than 3 weeks, coughing up blood, or a hoarse voice that doesn't go away can indicate lung or throat cancer.

Cough > 3 weeksBlood in sputum

Difficulty swallowing or indigestion

Ongoing trouble swallowing, or persistent indigestion, may be linked to esophageal, stomach, or throat cancer.

Food sticksLasts weeks

Unusual bleeding or bruising

Bleeding between periods, after menopause, or easy bruising can signal cervical, uterine, or blood cancers.

Post-menopausalFrequent bruises

When in doubt, get it checked. These signs are educational only. A clinician can rule things out quickly — and when cancer is found, early detection dramatically improves outcomes.

Environmental factors

The planet we live on shapes the cancer we get

The World Health Organization estimates that 19% of all cancers — and more than 1.3 million deaths a year — are linked to the environment we breathe, drink, and work in. Here are the biggest drivers being reported worldwide.

Cancer deaths linked to environment

1145K+

WHO · per year worldwide

Share of all cancers

≈ 19%

environmentally attributable

People breathing unsafe air

Rising

30Kattributable cancer deaths / year

PFAS detected in the blood of 99% of Americans tested. Emerging evidence; true global burden likely under-counted.

Linked cancers

Kidney, testicular, breast

Air-pollution cancer deaths · worldwide (thousands)

State of Global Air · IHME

Why this matters. Unlike genetic risk, environmental exposures are modifiable at scale. Cleaner air, safer chemicals, asbestos bans, and household-fuel transitions have already cut millions of future cancers — and remain among the most cost-effective levers in public health.

Latest research

New studies coming out about cancer

A live feed of recent reporting on cancer research, breakthroughs, and clinical trials from around the web.

A note on this data. Figures are rounded estimates compiled from the World Health Organization's GLOBOCAN 2022 database with IARC projections to 2025–2026, the American Cancer Society's Cancer Facts & Figures 2026, the CDC's United States Cancer Statistics (2017–2022), NCI SEER survival data, and the 2025 State of Global Air report. The "Latest research" feed pulls live news from the past month. This atlas is for general education — it is not medical advice. For personal guidance, please speak with a qualified clinician.

Cancer in numbers — and the long, hopeful arc of progress against it.

Six numbers that frame the picture

The shape of cancer, in numbers

Cancer by age, sex, and demographics

Incidence by age group

Top cancers in this slice

How cancer falls on the two sexes

US new cases by cancer type · 2026 projection

Cancers reported by age group

Children

Adolescents & young adults

Adults

Older adults

Cancer in dogs and cats

Most common cancers in dogs

Most common cancers in cats

Warning signs in pets

Where the global burden falls

What's driving each diagnosis

Lung

Breast

Colorectal

Prostate

Stomach

Liver

Thyroid

Cervical

The cancers we now cure — and what's curing them

Cure rate when caught early

Breakthroughs · 2025–2026

Cure rate by cancer type — all 20 major cancers

Six pillars of modern cures

Early detection

Surgery

Immunotherapy

Targeted therapy

CAR-T cell therapy

Vaccines & prevention

Cancer across the 50 states

New cases · 2026

Top cancer centers and oncologists

Northeast

South

Midwest

West

Death rate by cancer type

Total US deaths · 2026

Death rate by cancer type · worldwide

Total worldwide deaths · GLOBOCAN 2022

Death by state

Projected cancer deaths · 2026

Cancer risk by blood type

Relative risk vs Type O

Cancer risk: drinkers vs non-drinkers

Relative risk vs lifetime non-drinkers

Cancer risk: smokers vs non-smokers

Relative risk vs lifetime never-smokers

Cancer risk: red and white blood cell counts

Red cell findings → cancers to think of

Cancer mortality vs air quality, by state

Side-by-side: PM2.5 vs cancer mortality

Cancer vs technology and data center concentration

Side-by-side: data centers vs cancer mortality

Cancer mortality vs median household income, by state

Side-by-side: median income vs cancer mortality

What blood work reveals over the course of cancer

Classic tumor markers

How to actually screen for cancer — by sex and by decade

Ages 18 – 39

Ages 40 – 44

Ages 45 – 64

Ages 65 – 75

Ages 76+

Build your screening checklist

What you actually pay for screening

What cancer actually costs — by cancer and by treatment

The cost of cancer is itself a treatment side effect

What's new for each cancer (2020–2025)

Breast

Why everything new looks like a Greek letter